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Abstract 
The aim of this body of work was to characterise a novel cisplatin drug delivery 
system and to develop new tools based on biophotonic imaging that could be 
used to enhance studies of drug delivery in vivo. 
 
Cucurbiturils (CB) are macrocycles which are formed by acid catalysed 
condensation of glycoluril and formaldehyde. The internal cavity of CB[7] 
encapsulates a single molecule of cisplatin and the hypothesis was that 
encapsulation would reduce thiol degradation of the drug. Drug sensitivity 
studies in vitro with the cisplatin-sensitive human ovarian cancer cell line, 
A2780, and a cisplatin-resistant derivative, A2780/cp70, showed that the CB[7] 
encapsulated cisplatin retained activity but that this encapsulation drug delivery 
system was not able to overcome resistance to platinum. However, when these 
cell lines were grown as subcutaneous xenografts in nu/nu mice, the 
encapsulated cisplatin was able to reduce the growth of A2780/cp70 tumours 
which are resistant to the maximum tolerated dose of cisplatin in vivo. One 
possible explanation of this observation is that encapsulation might alter the 
pharmacokinetics of cisplatin and a method for the detection of platinum in 
biological samples by ICP-MS was established and validated. This assay was 
sufficiently sensitive to detect the low levels of platinum present in mouse 
plasma 24 hours after administration of either free or encapsulated cisplatin. 
Plasma and tissue pharmacokinetics show that encapsulation had no effect on 
the peak plasma concentration of cisplatin but did reduce the rate at which 
cisplatin was cleared from the plasma. The increased plasma AUC of cisplatin 
resulted in a non-selective increase in the delivery of cisplatin to both tumour 
and normal tissues. However, there was no apparent increase in toxicity which 
could be explained by the fact that encapsulation, unlike an increase in the dose 
of free cisplatin, had no effect on the peak plasma concentration. 
 
Subcutaneous xenografts lack critical features of human tumours. The 
development of more complex models for use in drug development has been 
limited due to lack of a method for monitoring tumour growth. Biophotonic 
imaging was, therefore, investigated to determine whether it is sufficiently 
sensitive and reproducible to be able to evaluate growth of disseminated 
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tumours in mice. The bioluminescent signal is dependent on the metabolism of 
luciferin by luciferase. Subcutaneous injection of luciferin was shown to produce 
a consistent signal in all injected mice. The bioluminescent signal was transient 
but reached a maximum intensity 6 minutes after injection and remained stable 
for about 4 minutes which defined the window during which measurements were 
taken. Sensitivity was shown to be dependent on the level of expression of 
luciferase by the cells. Injection of commercially available HCT116Luc cells, 
where the luciferase gene was inserted by a lentiviral system, was shown to 
allow detection of 10,000 cells in the lungs of mice. This sensitivity was about 10 
fold greater than was obtained by lipofectamine based gene transfection. When 
HCT116Luc cells were grown as subcutaneous xenografts in mice, an exponential 
growth pattern was easily detected by bioluminescence imaging and the 
reproducibility between mice was comparable to that routinely obtained by 
calliper measurements. 
 
Activity of encapsulated cisplatin was determined in a model of disseminated 
ovarian cancer. Rab25, a member of the RAS oncoprotein superfamily, is up-
regulated in around 80% of ovarian cancer samples compared to normal ovarian 
epithelium. Rab25 contributes to tumour progression by enabling the tumour 
cells to invade the extracellular matrix by altering the trafficking of integrin. 
Transfection of Rab25 into A2780 cells results in cells that can grow in the 
peritoneal cavity of mice. A2780-Rab25 cells were 4 fold resistant to cisplatin in 
vitro which confirms a previous observation that Rab25 expression in A2780 
makes them less sensitive to the induction of apoptosis in response to stress. 
A2780-Rab25 cells that express the luciferase gene (A2780-Rab25Luc) were 
injected into the peritoneal cavity of mice and growth was measured by 
biophotonic imaging. Exponential growth was clearly apparent at a stage at 
which no obvious abdominal distension was apparent. The disseminated A2780-
Rab25Luc tumour xenografts were less sensitive to cisplatin than are 
subcutaneous xenografts of A2780. This is the first study that suggests that 
Rab25 over-expression results in reduced drug sensitivity in vivo. In contrast, a 
very significant growth inhibition was observed when mice were treated with an 
equivalent dose of encapsulated cisplatin regardless of whether it was 
administered by the intraperitoneal or subcutaneous route. These results are 
very encouraging since they confirm the enhanced activity of encapsulated 
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cisplatin and also demonstrate the value of biophotonic imaging for 
measurement of tumour growth in vivo. 
 
Pharmacodynamic measures of drug activity in vivo in animal models are often 
based either on measures of surrogate tissue response or on single measures on 
tumour tissue removed at the end of the experiment. Biophotonic imaging in 
vivo allows the translation of reporter assays used in cell lines in vitro to studies 
of tumour response in vivo. A plasmid was prepared that links the p53 
transcriptional response element to the luciferase gene and it was then 
transfected in to A2780 cells which express wild type p53. Stable transfectants 
of A2780p53Luc were treated with cisplatin, doxorubicin and paclitaxel and 
induction of p53 determined by bioluminescence and confirmed by Western 
blotting. A very low bioluminescent signal was present in untreated cells and a 
clear dose dependent increase in bioluminescence was seen in response to all 
three drugs. When A2780p53Luc cells were grown as subcutaneous xenografts 
the bioluminescent signal was significant in untreated tumours but was markedly 
increased 24 hours after treatment of the mice with cisplatin. Induction of p53 
in the tumours was confirmed by immunohistochemistry and this also confirmed 
significant expression of p53 in untreated tumours.  
 
The possible implications of these findings for the improved delivery of cisplatin 
are discussed. 
 
5 
Table of Contents 
 
Abstract ...................................................................................... 2 
List of Figures .............................................................................. 13 
Acknowledgement ......................................................................... 17 
Author’s declaration ...................................................................... 18 
Definitions/Abbreviations ................................................................ 19 
1 General Introduction ................................................................ 22 
1.1 Cancer: A global problem ..................................................... 22 
1.2 Overview of chemotherapy .................................................... 23 
1.2.1 Treatment failure ......................................................... 24 
1.2.2 New drugs .................................................................. 24 
1.2.3 Need to improve current drugs .......................................... 25 
1.3 Cisplatin .......................................................................... 26 
1.3.1 Mechanism of action of cisplatin ........................................ 26 
1.3.2 Limitations of cisplatin chemotherapy ................................. 28 
1.4 Platinum analogues ............................................................. 30 
1.5 Drug delivery .................................................................... 32 
1.5.1 Polymer based drug delivery systems .................................. 35 
1.5.2 Lipids based drug delivery systems ..................................... 35 
1.5.3 Nanoparticle albumin based drug delivery system ................... 36 
1.6 Cisplatin based drug delivery systems ....................................... 38 
1.6.1 Polymer–cisplatin conjugates ............................................ 38 
1.6.2 Polymeric micelles based drug delivery system for cisplatin ....... 39 
1.6.3 Liposome based drug delivery system for cisplatin .................. 41 
1.7 Aims of the thesis ............................................................... 43 
1.8 Cucurbiturils: The drug delivery system .................................... 43 
6 
1.9 Layout of the thesis ............................................................ 47 
2 Materials and Methods .................................................................. 50 
2.1 Tissue culture techniques ..................................................... 50 
2.1.1 Materials .................................................................... 50 
2.1.2 Methods ..................................................................... 50 
2.1.3 Cryopreservation of cells ................................................. 51 
2.1.4 Quantitation of cells ...................................................... 52 
2.1.5 Extraction of protein from cultured cells .............................. 53 
2.1.6 Estimation of protein concentration ................................... 53 
2.2 Chemosensitivity assay ........................................................ 54 
2.3 Western Blotting ................................................................ 55 
2.3.1 Materials .................................................................... 56 
2.3.2 SDS-PAGE ................................................................... 56 
2.3.3 Immunoblotting ............................................................ 57 
2.3.4 Immunodetection of proteins............................................ 57 
2.4 Animal experiments ............................................................ 58 
2.4.1 Materials .................................................................... 58 
2.4.2 Development of subcutaneous xenografts ............................. 58 
2.5 Molecular Biology Techniques ................................................ 59 
2.5.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) ....... 59 
2.5.2 Restriction digest.......................................................... 60 
2.5.3 Bacterial Transformation ................................................. 60 
2.5.4 Extraction of DNA ......................................................... 61 
2.5.5 Quantification of DNA .................................................... 62 
2.5.6 Transfection with DNA .................................................... 63 
3 Activity of cucurbituril encapsulated cisplatin in ovarian cancer ............ 64 
3.1 Introduction ..................................................................... 64 
7 
3.1.1 Cucurbit[7]uril encapsulated cisplatin ................................. 66 
3.2 Methods .......................................................................... 67 
3.2.1 Synthesis of CB[7]cisplatin ............................................... 67 
3.2.2 Cytotoxicity of CB[7]cisplatin in vitro .................................. 68 
3.2.3 Induction of p53 and PARP inhibition .................................. 68 
3.2.4 Activity of CB[7]cisplatin in vivo ........................................ 69 
3.3 Results ............................................................................ 70 
3.3.1 Cytotoxicity of CB[7]cisplatin in vitro .................................. 70 
3.3.2 Induction of p53 ........................................................... 73 
3.3.3 PARP Expression ........................................................... 73 
3.3.4 Activity of CB[7]cisplatin in A2780 xenografts ........................ 75 
3.3.5 Activity of CB[7]cisplatin in A2780/cp70 xenografts ................. 75 
3.3.6 Activity of CB[7]cisplatin in HCT116 xenografts ...................... 78 
3.4 Discussion ........................................................................ 80 
3.4.1 Activity of CB[7]cisplatin in vitro ....................................... 80 
3.4.2 Activity of CB[7]cisplatin in vivo ........................................ 82 
3.5 Conclusion ....................................................................... 83 
4 Pharmacokinetics of cucurbituril encapsulated cisplatin ...................... 85 
4.1 Introduction ..................................................................... 85 
4.2 Platinum analysis with Inductively Coupled Plasma–Mass Spectrometry 86 
4.2.1 Basic principles of ICP-MS ................................................ 86 
4.2.2 Study design: Validation of ICP-MS ..................................... 88 
4.2.3 Materials .................................................................... 90 
4.2.4 Methods ..................................................................... 90 
4.3 Pharmacokinetics of cucurbit[7]uril cisplatin .............................. 94 
4.3.1 Preparation of tissue samples ........................................... 95 
4.3.2 Preparation of plasma samples .......................................... 96 
8 
4.3.3 Data analysis ............................................................... 96 
4.4 Results: Method development and validation of ICP-MS .................. 97 
4.4.1 Linearity .................................................................... 97 
4.4.2 Accuracy and precision .................................................. 100 
4.4.3 Level of Quantitation .................................................... 102 
4.4.4 Stability .................................................................... 102 
4.5 Results: Validation of ICP-MS in cellular samples ......................... 103 
4.5.1 Optimum duration of drug exposure .................................. 104 
4.5.2 Platinum uptake by A2780 cells with CB[7]cisplatin ................ 105 
4.6 Results: Plasma pharmacokinetics of CB[7]cisplatin ..................... 105 
4.7 Results: Tumour and tissue platinum levels ............................... 110 
4.8 Discussion ....................................................................... 113 
4.8.1 Validation of ICP-MS ..................................................... 113 
4.8.2 Cellular pharmacokinetics of CB[7]cisplatin ......................... 115 
4.8.3 Plasma pharmacokinetics of CB[7]cisplatin .......................... 115 
4.8.4 Choice of biological matrix ............................................. 118 
4.8.5 Tissue pharmacokinetics of CB[7]cisplatin ........................... 119 
4.9 Conclusion ...................................................................... 121 
5 Activity of Cucurbituril encapsulated cisplatin in disseminated model of 
ovarian cancer ............................................................................ 123 
5.1 Introduction .................................................................... 123 
5.2 Biophotonic imaging ........................................................... 125 
5.3 Assessment of tumour growth in vivo by bioluminescence imaging .... 127 
5.4 Rab25 model of disseminated ovarian cancer ............................. 128 
5.5 Methods ......................................................................... 129 
5.5.1 Bioluminescence imaging of animals .................................. 129 
5.5.2 Development of A2780-Rab25Luc ...................................... 130 
9 
5.5.3 Growth and drug sensitivity of A2780-Rab25Luc in vivo ............ 131 
5.6 Results ........................................................................... 131 
5.6.1 Route of administration of luciferin ................................... 131 
5.6.2 Sensitivity of bioluminescence measurement in vivo ............... 132 
5.6.3 Effect of seeding density on tumour growth ......................... 134 
5.6.4 Quantitation of tumour growth ........................................ 135 
5.6.5 Effect of subcutaneous administration of cisplatin on tumour 
growth 136 
5.6.6 Cisplatin sensitivity of A2780-Rab25Luc in vitro ..................... 137 
5.6.7 Growth of A2780-Rab25 in mice........................................ 137 
5.6.8 Cisplatin sensitivity of A2780-Rab25Luc in vivo ...................... 139 
5.7 Discussion ....................................................................... 141 
5.7.1 Route of administration ................................................. 141 
5.7.2 Sensitivity of bioluminescence imaging ............................... 142 
5.7.3 Development of A2780-Rab25Luc model .............................. 143 
5.7.4 Cisplatin sensitivity of A2780-Rab25Luc .............................. 145 
5.7.5 Effect of CB[7]cisplatin on growth of A2780-Rab25 in vivo ........ 145 
5.8 Conclusion ...................................................................... 146 
6 Development of a pharmacodynamic marker of drug activity................ 148 
6.1 Introduction .................................................................... 148 
6.2 Methods ......................................................................... 150 
6.2.1 Construction of the plasmid ............................................ 150 
6.2.2 Transfection ............................................................... 154 
6.3 Cytotoxic drug treatment .................................................... 154 
6.3.1 Bioluminescence .......................................................... 154 
6.3.2 Western blotting ......................................................... 154 
6.3.3 Human tumour xenografts .............................................. 155 
10 
6.3.4 Immunohistochemistry .................................................. 155 
6.4 Results ........................................................................... 156 
6.4.1 Confirmation of the construct sequence .............................. 156 
6.4.2 Confirmation of transfection ........................................... 157 
6.4.3 Induction of p53 in vitro ................................................ 159 
6.4.4 Induction of p53 in vivo ................................................. 161 
6.4.5 Detection of p53 expression by IHC ................................... 163 
6.5 Discussion ....................................................................... 165 
6.5.1 The plasmid ............................................................... 165 
6.5.2 Characterisation of  p53 reporter in vitro ............................ 166 
6.5.3 Characterisation of p53 reporter in vivo .............................. 167 
6.6 Conclusion ...................................................................... 169 
7 General Discussion .................................................................. 170 
7.1 Cucurbituril encapsulated cisplatin ......................................... 170 
7.1.1 Further development of the delivery system ........................ 171 
7.2 Biophotonic imaging ........................................................... 171 
7.3 A2780-Rab25 model of disseminated human ovarian cancer ............ 172 
7.4 The p53 reporter ............................................................... 173 
7.5 Conclusion ...................................................................... 173 
Appendix 1 Buffers, solution and media .............................................. 174 
Appendix 2 Suppliers ..................................................................... 177 
Appendix 3 Antibodies and drugs....................................................... 179 
List of References ........................................................................ 180 
Published papers ......................................................................... 194 
11 
List of Tables 
Table 1.1:  Physical and structural characteristics of CB[n] homologues. ........ 45 
Table 2.1: Origin, source and growth conditions of cell lines ...................... 51 
Table 3.1: Cytotoxicity of cisplatin and CB[7]cisplatin in cell lines in vitro as 
determined by MTT based growth inhibiton assay. ................................... 71 
Table 3.2: Resistance factors of A2780/cp70 and MCP1 to cisplatin and 
CB[7]cisplatin  relative to A2780 cells as calculated from MTT based growth 
inhibition assays. .......................................................................... 71 
Table 3.3: Tumour doubling times for A2780 and A2780/cp70 xenografts 
following treatment with either saline, CB[7], cisplatin or CB[7]cisplatin. ...... 78 
Table 4.1: Accuracy and precision of ICP-MS with  calibration standards and 
quality control samples prepared in 1% plasma in 1% nitric acid solution. ...... 100 
Table 4.2: Accuracy and precision of ICP-MS with calibration standards made 
from prepared in  1% nitric acid in ultrahigh pure deionised water and quality 
control samples prepared in 1% plasma in 1% nitric acid solution. ............... 101 
Table 4.3:  Accuracy and precision of ICP-MS in 1% nitric acid in ultrahigh pure 
deionised water based matrix for calibration and quality control samples. ..... 101 
Table 4.4: Platinum accumulation in A2780 cells with increasing doses of 
cisplatin. ................................................................................... 104 
Table 4.5: Plasma platinum levels in mice treated with cisplatin  or 
CB[7]cisplatin. ............................................................................ 106 
Table 4.6: Pharmacokinetic parameters for cisplatin and CB[7]cisplatin when 
administered as single intraperitoneal injection in nude mice. ................... 108 
Table 4.7: Pharmacokinetic parameters of cisplatin 6mg/kg, 8mg/kg and 
CB[7]cisplatin when administered as single intraperitoneal injection in nude 
mice ........................................................................................ 110 
12 
Table 5.1: Quantitation of the bioluminescent signal (total flux) for the mice 
injected with luciferase transfected cells ............................................ 133 
Table 5.2: Drug sensitivity to cisplatin and CB[7]cisplatin of the parental ovarian 
cancer cell line A2780 and A2780-Rab25Luc. ........................................ 137 
Table 5.3: Increase in bioluminescent signal in A2780-Rab25Luc xenografts. .. 140 
Table 6.1: Bioluminescent signal (flux) emitted by the cells in each well upon 
treatment with cisplatin or DMSO  for 24 hours. .................................... 158 
13 
List of Figures 
Figure 1.1: Mechanism of action of cisplatin .......................................... 28 
Figure 1.2: Chemical structure of platinum compounds used in cancer 
chemotherapy. ............................................................................. 31 
Figure 1.3: Chemical structure of cucurbit[n]uril.. .................................. 44 
Figure 1.4: Crystallography images of cucurbit[n]uril homologues.. .............. 45 
Figure 1.5: A schematic representation of CB[7]cisplatin. .......................... 46 
Figure 3.1: Representative NMR spectra of CB[7] cisplatin  and CB[7] in distilled 
water.. ...................................................................................... 68 
Figure 3.2: MTT based growth inhibition assay for A2780 cells treated with 
cisplatin or CB[7]cisplatin. ............................................................... 72 
Figure 3.3:  MTT based growth inhibition assay for A2780/cp70 cells treated with 
cisplatin or CB[7]cisplatin. The results are mean of three replicates with the 
error bars representing S.E.M. .......................................................... 72 
Figure 3.4: Induction of p53 expression by cisplatin   and CB[7]cisplatin  in A2780 
cells ......................................................................................... 74 
Figure 3.5: Induction of PARP cleavage by cisplatin   and CB[7]cisplatin  in A2780 
cells ......................................................................................... 74 
Figure 3.6: Growth of A2780 xenografts following single intraperitoneal injection 
of saline, CB[7], cisplatin or CB[7]cisplatin ........................................... 76 
Figure 3.7:  Relative body weight of mice following single intraperitoneal 
injection of saline, CB[7], cisplatin or CB[7]cisplatin ................................ 76 
Figure 3.8:  Growth of A2780/cp70 xenografts following single intraperitoneal 
injection of saline, CB[7], cisplatin or CB[7]cisplatin. ............................... 77 
14 
Figure 3.9: Relative body weight of mice with A2780/cp70 xenografts following 
single intraperitoneal injection of saline, CB[7], cisplatin or CB[7]cisplatin ..... 77 
Figure 3.10: Growth of HCT116 xenografts following single intraperitoneal 
injection of saline, CB[7], cisplatin or CB[7]cisplatin ................................ 79 
Figure 3.11: Relative body weight of mice with HCT116 xenografts following 
single intraperitoneal injection of saline, CB[7], cisplatin or CB[7]cisplatin ..... 79 
Figure 4.1: Detection of the 3 platinum isotopes when prepared in a matrix of 1% 
nitric acid by ICP-MS. ..................................................................... 98 
Figure 4.2: Detection of the 3 platinum isotopes when calibration standards and 
quality control samples were prepared with 1% plasma in 1% nitric acid as 
measured by ICP-MS ....................................................................... 99 
Figure 4.3: Stability of platinum isotope in a matric containing 1% plasma in 1% 
nitric acid .................................................................................. 102 
Figure 4.4: Uptake of platinum by A2780 cells with increasing concentrations of 
cisplatin. ................................................................................... 103 
Figure 4.5: Platinum uptake by A2780 cells incubated with 5μM of cisplatin at 
increasing time ........................................................................... 104 
Figure 4.6: Platinum uptake by A2780 cells when incubated with cisplatin  or 
CB[7]cisplatin for varying time interval ............................................... 105 
Figure 4.7: Plasma platinum concentration measured at various times following 
single intraperitoneal dose of cisplatin or CB[7]cisplatin .......................... 107 
Figure 4.8: Plasma platinum concentration measured at various times following 
single intraperitoneal dose of either cisplatin (6mg/kg,   or 8mg/kg) or 
CB[7]cisplatin. ............................................................................ 109 
Figure 4.9: Platinum levels in A2780 and A2780/cp70  xenografts measured 
following single intraperitoneal injection of cisplatin or CB[7]cisplatin . ....... 111 
15 
Figure 4.10: Platinum levels in liver  and kidney  of mice treated with single 
intraperitoneal injection of cisplatin or CB[7]cisplatin . ........................... 111 
Figure 5.1: Bioluminescent signal (flux) obtained at various times after 
administration of D-luciferin to HCT116Luc tumour bearing mice ................ 132 
Figure 5.2: Bioluminescent signal (total flux) in the mice injected with luciferase 
transfected cells .......................................................................... 133 
Figure 5.3: Bioluminescent signal (flux) in mice measured at various times 
following subcutaneous injection of HCT116Luc cells at a range of seeding 
densities. .................................................................................. 134 
Figure 5.4: Tumour growth measured by bioluminescence following subcutaneous 
injection of HCT116Luc cells . .......................................................... 135 
Figure 5.5: Growth of A2780 xenografts following treatment with PBS or cisplatin 
(i.p or s.c). ................................................................................ 136 
Figure 5.6: Growth of A2780-Luc and A2780-Rab25Luc  cells in the peritoneal 
cavity of nude mice. ..................................................................... 138 
Figure 5.7: Growth of A2780-Rab25Luc cells as a disseminated tumour in nude 
mice measured by bioluminescence imaging ......................................... 139 
Figure 5.8: Body weight of mice bearing A2780-Rab25Luc disseminated tumours 
after treatment with PBS, cisplatin or CB[7]cisplatin . ............................. 140 
Figure 6.1: Schematic representation of development of bioluminescent reporter 
containing p53 reporter ................................................................. 150 
Figure 6.2: Restriction fragment of pLentip53RELuc2 plasmid DNA  using Ecor V 
restriction enzyme ....................................................................... 157 
Figure 6.3: Bioluminescence imaging of cells parental A2780 cells and A2780 
cells transfected with pLentip53RELuc2 or pLentiTATALuc2 . ..................... 158 
Figure 6.4: Induction of p53 in A2780pLenti6p53RELuc2 cells  and A2780 cells  
upon treatment with paclitaxel, doxorubicin or cisplatin.. ........................ 159 
16 
Figure 6.5: Bioluminescent images of the induction of luciferase gene expression 
in A2780pLenti6p53RELuc2 cells 24hours after treatment with increasing doses of 
cisplatin, doxorubicin or paclitaxel . .................................................. 160 
Figure 6.6: Bioluminescence imaging of induction of p53 in vivo in mice bearing 
A2780pLenti6p53RELuc2 tumours. ..................................................... 162 
Figure 6.7: Expression of p53 determined by immunohistochemistry in mice 
bearing A2780 tumours treated with PBS.. ........................................... 163 
Figure 6.8: Expression of p53 determined by immunohistochemistry in mice 
bearing A2780 tumours treated with cisplatin .. .................................... 164 
Figure 6.9: Expression of p53 determined by immunohistochemistry in mice 
bearing A2780 tumours treated with CB[7]cisplatin................................. 164 
 
 
17 
Acknowledgement 
I would like to thank my supervisors Prof Jim Cassidy and Dr Jane Plumb for their 
support and guidance throughout my project and even after moving on to other 
jobs.  I appreciate the assistance provided by all the members of O3 group; 
Fiona McGregor, Natividad-Roman Gomez and Alyson Sim in teaching me various 
laboratory techniques and for the useful discussions. I also thank Colin Nixon for 
guiding me with immunohistochemistry and all the members of central and 
biological services at Beatson Institute.  
I specially thank my research adviser and clinical mentor Prof Jeff Evans whose 
steadfast support has motivated me to complete my research and continued to 
help in my professional development. I extend my gratitude to our collaborators 
David Stirling and Prof Andrew Hursthouse at University of West of Scotland who 
were helpful in ICP-MS and Dr Nial Wheate at University of Strathclyde for 
providing us the novel drug. 
I thank my parents for giving their best for me without whom I would not be 
where I am. I am gifted to have Preethy as my wife who always stands by me in 
particular on occasions when I have doubted myself. I specially thank her for her 
patience and understanding when I spent long evenings and weekends in the labs 
away from my lovely daughter and son.  
I dedicate this thesis to my brother, Dr V Aravinth and my father-in-law,           
Dr G Subash whose untimely demises have left a huge vacuum in my life but 
remain a key driving force in all my endeavours. 
 
This work was funded by Cancer Research UK. 
 
18 
Author’s declaration 
I hereby declare that I am the sole author of this thesis. The body of work 
discussed in chapter 5 is partly that of my colleague Dr Gomez-Roman and partly 
done in collaboration. Unless otherwise stated all the other work presented in 
this thesis was performed by me. 
19 
Definitions/Abbreviations 
 
µL  Microlitre 
µg  Microgram 
µM  Micromole 
AUC  Area under concentration 
BLI  Bioluminescence imaging 
C  Celsius 
CB[7]  Cucurbit[7]uril 
Cmax  Maximum concentration 
CO2  Carbon dioxide 
DLT  Dose limiting toxicity 
DNA  Deoxyribo nucleic acid 
DMSO  Dimethylsuphoxide 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetracaetic acid 
FCS  Foetal calf serum 
HCl  Hydrochloric acid 
Hrs  Hours 
HNO3  Nitric acid 
ICP-MS Inductively coupled plasma mass spectrometry 
ICPS  Integrated counts per second 
In  Indium  
i.p  Intraperitoneal 
i.v   Intravenous 
kDa  Kilo Dalton 
Kg  Kilogram 
LLOQ  Lower limit of Quantitation 
20 
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T1/2  Half-time 
Tmax  Time to reach maximum concentration   
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1 General Introduction 
 
1.1 Cancer: A global problem 
Cancer remains the leading cause of mortality both in economically developed 
and developing countries with incidence of 12.7 million cancer cases worldwide 
and an associated mortality of 7.6 million lives in 2008. Overall the incidence of 
cancer continues to rise globally (Coleman, Quaresma et al. 2008; Ferlay, Shin et 
al. 2010). In the United Kingdom, the age standardised incidence rate for all 
cancers has increased by 20% in males (from 354/100,000 in 1975-77 to 
426/100,000 in 2007-09) and by 40% in females (from 265/100,000 in 1975-77 to 
370/100,000 in 2007-09) (www.cancerresearchuk.org/cancerstats). 
Significant improvements in the awareness and healthy life style, better 
screening programmes, novel surgical techniques, radiotherapy and modern 
cytotoxic and targeted agents have all resulted in improvement in cancer 
related survival rate. For example, population based screening programmes for 
breast cancer have clearly demonstrated a significant improvement in cancer 
related mortality (Broeders, Moss et al. 2012). The use of adjuvant 
chemotherapy and hormone therapy has  resulted in 57% reduction in the risk of 
death in women with oestrogen receptor (ER) positive, early stage  breast cancer 
(EBCTCG 2005). Similarly  downsizing of tumour with chemotherapy and better 
oncosurgical approaches  in patients with colorectal liver metastases have  
raised the hope of cure and long term disease eradication  in patients deemed to 
have  unresectable metastatic disease (Adam, Wicherts et al. 2009). 
Cumulatively this has led to fall in cancer related mortality in the UK, which has 
decreased by 11% from 219 to 189 deaths per 100,000 of population in 2007.  
Despite these advances cancer remains a major health burden and was 
attributed in 28% of deaths in the U.K. In 2010, there were 157,275 deaths in the 
U.K due to cancer indicating that cancer is a major health problem 
(CancerResearchUK 2012) (www.cancerresearchuk.org/cancerstats). 
Chapter 1   23 
1.2 Overview of chemotherapy 
Chemotherapy plays a vital role in the reduction of cancer related mortality 
although prevention and early detection of cancer along with combined modality 
treatments have all contributed to the reduction in deaths. The origin of 
cytotoxic chemotherapy dates back to 1942 when Goodman and Gilman observed 
that exposure to nitrogen mustard in the soldiers of First World War, resulted in 
lymphoid hypoplasia and myelosuppression. These pharmacologists injected the 
active component of nitrogen mustard into a patient with non–Hodgkin 
lymphoma and observed the regression of mediastinal and lymphatic mass 
(Gilman and Philips 1946; DeVita and Chu 2008). Despite the initial promising 
response this patient had progression of the disease after a few weeks. 
Nevertheless this observation had established that drugs could be used to treat 
cancer. In parallel, Sydney Farber and colleagues discovered that folic acid was 
required for DNA synthesis and depletion of folates in the body resulted in 
tumour regression. This discovery led to the development of aminopterin and 
methotrexate which was successfully used to treated acute leukaemia (Farber, 
Diamond et al. 1948). National drug screening programmes then resulted in 
screening a variety of natural compounds yielding an array of cytotoxics 
including camptothecins, actinomycin D, mercapto-purines and paclitaxel which 
were approved for clinical use once the issues with mass production were 
overcome (Chabner and Roberts 2005).  
The concept of curing cancer with combination chemotherapy was established 
by De Vita and colleagues, who used the combination of nitrogen mustard, 
vincristine, procarbazine and prednisolone (MOPP) to treat advanced Hodgkin’s 
disease and demonstrated complete remission in 81% of treated patients (Devita, 
Serpick et al. 1970). During the same period Skipper’s cell kill hypothesis that 
drugs achieve better cell-kill when the tumour burden is small and, eradicating 
micro-metastatic disease translates into better survival outcomes  led to the 
concept of adjuvant chemotherapy (Bonadonna, Brusamolino et al. 1976). 
Although Li and colleagues reported curing  gestational trophoblastic cancer 
with methotrexate (Li, Hertz et al. 1958), the concept of curing cancer with 
primary chemotherapy in solid malignancies was established by Lawrence 
Einhorn and his team who used the combination of cisplatin bleomycin and 
vinblastine and were able to cure 70% of patients with metastatic germ cell 
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cancer. To date, this cisplatin based chemotherapy remains a model of cure for 
treating solid malignancies (Einhorn 2002; Calabro, Albers et al. 2012). 
1.2.1 Treatment failure 
Conventional chemotherapeutics and drug discovery programs have been based 
on the principle that rapidly proliferating cancer cells are more susceptible to 
chemotherapy than normal cells. Whilst this principle still holds good, it is now 
apparent that cytotoxics kill all proliferating cells in a non-selective manner and 
this non-selective cell kill results in intolerable toxicities to normal tissues. 
Though the newer generation targeted agents are  thought to selectively target 
the aberrant cancer pathway they also result in significant toxicities, e.g. 
hypertension, thromboembolic disease and delayed wound healing noted with 
anti-angiogenic agents (Stone, Sood et al. 2010). These toxicities preclude the 
safe and effective delivery of many active cytotoxic drugs due to their narrow 
therapeutic index. In addition, cancer is a genetically and phenotypically 
heterogeneous disease  which is not reliant of single oncogenic pathway and is 
characterised by genomic instability with associated redundancies and crosstalk 
between the cell signalling pathways (Hanahan and Weinberg 2011). 
Cumulatively these properties result in tumour drug resistance and failure of 
treatment. 
1.2.2 New drugs 
Advances in the understanding of molecular biology of cancer and better drug 
screening process have resulted in the approval of number of novel 
chemotherapeutic agents. At least 68 drugs have been approved by the US FDA  
from 1990 till 2005  for the treatment of cancer (DiMasi and Grabowski 2007). In 
addition to the targeted therapies, most of the recently approved new drugs 
have been utilising drug delivery systems. Nano-particle albumin bound (nab-
paclitaxel) has proven to improve the tolerance and also the overall survival in 
patients with metastatic breast cancer. The clinical development of na-pacltaxel 
is discussed in detail in following sections. Besides drug delivery, antibody-
cytotoxic drug conjugates have also been successfully developed for the 
treatment of cancer. Trastuzumab emtansine (T-DM1) is an antibody-drug 
conjugate composed of emtansine, a derivative of anti-microtubule agent 
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maytansine and trastuzumab (Lewis Phillips, Li et al. 2008). T-DM1 combined the 
cytotoxic properties of the emtansine with the Her2 receptor targeted delivery 
of trastuzumab in patients with metastatic breast cancer and has resulted in 
improved progression free survival of these patients both in first line setting and 
in previously treated patients (Hammond, Hayes et al. 2010; Krop, LoRusso et al. 
2012; Hurvitz, Dirix et al. 2013).  Clearly these new drugs have resulted in an 
improvement of median survival of patients with cancer. In early 1990s,    5-
fluoro uracil (5-FU) was the only therapeutic option for patients with metastatic 
colorectal cancer with median overall survival was only 12 months. With the  
addition of oxaliplatin, irinotecan and biologicals namely bevacizumab and 
cetuximab, there have been incremental improvements in overall survival and  
the median survival has nearly doubled to 24 months (Venugopal and Cassidy 
2009).  
1.2.3 Need to improve current drugs 
Despite the advances in the understanding of cancer biology and the advent of 
molecularly targeted agents, cancer associated mortality is still high and there 
remains an unmet need to design better drugs to treat cancer.  The inability to 
accurately recapitulate the tumour microenvironment in preclinical cancer 
models, lack of specificity of the drug and absence of suitable pharmacodynamic 
marker are some of the frequently implicated causes for the failure of a novel 
drug (Sharpless and DePinho 2006). There is clearly a need to improve the 
processes involved in the preclinical evaluation of drug.  In addition to 
evaluating the aberrant molecular pathways in cancer and developing novel 
targeted therapy, targeted drug delivery to tumour is a strategy that can 
improve cancer treatment outcomes. Trastuzumab emtansine is a drug conjugate 
of trastuzumab and vinca alkaloid emtansine which has shown to be effective in 
breast cancer (Krop, LoRusso et al. 2012; Hurvitz, Dirix et al. 2013). Even before 
the advent of new era of cytotoxics Paul Ehrlich, the eminent German physician 
who coined the word chemotherapy, conceptualised the idea of “magic bullet” 
that would selectively target and destroy microbial organisms or tumour cells 
(Strebhardt and Ullrich 2008). Hence the focus is on finding novel ways to 
improve the currently available chemotherapeutics using drug delivery systems.  
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1.3 Cisplatin 
Cisplatin was discovered serendipitously by Barrett Rosenberg and colleagues 
from Michigan State University who, when investigating the growth effect of 
electromagnetic field on bacteria, observed that Escherichia coli ceased dividing 
and began to elongate when grown in an electrical chamber with platinum 
electrodes. This inhibition of cell division without an apparent reduction in the 
growth was attributed to the elution of platinum compounds from the platinum 
electrodes used in the chamber (Rosenberg, Van Camp et al. 1965).  Further 
experiments and analysis of platinum compounds led to the identification of cis-
diammine dichloroplatinum(II)  (cisplatin) as the compound that exerted the 
anti-proliferative actions.  Cisplatin, subsequently was demonstrated to have 
significant preclinical anti-tumour activity in mice with transplantable sarcoma 
(S180) and leukaemia L1210 (Rosenberg, Vancamp et al. 1969). Cisplatin was 
approved by the US Food and Drug Administration (FDA) for use as anti-cancer 
treatment in 1978 (Kelland 2007). 
Cisplatin is now a widely used chemotherapeutic agent in the treatment of a 
variety of malignancies including testicular, ovarian, lung, gastric and bladder 
cancers  and also in paediatric malignancies (von der Maase, Hansen et al. 2000; 
Einhorn 2002; Schiller, Harrington et al. 2002; Cunningham, Allum et al. 2006; 
Hennessy, Coleman et al. 2009). Treatment with cisplatin based chemotherapy 
regimen results in cure in 70% of patients with testicular cancer and, in early 
stage testicular cancer nearly 100% of patients can be cured (Jones and Vasey 
2003). In addition, cisplatin is used in palliative treatment of various other 
cancers with varying response rates.  
1.3.1 Mechanism of action of cisplatin 
Despite the extensive clinical experience with cisplatin, the precise mechanism 
of action of cisplatin is not clearly understood and it is widely accepted that the 
main target of cisplatin is DNA (Jamieson and Lippard 1999; Wang and Lippard 
2005; Kelland 2007). Cisplatin is a neutral charged moiety which needs to be 
activated in order to react with DNA, the key intracellular target. Cisplatin 
enters the cells by passive diffusion where it undergoes aquation. The 
extracellular compartment or serum has a high concentration of chloride ions 
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(90-100mM) compared to intracellular compartment (3-20mM). The high chloride 
concentration in serum stabilises the cisplatin which, following entry into cells, 
undergoes aquation reaction resulting in the loss of one or both of the chloride 
moiety of cisplatin. The mono-hydrated and di-hydrated cisplatin reacts readily 
with DNA and forms platinum adducts (Figure 1.1). The platinum atom of 
cisplatin binds covalently to the N7 position of the purine bases, primarily with 
guanine but also with adenine, to form intra-strand and inter-strand crosslinks. 
60-65% of the DNA-platinum adducts occurs at the same strand of the DNA (intra- 
strand) and 20-25% of crosslinks are between the purine bases at opposite 
strands (inter-strand).  Eventually the DNA-platinum adducts distort the helical 
structure of the DNA by unwinding and bending of the helix and evoke a variety 
of cellular responses  resulting in transcription inhibition, replication inhibition, 
cell cycle arrest, DNA damage all of which eventually culminates in  cellular 
apoptosis (Jamieson and Lippard 1999; Wang and Lippard 2005; Kelland 2007). 
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Figure 1.1: Mechanism of action of cisplatin 
 
1.3.2 Limitations of cisplatin chemotherapy 
The key limitations of cisplatin, as with most other cytotoxic chemotherapy, are 
toxicity and resistance both inherent and acquired. The cytotoxic action of 
cisplatin is not specifically targeted against tumour cells and all proliferating 
cells are targeted. This non-selective cytotoxic action results in significant 
clinical toxicities. The dose-limiting toxicity of cisplatin is nephrotoxicity as 
cisplatin is primarily excreted by kidneys. In addition to nephrotoxicity, other 
toxicities include ototoxicity resulting in sensori-neural deafness, emetogenicity, 
and neurotoxicity (Hartmann and Lipp 2003). Aggressive hydration with 0.9% 
saline before and after the infusion of cisplatin has significantly reduced the 
nephrotoxicity of cisplatin (Cornelison and Reed 1993). The use of effective anti-
emetics has attenuated the emetogenic side effects of cisplatin respectively 
(Marty, Pouillart et al. 1990; Hesketh, Grunberg et al. 2003). Cancer cells either 
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are inherently resistant to cisplatin or acquire resistance after a few cycles of 
treatment with cisplatin. Ovarian cancer has a good overall response rate to 
treatment with cisplatin, both in early stage and advanced stage disease, but 
the response is not sustained as the tumour eventually becomes resistant to 
cisplatin (Hennessy, Coleman et al. 2009).  Resistance to cisplatin can be 
multifactorial and  includes decreased cellular uptake, increased inactivation 
and degradation, increased DNA damage repair, decreased ability to induce 
apoptosis and increased cellular efflux of cisplatin (Siddik 2003; Galluzzi, 
Senovilla et al. 2012). 
Cisplatin enters cells through a non-saturable process of passive diffusion, and 
current evidence also suggests that the influx of cisplatin is mediated by high 
affinity copper transporter which is encoded by copper transporter (CTR1) gene. 
Deletion of CTR1 gene decreases the intracellular accumulation of cisplatin and 
results in increased resistance to cisplatin (Ishida, Lee et al. 2002; Wang and 
Lippard 2005; Kelland 2007). In addition to drug influx, efflux of platinum 
mediated by ATP binding cassette subfamily C2 (ABCC2) which is also known as 
multi-drug resistance protein 1 (MRP1) or canalicular multi-specific organic anion 
transporters (cMOAT) also appears to play a role in intracellular accumulation of 
cisplatin by promoting its efflux from the cells (Galluzzi, Senovilla et al. 2012). 
Inactivation of cisplatin even before their interaction with DNA by intracellular 
thiol-containing molecules has emerged as a key determinant of drug resistance 
to cisplatin (Siddik 2003; Galluzzi, Senovilla et al. 2012). Cisplatin, once inside 
the cells, does not primarily react with DNA but also with other nucleophiles 
including cysteine rich metallothionein and glutathione. Glutathione (L- γ-
glutamyl-L-cysteinyl-glycine; GSH), a non-protein thiol which is abundant in 
mammalian cells, acts as a reducing agent by scavenging free radicals and 
defends the cells from variety of xenobiotics. Cisplatin interacts with these 
sulphur containing molecules through conjugation and forms cisplatin-thiol 
conjugate which eventually deplete the levels of intracellular cisplatin (Siddik 
2003; Galluzzi, Senovilla et al. 2012). Even in early 1990s, cells with high levels 
of glutathione were shown to be resistant to cisplatin (Godwin, Meister et al. 
1992). Glutathione also protects the cells from cisplatin induced cytotoxicity by 
interaction with reactive oxygen species and anti-apoptotic proteins like Bcl2 
(Brozovic, Ambriović-Ristov et al. 2010). Despite the absence of understanding 
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of the precise mechanism of glutathione-cisplatin interaction, it is evident that 
glutathione does play a significant role in cisplatin resistance. 
Mismatch repair proteins (MMR) are DNA damage repair proteins which recognise 
and repair mismatched or damaged DNA. hMLH1, the human homologues of 
bacterial protein MutS, plays a vital role in cisplatin resistance and cells 
deficient of hMLH1 lose their ability to undergo apoptosis due to cisplatin 
induced DNA damage. This resistance to cisplatin could be acquired by 
epigenetic modification, primarily by demethylation (Brown, Hirst et al. 1997; 
Strathdee, MacKean et al. 1999; Plumb, Strathdee et al. 2000). Clinical studies 
have shown that such methylation of hMLH1 confers resistance to patients who 
are treated with cisplatin (Gifford, Paul et al. 2004).  
Malignant cells can also develop resistance to cisplatin through the increased 
repair of DNA damage. The key effector of the cytotoxic action of cisplatin is the 
platinum-DNA adduct and cells which repair or remove the platinum adducts 
from the DNA could remain free from the cytotoxic effects of cisplatin. 
Nucleotide Excision Repair (NER) pathway is the key pathway through which the 
platinum-DNA adduct, that alters the helical structure of DNA, is excised and the 
integrity of genome is maintained. Excision repair cross-complementation group 
1  (ERCC1), a NER protein dimerises with Xeroderma pigmentosa complex which 
eventually results in the excision of damaged DNA containing the platinum 
adduct (Martin, Hamilton et al. 2008). This NER pathway plays a significant role 
in mediation of cisplatin resistance and patients with lung cancer who have high 
expression of XRCC1 do not appear to derive clinical benefit when treated with 
cisplatin based chemotherapy (Olaussen, Dunant et al. 2006). The mechanisms of 
resistance to cisplatin discussed thus far is not exhaustive but gives an 
understanding of the reasons for treatment failure and allows us to evaluate the 
novel ways to improve the efficacy of cisplatin. 
 
1.4 Platinum analogues 
To overcome the toxicities of cisplatin and to circumvent chemo-resistance to 
cisplatin numerous analogues of platinum have been studied. However, to date, 
Chapter 1   31 
carboplatin and oxaliplatin are the only other platinum compounds that have 
been approved in clinical practice (Figure 1.2). As discussed in earlier sections, 
cisplatin undergoes aquation reaction and loses one or both of the chloride 
groups, which are called the “leaving groups”. The two ammine groups are 
called the “carrier ligands” which remain attached to the platinum, the warhead 
which forms adducts with DNA. Numerous strategies have been employed to 
modify the leaving group and carrier ligand of cisplatin with the hope of 
improving the stability and efficacy of cisplatin. 
 
Figure 1.2: Chemical structure of platinum compounds used in cancer chemotherapy. 
 
 
On the basis of the hypothesis that cisplatin toxicity is related to the speed of 
aquation reaction, it was thought that stabilising the leaving groups could 
decrease the toxicity of cisplatin. Hence the chloride groups were substituted by 
cyclobutane dicarboxylate ligands which are more stable than chloride        
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groups of cisplatin which resulted in the genesis of the new platinum  compound, 
carboplatin (Diammine[1,1-cyclobutanedicarboxylato(2-)-O,O’]platinum(II) 
(Figure 1.2). Carboplatin forms similar platinum-DNA adducts but at a slower 
rate and requires higher concentration of the drug to achieve cell kill (Harrap 
1985). However it differs from cisplatin in that the dose limiting toxicity is 
thrombocytopaenia with sparing of nephrotoxicity when administered according 
to patient’s renal function (Calvert, Newell et al. 1989). Carboplatin maintains a 
similar spectrum of anti-cancer activity as compared to cisplatin. Carboplatin is 
the mainstay in the treatment of ovarian cancer where it has replaced cisplatin 
as the platinum drug of choice (Konstantinopoulos Pa 2012). Carboplatin also 
demonstrates comparable clinical efficacy to cisplatin in non-small cell lung 
cancer (Schiller, Harrington et al. 2002; Hotta, Matsuo et al. 2004; Ardizzoni, 
Boni et al. 2007). 
Other researchers have modified the structure of cisplatin by amending the 
binding ligands in addition to replacing the leaving groups. Oxaliplatin            
(1R, 2R-diaminocyclohexane oxalatoplatinum [II]) is one such compound with a 
bulky carrier ligand (1,2,diaminocyclohexane-DACH) which exhibits improved 
and divergent anti-cancer activity in comparison with cisplatin (Figure 1.2). 
Oxaliplatin entry into the cells is relatively less dependent upon copper 
transporters (Holzer, Manorek et al. 2006) and the platinum-DNA adducts are not 
recognised by MMR proteins (Kelland 2007). In addition, oxaliplatin also exhibits 
cytotoxic actions against cells lines like L1210 and HT29 cells (which are 
resistant to cisplatin) indicating the divergent mechanistic action of oxaliplatin 
(Rixe, Ortuzar et al. 1996; Raymond, Chaney et al. 1998). Based on the 
convincing pre-clinical and robust clinical data, oxaliplatin is now standard 
chemotherapy in combination with fluoropyrimidines for the treatment of 
colorectal cancer (Engstrom, Arnoletti et al. 2009). Besides modifying the carrier 
ligands and leaving groups, attempts to improve platinum drugs were made by 
using platinum (IV) complexes and the most notable was satraplatin which has 
largely been unsuccessful in clinical practice (Choy, Park et al. 2008).  
1.5 Drug delivery 
A variety of other platinum based drugs namely nedaplatin, lipoplatin and 
picoplatin have been tested in clinical trials. However none of the newer 
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platinum analogues have gained wide spread clinical acceptance (Wheate, 
Walker et al. 2010). In order to augment the clinical efficacy of cisplatin 
advances have been achieved through modifying the chemotherapy partner of 
cisplatin. In ovarian cancer, the combination of cisplatin and paclitaxel resulted 
in a significant survival advantage compared to the combination of cisplatin and 
cyclophosphamide (Piccart, Bertelsen et al. 2000).  
Another approach to improve the efficacy of established chemotherapeutics is 
through improved drug delivery. The clinical efficacy and toxicity profile of 
doxorubicin has been significantly modified using drug delivery with pegylated 
liposomes. Pegylated liposomal doxorubicin (caelyx) is a licenced indication for 
the treatment of ovarian cancer and unlike doxorubicin, cardiac toxicity is not a 
major concern (Gordon, Fleagle et al. 2001). In addition to altered drug 
pharmacology, drug delivery systems can also increase the selective delivery of 
drugs to the tumour either by passive or active targeting (Danhier, Feron et al. 
2010). Passively targeted drug delivery systems exploit the inherent deficiencies 
in tumour vasculature and microenvironment. Active targeting relies on the 
knowledge of tumour biology and could also be termed ligand targeted 
therapeutics.  
Maeda and Matsumura reported that tumour vasculature has widespread 
fenestrations resulting in increased permeability through which macromolecules 
can extravasate from the blood vessel (Matsumura and Maeda 1986). In addition, 
due to poorly formed lymphatic drainage the macromolecular drug gets trapped 
in the interstitium. This unique patho-physiological phenomenon was termed as 
“enhanced permeability and retention” (EPR) effect and could be exploited for 
drug delivery. The macromolecular drug delivery system along with its drug 
permeates into the tumour where they are trapped due to poorly formed 
lymphatics and the drug dissociates preferentially into the tumour (Matsumura 
and Maeda 1986). The defective angiogenesis in the tumours results in wide gaps 
between the endothelial cells ranging from 400-600nm (Yuan, Dellian et al. 
1995). Matsumura and Meada observed that polymer-drug conjugate, SMANCS, 
which is a co-polymer of styrene and maleic acid (SMA) conjugated to cytotoxic 
drug, neocarzinostatin (NCS), exhibited tumoritrophic properties when compared 
to free drug (NCS) and the T1/2 of SMANCS was almost 20 times that of free NCS. 
They were then able to demonstrate that Evans blue dye tagged to albumin, due 
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to the large molecular size of albumin (68kDa), was preferentially deposited in 
these tumours than in normal skin or tissues (Matsumura and Maeda 1986).  
Conventional nanoparticles ranging from 5-15nm, due to their small size, are 
rapidly excreted from the body through renal clearance (Choi, Liu et al. 2007; 
Petros and DeSimone 2010). Conversely, if the drug carrier size increases 
towards micro-molar range they get deposited in the reticulo-endothelial 
systems primarily in the liver, spleen and bone marrow where they undergo 
sequestration. The average size of the sinusoids in the liver and spleen is 150-
200nm and the drug carriers should not be over this size in order to avoid 
sequestration (Wisse, Braet et al. 1996). The defective angiogenesis in the 
tumours results in wide gaps between the endothelial cells ranging from 400-
600nm (Yuan, Dellian et al. 1995). In order to exploit the defective tumour 
vasculature and EPR phenomenon, the size of the drug carrier should be within a 
specific range of 5-100nm (Cho, Wang et al. 2008). However this is a reductionist 
view of drug delivery and various other factors like the surface charge, shape 
and immunogenicity of the drug-carriers and unique characterises of the tumour 
micro-environment, pH and interstitial pressure play a significant role in the 
effective drug delivery (Petros and DeSimone 2010). Drug penetration in solid 
tumours is not uniform and is dependent on the distance from the blood vessel 
and while EPR phenomenon could increase the passive targeting of drugs the 
defective vasculature can also result in increased interstitial pressure which 
could also hamper drug delivery (Minchinton and Tannock 2006).  
Active targeting involves tagging a ligand to the drug delivery system which 
could then target the cancer cells that overexpress the receptors for the ligands. 
To date, the commonly used ligands are folic acid and transferrin. Rapidly 
dividing malignant cells express folic acid receptors which help in the 
proliferation and drug carriers attached to folic acid or folic acid receptor 
antibodies which then gets internalised through folate receptor mediated 
endocytosis. Overexpression of folic acid receptor is demonstrated in breast and 
ovarian cancer. This principle could also be used for conjugating 
chemotherapeutics as well as imaging agents (Hartmann, Keeney et al. 2007; 
Low, Henne et al. 2007; Salazar and Ratnam 2007).  Promising in vivo studies 
have demonstrated increased tumour delivery of doxorubicin when administered 
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as folate targeted liposomal derivative and clinical studies are awaited (Yamada, 
Taniguchi et al. 2008).  
Drug delivery systems are broadly divided into polymer based and lipids based 
systems and are briefly discussed in the following sections. However recently 
protein bound drug delivery systems have also been successful. 
1.5.1 Polymer based drug delivery systems 
The concept of polymer based drug delivery was established by Helmut Ringsdorf 
in 1975 wherein he elegantly explained that polymer backbone bound to 
“pharamacon” (the compounds which elicit the therapeutic response) or drug 
could be used to develop a pharmacologically active compound. Typically the 
drug delivery system consists of a water soluble polymer linked to the drug via a 
biodegradable linker and the strength of the linker influences the rate of release 
of the drug from the polymer chain (Ringsdorf 1975).  
Polymer-drug conjugates increase the circulatory half-life of the compounds and 
exploit the EPR effect in tumours (Maeda, Bharate et al. 2009). Cassidy and 
colleagues have demonstrated that polymer conjugated duanorubicin was 
preferentially deposited in tumour through EPR effect (Cassidy, Duncan et al. 
1989). In addition to decreasing the renal clearance and increasing the bio-
distribution of the payload, polymer-drug conjugates also increase the protein 
solubility, decrease the immunogenicity and reduce the receptor mediated 
clearance in the reticulo-endothelial system. Polymer-drug conjugates involve 
covalent bonding of the polymer to the active drug through a linker which is 
commonly a peptide sequence which could be broken in an acid pH, which is 
called lysosomotropic delivery. Currently the term polymer therapeutics 
encompasses polymer-drug conjugates, polymeric micelles and polymer–
protein/enzyme conjugates (Duncan 2006). Polyethyleneglycol (PEG), N-(2-
hydroxypropyl) methacrylamide (HPMA) and polyglutamic acid (PGA) are the 
commonly used polymers for drug delivery (Duncan 2006).  
1.5.2 Lipids based drug delivery systems 
Liposomes are microscopic vesicles that are made of phospholipid bilayer 
comprising a central aqueous core which can carry hydrophobic drugs. Liposomes 
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were discovered in 1965  by Bangham and colleagues and were initially termed 
as phospholipid spherules (Bangham, Standish et al. 1965). Liposomes, due to 
their physico-chemical properties, have been extensively researched as drug 
delivery systems. Liposomes have a size range of 50-250nm and have been used 
in the delivery of number of chemotherapeutics of which doxorubicin needs 
special mention. Consistent with other nanoparticle based drug delivery systems, 
liposomes also target the tumour passively through EPR effect. Liposome 
encapsulated doxorubicin was demonstrated to be non-inferior to free 
doxorubicin but with the advantages of reduced cardiotoxicity. However the 
pharmacokinetic profile was not superior to free doxorubicin and this was due to 
rapid clearance of the drug from circulation (Batist, Ramakrishnan et al. 2001). 
Liposomes could be rapidly cleared from circulation by the reticulo-endothelial 
system (RES) by a process called opsonisation. Adsorption of specific protein to 
the particles surface owing to their surface characteristics results in targeting 
the liposomes to the reticulo-endothelial system where they get sequestered. 
Covalent bonding or simple attachment of PEG moiety  to the liposomes or other 
nano-carrier, termed pegylation, alters the  physico-chemical property of the 
nano-carriers, which escape opsonisation and  eventual sequestration  by the 
reticulo-endothelial system (Howard, Jay et al. 2008). The pegylated liposomes 
are also called “stealth” liposomes due to evasion of immunological detection by 
reticulo-endothelial system. Unlike polymer based drug delivery systems, 
liposomes based drug delivery systems have  been reasonably  successful in 
clinical practice (Hofheinz, Gnad-Vogt et al. 2005).    
1.5.3 Nanoparticle albumin based drug delivery system 
In addition to conventional polymer based and lipid based DDS, novel DDS based 
on nanoparticle bound albumin (nab) have been shown to be clinically effective. 
Once such compound is ABI-007, nanoparticle albumin bound paclitaxel 
(Abraxane) with a mean diameter of 130nm. ABI-007 is produced by high 
pressure homogenisation of paclitaxel along with human serum albumin which 
results in nanoparticle colloidal suspension which is free of Cremophor, the 
solvent implicated in the hypersensitivity reactions associated with paclitaxel 
(Ibrahim, Desai et al. 2002).   
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Taxanes which include paclitaxel and docetaxel are commonly used 
chemotherapy in management of breast and lung cancers. In addition to the 
myelosuppression typically seen with cytotoxic chemotherapy, paclitaxel also 
causes hypersensitivity reactions which is due to the non-ionic surfactant, 
polyoxyethylated castor oil (Cremophor EL)(Weiss, Donehower et al. 1990). 
Despite pre-medication with  steroids  and better management of 
hypersensitivity reactions, safe and effective administration of paclitaxel is still 
restricted due to hypersensitivity reactions (Markman, Kennedy et al. 2000). In 
addition to hypersensitivity reactions, neurotoxicity is a recognised toxicity of 
cremophor, and these adverse events related to the solvent are not unique to 
paclitaxel. Various other non-ionic solvents used in the formulation of 
hydrophobic drugs namely polysorbate and Teewn20 have also been implicated 
to cause adverse events (ten Tije, Verweij et al. 2003).  Research efforts to find 
a paclitaxel formulation which is free of cremophor led to the development of 
ABI-007.  
1.5.3.1 Clinical experience with nanoparticle albumin bound 
paclitaxel 
Phase I clinical trials with ABI-007 established the maximum tolerated dose 
(MTD) as 300mg/m2 for 3 weekly regimes and 150mg/m2 for weekly regimes 
which is 70-80% higher than the reported MTD for standard paclitaxel (Ibrahim, 
Desai et al. 2002; Sparreboom, Scripture et al. 2005). Comparative preclinical 
and clinical pharmacokinetic analysis of ABI-007 and paclitaxel revealed that 
paclitaxel clearance  and volume of distribution was significantly higher for ABI-
007  than standard paclitaxel, underpinning a distinct pharmacokinetic profile 
for ABI-007 (Sparreboom, Scripture et al. 2005). Phase III clinical trial comparing 
ABI-007 with paclitaxel in metastatic breast cancer has been conducted where 
the dose of ABI was 270mg/m2. The overall response rate was significantly higher 
in patients treated with ABI-007 than standard paclitaxel; 33% versus 19% 
respectively, p=0.001. Median time to progression was significantly longer for 
ABI-007 treated patients (23.0 versus 16.9 weeks, HR: 0.75; P=0.006) when 
compared to paclitaxel treated patients (Gradishar, Tjulandin et al. 2005). 
Notably, significantly lower incidence of grade IV neutropaenia was seen with 
ABI-007 than paclitaxel (9% versus 22%, p<0.001) and none of the ABI-007 treated 
patients experienced severe (grade3/4) hypersensitivity reactions. ABI-007 has 
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been approved in metastatic breast cancer patients who have progressed after 
anthracycline based chemotherapy (Yamamoto, Kawano et al. 2011). On the 
basis of these promising results, ABI-007 is being evaluated in other tumour sites 
where taxanes chemotherapy has shown efficacy. 
1.6 Cisplatin based drug delivery systems 
A number of research groups have attempted to improve the delivery of 
cisplatin. These studies include a wide range of drug delivery systems which 
include both the polymer based and lipid based drug delivery systems. 
1.6.1 Polymer–cisplatin conjugates 
AP5280 is a polymer–platinum conjugate which was produced by the reaction 
between HPMA-containing peptidyl side chain and cisplatin in a multistep 
process. The molecular weight of AP5280 is 28kDa and the platinum loading is 
approximately 8%. As with other polymer-drug conjugates, the pharmacokinetic 
analysis indicated prolonged systemic exposure of the drug (platinum) and this 
was associated with reduced toxicity (Gianasi, Wasil et al. 1999; Lin, Zhang et 
al. 2004). The release of platinum from the polymer was facilitated by acidic 
milieu found in hypoxic regions of tumours and intracellularly in lysosomes.  
Phase I study of AP5280 in patients with refractory cancers was conducted in two 
centres in Netherlands and France, and patients were treated with three weekly 
infusion of AP5280 in 1 litre of 5% dextrose over 1 hour. Doses ranging from 90 
mg Pt/m2 to 4500 mg Pt/m2 were evaluated in 29 patients. Nausea and vomiting 
was noted at dose of 4500 mg Pt/m2 which was deemed as the maximum 
tolerated dose (MTD) and 3300 mg Pt/m2 was the recommended dose (RD) for 
phase II trials. There was a dose proportional increase in AUC and Tmax of 
platinum but this correlation was not pronounced in Pt-DNA adduct formation. 
Despite the favourable pharmacokinetic profile, the Pt-DNA adduct formation 
was significantly lower compared to standard cisplatin thereby raising questions 
about its clinical efficacy. It has to noted that although the doses appear to be 
high, the actual platinum content in these polymer conjugates was less than 10% 
(Rademaker-Lakhai, Terret et al. 2004). 
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AP5346 (ProLindac) is a pro-drug comprising a linear polymer and DACH platinum 
(the active component of oxaliplatin) attached together by a peptidyl linker. 
Preclinical studies of AP5346 in mice bearing melanoma and ovarian cancers 
revealed substantially higher platinum delivery both to tumour and DNA when 
compared with oxaliplatin. In vitro, there was a conclusive evidence of platinum 
release at pH 5.4 when suspended in dextrose (Rice, Gerberich et al. 2006). In 
the phase I study of AP5346, doses from 40 mg/m2 to 1280mg/m2 administered in 
3 out of 4 weeks were explored and the commonly noted adverse events were 
nausea, vomiting and hypersensitivity reactions. Patients who did not get 
pre/post hydration also experienced nephrotoxicity and one patient died of 
renal failure which was related to AP5346. Even in this group of heavily pre-
treated patients, two of 15 evaluable patients achieved partial response. The 
MTD of AP5346 was established as 900 mg/m2 (Campone, Rademaker-Lakhai et 
al. 2007). A subsequent phase II exploring different schedules of AP5236 in 
patients with platinum resistant ovarian cancer was reported to show CA125 
marker response in more than 10% of the 23 patients. However the final results 
of this trial is yet to be published (Nowotnik and Cvitkovic 2009).  
1.6.2 Polymeric micelles based drug delivery system for cisplatin 
Polymeric micelles incorporating cisplatin has been shown to have effective anti-
tumour activity. Polymeric micelles containing cisplatin was formulated through 
polymer-metal complex formation between cisplatin and block polymers             
(polyethylene glycol and polyglutamic acid) with a size of 23nm. Nishiyama and 
colleagues published the results of their experiments in nude mice bearing Lewis 
lung carcinoma and C26 (murine colon carcinoma cell line) which were treated 
with cisplatin-incorporated polymeric micelles. Mice treated with cisplatin-
incorporated polymeric micelles demonstrated significant anti-tumour activity 
and increased tumour platinum accumulation through EPR effect. The platinum 
circulation time in the plasma was also prolonged (Nishiyama, Okazaki et al. 
2003). Subsequent studies of cisplatin incorporated polymeric micelles in mice 
also demonstrated that there was decreased incidence of nephrotoxicity and 
neurotoxicity and increased anti-tumour activity in comparison with standard 
cisplatin (Uchino, Matsumura et al. 2005). 
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A phase I clinical study of cisplatin–incorporated polymeric micelles (NC-6004) 
has been recently published. Patients with advanced malignancies who had 
failed standard therapy with adequate haematological, renal and hepatic 
functions were administered NC-6004 as an one hour infusion, every three weeks 
starting at a dose of 10mg/m2. Unexpectedly, higher proportion of patients 
developed hypersensitivity reactions from dose level 90mg/m2 onwards and 
patients also experienced nephrotoxicity at 40mg/m2 which warranted post-
infusion hydration (1.0 to 1.5 litres of fluid over 2 hours). In view of the 
nephrotoxicity and hypersensitivity reactions, although dose level beyond 
120mg/m2  was not explored, the MTD was established as 120mg/m2  and 
recommended dose for phase II studies was estimated to be  90mg/m2 
(Plummer, Wilson et al. 2011).  Hypersensitivity reactions occurred in six out of 
17 patients and one patient treated at 120mg/m2 suffered hypersensitivity 
despite prophylaxis with dexamethasone, chlorphenamine and ranitidine, which 
was hypothesised to be secondary to plasma protein-bound cisplatin.   
The plasma levels of ultra-filterable free platinum species including cisplatin and 
micellar platinum were measured. The pharmacokinetic parameters, however, 
were notable. In total plasma platinum, the AUCinf was 11 fold higher for NC-
6004 in comparison with published data for cisplatin.  The T1/2 was longer and 
clearance (Cl) was shorter indicating prolonged systemic circulation of platinum 
in plasma. Notably, both the T1/2 and AUCinf of ultra-filterable platinum was 
longer with NC-6004.  The value of micellar platinum mirrored the value of total 
platinum. The author conclude that the reduced Cmax has resulted in 
attenuated nephrotoxicity whereas the prolonged circulation of free platinum  
has resulted in  enhanced anti-tumour activity(Plummer, Wilson et al. 2011). 
These data indicate the sustained and controlled release of cisplatin from the 
drug delivery system. Clearly the hypersensitivity reactions and nephrotoxicity 
have reduced the therapeutic index of this drug although preclinical studies did 
not show significant nephrotoxicity in mice. Better ways to reduce the 
hypersensitivity reactions and nephrotoxicity are required to optimise this 
compound in light of the favourable pharmacokinetic profile. 
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1.6.3 Liposome based drug delivery system for cisplatin 
1.6.3.1 Liposomal cisplatin  
Liposomal cisplatin, lipoplatin was formed from cisplatin and liposomes based on 
methoxypolyethylene glycol-disteaoryl phophatidylethanolamine (mPEG2000-
DSPE), dipalmitoyl phosphatidyl glycerol (DPPG) and soy phosphatidyl choline 
(SPC-3) (Boulikas 2009; Stathopoulos 2010). In vivo experiments in rats which 
were administered lipoplatin (30mg/kg) intraperitoneally, demonstrated the 
absence of nephrotoxicity in comparison with cisplatin. In immunodeficient mice  
with human  breast and prostate cancer xenografts, the anti-tumour activity was 
maintained (Boulikas 2004). Initial phase I studies established the MTD as 
125mg/m2 and combination studies were done with 5FU at this dose level 
(Stathopoulos, Boulikas et al. 2005).  Preliminary comparative pharmacokinetic 
analysis  between lipoplatin and cisplatin when administered in combination 
with 5-Fluorouracil revealed an interesting pharmacokinetic profile whereby 
lipoplatin had significantly shorter T1/2 and increased clearance(CL) than 
cisplatin (Jehn, Boulikas et al. 2007). However, the dose of lipoplatin was only 
100mg/m2 in this study which was far lesser than the updated MTD either as 
monotherapy or a as combination. The result of the dose escalating phase I trial 
of liposomal cisplatin in patients with advanced cancer was recently reported.  
The starting dose of lipoplatin was 125mg/m2 and the final MTD was derived as 
300mg/m2 when administered intravenously every two weeks as monotherapy  
and  200mg/m2 when administered in combination with paclitaxel (Stathopoulos, 
Rigatos et al. 2010).  Lipoplatin in combination with gemcitabine has shown 
comparable activity to gemcitabine and cisplatin in patients with advanced non-
small cell lung cancer (Mylonakis, Athanasiou et al. 2010). A randomised phase III 
trial was conducted in patients with advanced non-small cell lung cancer where 
patients were randomised to the combination of lipoplatin (200mg/m2) plus  
paclitaxel (135mg/m2) [Arm A] or cisplatin (75mg/m2) plus paclitaxel 
(135mg/m2) [Arm B] administered intravenously every two weeks (Stathopoulos, 
Antoniou et al. 2010). The primary endpoint was toxicity analysis and there was 
a significant reduction in cisplatin associated toxicity namely nephrotoxicity 
(6.1% in Arm A versus 40% in Arm B, P<0.001), neutropaenia (33.3% in Arm A 
versus 45.2% in Arm B, P=0.017) and nausea/vomiting (32.5% in Arm A versus 
45.2% in Arm B, P=0.042). Although the overall response rate was numerically 
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higher in lipoplatin compared with cisplatin (58.8% versus 47.0%, P=0.073), the 
median overall survival was similar in both groups of patients (9 versus 10 
months, P=0.57). Pre-hydration was not required but lipoplatin had to be 
administered over an 8-hour infusion period (Stathopoulos, Antoniou et al. 
2010). Lipoplatin has been tested in combination with gemcitabine and 5FU in 
non-small cell lung cancers and squamous cell cancers of the head and neck but 
the results of these trials have not been published yet. Lipoplatin has 
demonstrated that the nephrotoxicity associated with cisplatin could be offset 
by the liposomal formulation without the loss of anti-tumour activity. However, 
robust clinical data to support optimum dosing and clinical efficacy is 
warranted. 
1.6.3.2  SPI-777 
Stealth liposomal cisplatin (SPI-077) is formulation of cisplatin encapsulated in 
liposomes containing methoxy-polyethyleneglycol (mPEG). SPI-077 exhibited 
remarkable in vivo  anti-tumour activity in colon  and lung cancer models with 
prolonged circulation time and increased tumour deposition of platinum   
(Newman, Colbern et al. 1999). A phase I clinical trial of pegylated liposomal 
cisplatin with dose up to 420mg/m2 administered intravenously every four weeks 
was conducted in patients with advanced stage cancer. Significant gastro-
intestinal and renal toxicities were not seen. Consistent with in vivo data, the 
pharmacokinetic profile in patients indicated that liposomal delivery of cisplatin 
resulted in increased circulation time and decreased clearance of platinum 
(Meerum Terwogt, Groenewegen et al. 2002). Phase II trial of SPI-077 in non-
small cell lung cancer did not demonstrate meaningful clinical response although 
no significant neurotoxicity or ototoxicity was noted. Similar results were also 
noted in a phase I/II trial in patents with inoperable head and neck cancer (Kim, 
Lu et al. 2001; White, Lorigan et al. 2006). Clinical development of this drug was 
abandoned due to these disappointing results and preclinical experiments were 
repeated to ascertain the reasons for failure. In tumour models of melanoma 
treated with SPI-077 (with a dose of 10mg/kg) or cisplatin (with a dose of 
10mg/kg), there was evidence of increased accumulation of platinum in tumour 
with total platinum in tumour homogenates (3.12 ± 1.2 µg/g for cisplatin 
compared with 11.9 ± 3.0µg/g for SPI-077) but unbound platinum was not 
detected with SPI-077. This indicates that although the liposomal drug delivery 
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system for cisplatin  was effective in tumour platinum delivery, it was not 
released from its liposomal formulation, as was also shown by Plummer and 
colleagues (Zamboni, Gervais et al. 2004; Plummer, Wilson et al. 2011). These 
data again illustrate the complexities faced with drug delivery and demonstrate 
that the drug-release from the drug delivery system is vital for anti-tumour 
activity of the drug. 
1.7 Aims of the thesis 
None of the drug delivery systems described for cisplatin is ideal and there is a 
clear need for new drug delivery systems. The aims of the thesis can be 
summarised as follows: 
1) To characterise the activity of a novel drug delivery system for cisplatin in 
a well characterised human ovarian cancer cell line both in vitro and in 
vivo. 
2) To compare the pharmacokinetics of free cisplatin with that of the drug 
delivery system. 
3) To evaluate the use of bioluminescence imaging in vivo to monitor growth 
and drug sensitivity of a novel model of disseminated ovarian cancer. 
4) To exploit bioluminescence imaging to develop a pharmacodynamic 
measure of cytotoxic drug activity in human tumour xenograft model in 
vivo.  
1.8 Cucurbiturils: The drug delivery system 
Cucurbiturils are macrocycles which are formed by acid catalysed condensation 
reaction between glycoluril and formaldehyde. Behrend and colleagues, in 1905, 
reported that condensation of glycoluril and formaldehyde in the presence of 
concentrated hydrochloric acid resulted in a polymeric substance which was 
named Behrend’s polymer (Freeman, Mock et al. 1981). Though it was shown to 
form inclusion complexes with various dyes including Congo red and methylene 
blue, it was not until 1981 when Mock and colleagues characterised the 
compound and discovered the hexagonal macrocyclic structure with a hollow 
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core containing 6 glycoluril rings and 12 methylene bridges. This compound was 
subsequently called cucurbit[6]uril (CB[6]) with molecular formula of 
C36H36N24012 (Mock and Shih 2002). It is a pumpkin shaped molecule with a wider 
cavity and a narrow portal on both sides. Hence it derived its name from 
cucurbitaceae, the taxonomical name for the family of pumpkins or gourds. In 
simple terms, it could be described as a “Halloween pumpkin” which has been 
hollowed out in the centre with holes drilled at the top and bottom. 
Cucurbiturils are characterised by hydrophobic cavity which is capable of hosting 
a variety of guest molecules and hydrophilic carbonyl lined portals which serve 
as entry and exit points for the cavity (Jason, Pritam et al. 2005). 
Kim and colleagues and other researchers (Kim, Jung et al. 2000; Day, Arnold et 
al. 2001), characterised cucurbit[6]uril and developed other homologues namely 
cucurbit[n]urils (n=5,7,8) with “n” denoting the number of glycoluril rings 
(Figure 1.3). In brief, in variation with the initial synthesis of cucurbit[6]uril 
where higher temperature was used, reaction between glycoluril and 
formaldehyde catalysed by sulphuric acid at 75-90oC for 24 hours resulted in a 
mixture of cucurbit[n]uril family. The resultant cucurbituril homologues (CB[5], 
CB[7] and CB[8]) were then separated by fractional crystallisation and 
characterised by X-ray crystallography. The ratio of the different cucurbit[n]urils 
could be altered by varying the concentration of the acid and temperature of 
reaction. 
 
Figure 1.3: Chemical structure of cucurbit[n]uril, where “n” denotes number of glycoluril 
rings. 
 
Chapter 1   45 
The size of internal cavity and portal of the CB homologues increases with the 
number of glycoluril rings and a variety of organic compounds including but not 
restricted to ranitidine, proflavine, curcumin and platinum based agents could 
be encapsulated within the cavity of CB homologues. Similarly the solubility also 
varies between the cucurbit[n]uril homologues (Lee, Samal et al. 2003; Jason, 
Pritam et al. 2005; Kim, Selvapalam et al. 2007). The X-ray crystallography of 
cucurbituril homologues (CB[5], CB[7] and CB[8]) and their physical properties 
are shown in figure 1.4 and table 1.1. 
 
Figure 1.4: Top and side views of X-ray crystallography images of cucurbit[n]uril 
homologues. The red colour indicates carbonyl oxygen atoms lined portals (adapted from 
Jason, Pritam et al. 2005). 
 
 
CB homologue Portal width(Å) Cavity width(Å) Mass Solubility in 
water (mM) 
CB[6] 3.9 5.8 996.3 <0.05 
CB[7] 5.4 7.3 1162.4 3.5 
CB[8] 6.9 8.8 1328.4 <0.05 
Table 1.1:  Physical and structural characteristics of CB[n] homologues (Å=angstrom). 
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Cucurbit[7]uril exhibits many properties of an ideal drug delivery system. 
Cucurbit[7]uril is thermally stable and  study of host guest chemistry reveals that 
a complex of di-platinum and CB[7] is stable at temperatures up to 290oC 
(Kennedy, Florence et al. 2009). Homologues of cucurbit[7]urils  are also capable 
of slow release of carrier drugs like ruthenium complexes (Pisani, Zhao et al. 
2010). CB[7] is a biologically inert compound without inherent cytotoxic activity 
(Hettiarachchi, Nguyen et al. 2010) and maximum tolerated dose upon 
intravenous administration in mice was  250mg/kg (Uzunova, Cullinane et al. 
2010). 
Besides encapsulating various organic compounds, CB homologues in particular, 
CB[7] can encapsulate platinum compounds including cisplatin and oxaliplatin 
(Wheate 2008; Walker, Oun et al. 2011). Of note, the cavity of cucurbit[7]uril is 
adequate enough to  encapsulate cisplatin to form inclusion complex in 1:1 
ratio, and  is relatively most soluble of all the CB homologues. Cisplatin upon 
encapsulation within CB[7]  is completely within the cavity and when hydrolysed 
appears to be bound to the portals (Wheate 2008). These properties make CB[7] 
a suitable drug delivery system for cisplatin. A schematic representation of 
molecular modelling of CB[7]cisplatin with cisplatin encapsulated within the 
cavity of CB[7] is illustrated in figure 1.5. 
 
Figure 1.5: A schematic representation of CB[7]cisplatin. Cisplatin (central insert) is bound 
to the carbonyl lined portal of CB[7] (red bulb)  through four hydrogen bonds (green dotted 
line) from the ammine group of cisplatin. (Figure reproduced with permission from Plumb, 
Venugopal et al. 2012). 
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1.9 Layout of the thesis 
Chapter 2 describes the general methods used throughout these studies. 
Chapter 3 describes the activity of CB[7] encapsulated cisplatin. This study was 
carried out in collaboration with Dr Nial Wheate (Strathclyde Institute of 
Pharmacy and Biological Sciences, Glasgow), a chemist with expertise in 
platinum delivery systems. Very little was known about activity of cucurbituril 
encapsulated cisplatin but it was known that cucurbiturils were well tolerated 
by mice at doses well above those required for drug delivery (250mg/kg, Wheate 
personal communication). The cell line model chosen for this study was, the well 
characterised human ovarian cancer cell line A2780, and the cisplatin-resistant 
derivative, A2780/cp70 (Plumb, Strathdee et al. 2000). This model was 
established in the department and the mechanism of resistance to cisplatin, loss 
of DNA mismatch repair through loss of MLH1 expression had already been shown 
to be clinically relevant (Plumb, Strathdee et al. 2000). Furthermore A2780 cell 
line is very sensitive to cisplatin and shows a clear dose response to treatment 
when grown as a xenograft in nude mice and small changes in cisplatin activity 
resulting from encapsulation should be detectable. 
Chapter 4 describes the pharmacokinetics of cucurbituril encapsulated cisplatin 
in tumour bearing mice. Although the department had extensive experience of 
pharmacology associated with clinical trials there was no assay available for the 
estimation of cisplatin in biological samples. Cisplatin is a small molecule and is 
not suitable for the more traditional approaches to drug detection such as high-
performance liquid chromatography (HPLC). Measurement of free platinum 
metal by mass spectroscopy has been widely used to establish the 
pharmacokinetic properties of platinum compounds (Graham, Lockwood et al. 
2000). In order to detect the very low concentrations of platinum present in 
plasma and tumour samples the more sensitive Inductively Coupled Plasma Mass 
Spectroscopy (ICP-MS) has been used. This specialised equipment was not 
available in the department and the work was, therefore, carried out in 
collaboration with Professor Andrew Hursthouse (Professor of Environmental 
Geochemistry, School of Science, University of the West of Scotland, Paisley). He 
had extensive experience of elemental analysis but had no experience of 
elemental analysis of biological samples. This chapter, therefore, describes both 
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the development and validation of a method for the analysis of platinum and the 
application of the assay in a study of the pharmacokinetics of free and 
encapsulated cisplatin. 
Human tumour xenografts are widely used in drug development studies. They 
are attractive since they are based on cell lines derived from human tumours 
and are thus thought to represent the characteristics of these tumours when 
grown in vivo. Studies with cell lines in vitro can give valuable information about 
the mechanism of action of drugs but do not take account of the pharmacology 
of the drug or of the effects on normal tissues and physiological processes. 
Xenografts are not ideal models of human cancers. They lack the appropriate 
tumour vasculature and microenvironment. Alternative models including 
orthotopic tumour implantation and those that display disseminated tumour 
growth are attractive but have lacked a suitable method for estimation of 
tumour growth. Even for subcutaneous xenografts, calliper measurements of 
tumour size do not give a true representation of the viable tumour mass and may 
underestimate growth inhibition. The development of technology that allows 
biophotonic imaging in vivo provides a mechanism for monitoring tumour cell 
burden in these more complex models. This technology was available in the 
department and the application and optimisation of bioluminescence imaging to 
monitor tumour cell growth in vivo in mice is described in chapter 5. This work 
enabled the assessment of drug sensitivity in a disseminated model of ovarian 
cancer. The disseminated ovarian cancer model was developed by a colleague, 
Dr Natividad Gomez-Roman, who also carried out the drug sensitivity study in 
vivo. The results are included in this thesis since the drug sensitivity study was a 
collaboration designed to evaluate the activity of both free and encapsulated 
cisplatin and the results clearly demonstrate the value of the more complex 
model. 
Development of pharmacodynamic markers of drug activity is now an integral 
part of preclinical drug development. Whilst these assays are relatively easily 
applied to studies in vitro they do not readily translate to studies in animal 
models in vivo due to limited access to tumour tissue. In addition to 
measurement of tumour growth biophotonic imaging in vivo should allow the 
development of dynamic real-time markers of drug activity. Chapter 6 describes 
the development and evaluation of a luciferase based reporter of p53 activity 
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both in vitro and in vivo. The results are compared with those obtained by 
Western blotting and immunohistochemistry. 
The final conclusions of the body of work are presented in chapter 7  
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2 Materials and Methods 
Please refer appendix 1 for buffer and tissue culture media recipes, appendix 2 
for contact details of manufacturers and suppliers and appendix 3 for antibodies 
and drugs. 
2.1 Tissue culture techniques 
2.1.1 Materials  
Iwaki T75 sterile tissue culture flasks   Becton Dickinson 
Iwaki T25 sterile tissue culture flasks   Becton Dickinson 
Iwaki 6 well tissue culture plates      Becton Dickinson 
Iwaki 24 well tissue culture plates      Becton Dickinson 
Iwaki 96 well microtitre plates      Becton Dickinson  
Petri dishes (5cm, 10cm)     Bibby Sterlin 
Bijous (5mL)       Bibby Sterlin 
Pippette aid pippetor     Drummond scientific 
Costar pipettes (1mL, 5mL, 10mL, 25mL)  Corning, USA 
Disposable tips       Central services, Beatson 
Casy-1 cell counter      Scharfe system 
Nunc Cryotubes      Thermo scientific 
Growth medium (DMEM, RPMI)    Invitrogen 
Fetal calf serum       Invitrogen 
L-Glutamine       Invitrogen 
Trypsin 2.5%       Invitrogen 
Penicillin-Streptomycin     Invitrogen 
Blasticidin       Invitrogen 
Genetecin (G418)      Invitrogen 
Phosphate buffered saline (PBS)    Refer appendix 1 
Dimethylsulphoxide (DMSO)    Fisher 
Large centrifuge 4K15     Sigma 
 
2.1.2 Methods 
Tissue culture was done under aseptic conditions in a microbiological safety 
cabinet with vertical laminar flow hood. Adherent human cancer cell lines were 
used for routine tissue culture. Cells were propagated by suspending them in 
growth medium supplemented with foetal calf serum (10%) and glutamine (2mM) 
in 75 cm2 Iwaki flasks which were equilibrated with 5-10% CO2. The cells were 
allowed to attach and grow by incubating in a humidified incubator at 37ºC. The 
culture medium was changed after 3-4 days and cells were sub-cultured once a 
subconfluent monolayer was formed. 
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Subconfluent monolayer culture was trypsinised by aspirating off the old 
medium, rinsing the cell monolayer with PBS to wash off the serum and adding 
trypsin solution (10mL of 2.5% trypsin [10 x] in 90mL PBS containing 1mM EDTA) 
to the cells. The volume of trypsin solution was dependant on the area of the 
flask and approximately 0.05mL of trypsin per cm2 of flask was used. 
Subsequently the flask was left at 37ºC in humidified incubator for 2-3 minutes. 
The cells were examined under a microscope to confirm the detachment and 
then resuspended in growth medium to neutralise the trypsin. The cells were 
counted and aliquots of the cell suspension were added to flasks with fresh 
growth medium for further propagation.  Cells were regularly monitored for 
mycoplasma contamination.  
The source, origin and growth conditions of the cells are given in table 2.1 
Cell line Tumour type Source Growth conditions 
A2780 Ovarian 
adenocarcinoma 
Dr R F Ozols, Fox Chase 
Cancer center, 
Philadelphia, USA 
RPMI 1640+10% FCS, 
5% CO2 
A2780/cp70 Ovarian 
adenocarcinoma 
Dr R F Ozols, Fox Chase 
Cancer center, 
Philadelphia, USA 
RPMI 1640+10% FCS, 
5% CO2 
MCP1 Ovary Established “in house”  
(Strathdee, MacKean et 
al. 1999) 
RPMI 1640+10% FCS, 
5% CO2 
HCT116 Colon American Type Culture 
Collection (ATCC), 
Maryland, USA 
DMEM+10% FCS, 10% 
CO2 
Table 2.1: Origin, source and growth conditions of cell lines 
 
2.1.3 Cryopreservation of cells 
2.1.3.1 Materials 
Routine tissue culture materials     Refer section 2.1.1 
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-70ºC freezer      NuAire, U.K 
Liquid nitrogen freezer     Sanyo, U.K  
 
2.1.3.2 Method 
Adherent cells in exponential growth phase were trypsinised and resuspended in 
growth medium. The cells were centrifuged at 300g for 5 minutes at room 
temperature. The supernatant was aspirated and discarded and the cell pellet 
was resuspended at a density of at least 106/mL in growth medium containing 
DMSO (10%). 1mL aliquots of the cell suspension were transferred to labelled 
cryotubeTM vials.  Cells were cryofrozen in a two-step process. Cryotubes were 
placed in a polystyrene foam box which was wrapped in cotton wool and frozen 
overnight to -70oC in a freezer. Once the cells were frozen at -70ºC, the vials 
were transferred to isothermal dry storage liquid nitrogen freezer to be stored 
at -190ºC. 
Thawing of cryopreserved cells was done by placing the cryotube vial in a 
waterbath at 37ºC. The contents of the cryotube vial were transferred to an 
universal container, resuspended in warm growth media and then centrifuged at 
300g for 5 minutes at room temperature. The supernatant media containing 
DMSO was aspirated after which the cell pellet was resuspended in fresh growth 
media and seeded in a culture flask. After 24 hours, the cells were re-fed or sub-
cultured depending on their confluency. 
2.1.4 Quantitation of cells 
2.1.4.1 Materials 
Routine tissue culture materials     Refer section 2.1.1.1 
 
 
2.1.4.2 Method 
Subconfluent monolayer cultures were trypsinised and collected in growth 
medium. Cells were then centrifuged at 300g for 5 minutes and the cell pellet 
was resuspended in growth medium. 400µL of the cell suspension was added to a 
counting cup and 19.6mL of Casyton solution added.  They were counted in a 
CASYTM electronic cell counter. 
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2.1.5 Extraction of protein from cultured cells 
2.1.5.1 Materials 
PBS        Refer appendix 1 
Trypsin 0.25% solution     Refer appendix 1 
Protein lysis buffer      Refer appendix 1 
Complete protease inhibitor cocktail tablets  Roche diagnostics, U.K 
Large centrifuge 4K15     Sigma 
Refrigerated centrifuge 5415R    Eppendorf 
Soniprep 150        Thermo life sciences 
 
2.1.5.2 Method 
Growth medium from flasks containing a subconfluent monolayer culture was 
aspirated and the cells were washed twice with ice-cold PBS. Remnants of the 
PBS were aspirated and appropriate volume of protein lysis buffer was added to 
the cells and the cells incubated on ice for 20 minutes. Typically 100µL of 
protein lysis buffer was added to a 25cm2 volume flask. The lysed cells were 
then scrapped from the flasks and transferred to 1.5mL microfuge (Eppendorf TM) 
tubes which were placed on ice. Cells were sonicated with Soniprep 150 
Sonifier® (ultrasonic cell disintegrator).  The cell lysate was centrifuged in a 
bench top centrifuge at 12,000g for 30 minutes at 4ºC to remove cell debris.  
The supernatant, containing the protein, was collected and stored at -20ºC until 
further analysis. 
2.1.6 Estimation of protein concentration 
2.1.6.1 Materials 
Bovine serum albumin   Sigma Aldrich, U.K 
Bio-rad protein dye    Bio Rad laboratories 
UV/Vis spectrophotometer  Perkin Elmer 
Plastic cuvettes    Elkay Laboratory, U.K 
Deionised water    Millipore 
 
 
2.1.6.2 Method    
 
Estimation of protein concentration was carried out by a calorimetric assay 
based on Bradford dye binding procedure (Bradford 1976). Protein standards, at 
concentrations ranging from 0.2mg/mL to 1 mg/mL, were prepared with bovine 
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serum albumin to generate a standard curve. Protein samples, to be analysed, 
were diluted ten-fold with distilled water. 800µL of distilled water was added to 
plastic cuvettes to which 10µL of diluted protein samples was added. Finally, 
200µL of Bio-Rad protein assay dye reagent was added to all the cuvettes and 
the solution was thoroughly mixed by inversion. The absorbance was measured 
at a wavelength of 595nm with Parkin Elmer Lambda 25 UV/Vis 
spectrophotometer. UV WinlabTM software was used to determine the protein 
concentration.  
2.2 Chemosensitivity assay 
The drug sensitivity of cells was assessed using a tetrazolium dye-based 
microtitration assay (Plumb, Milroy et al. 1989). MTT (3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide), a yellow water soluble tetrazolium dye, is 
reduced by viable cells to a purple MTT-formazan dye which is insoluble in 
aqueous solution. The amount of MTT-formazan produced corresponds to the 
surviving cell number. Upon solubilisation with DMSO, the amount of MTT-
formazan produced can be determined spectrophotometrically, which provides 
an estimate of the surviving cell fraction. 
2.2.1.1 Materials  
Costar multichannel pipette    Corning International 
96-well microtitre plates, flat bottomed  Iwaki 
3-(4, 5-dimethylthiazol-2-yl)-2,  
5-diphenyltetrazolium bromide (MTT)   Sigma 
Sorensen’s glycine buffer     Refer appendix 1 
Labsystems multidrop 384 dispenser   Thermo Electron 
Plate reader       Molecular devices 
Routine tissue culture materials     Refer section 2.1.1 
 
 
2.2.1.2 Method 
A subconfluent monolayer culture was trypsinised, resuspended in growth 
medium. Cells were counted and diluted to the appropriate plating density 
(ranging from 1.5 to 10 x 103 cells/mL) in fresh growth medium. A multi-channel 
pipette was used to dispense 200µL of cell solution in to microtitre plates from 
columns 2 to column 11. 200µL of growth medium alone was added to columns 1 
and 12. Cells were allowed to attach and grow in a humidified incubator at 37ºC 
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for 2-3 days. Drug solutions with 8 different concentrations of drug in growth 
medium were freshly prepared by serial dilution with a starting concentration, 
which typically was 100µM. The concentrations of the drug were chosen such 
that the highest concentration would achieve 100% cell-kill and the lowest 
concentration would not result in cell-kill. The growth medium was removed and 
the cells in columns 2 and 11 were fed with drug free growth medium. The drug 
containing growth medium was added to the cells in columns 3 to 10 (4 
wells/concentration). The plates were then incubated in a humidified 
atmosphere at 37ºC for 24 hours. The medium was removed and replaced with 
200µL of fresh drug-free growth medium. After 2-3 days the cells were fed with 
200µL of fresh growth medium and 50µL of MTT was added to wells from column 
1 to column 11. The plates were wrapped in aluminium foil to protect from light 
exposure and incubated in a humidified atmosphere at 37ºC. After 4-6 hours of 
incubation with MTT, both medium and MTT were removed from all the wells. 
The purple MTT-formazan crystals were dissolved by the addition of 200µL of 
DMSO, which was dispensed with microplate dispenser. 25µL of Sorensen’s 
glycine buffer was added to all the wells in columns 1 to column 11 to shift the 
pH of the wells to 10.5 and the absorbance was recorded at 570nm in a 
microtitre plate reader. The absorbance was plotted in Y axis against drug 
concentration plotted in X axis and a graph was generated using software 
programme, Softmax PROTM. The mean absorbance from the wells in columns 2 
and 11 was used as a control and the IC50 was determined as the drug 
concentration that results in 50% reduction of the absorbance of the control. 
Each experiment was carried out in triplicate and repeated at least once. The 
results are presented as mean ± S.E.M of a representative experiment. 
2.3 Western Blotting 
Western blotting is an effective technique for immunodetection of proteins 
based on their molecular weight. Proteins, under denatured and reducing 
conditions (by addition of DTT and heating), are separated using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The addition of 
negatively charged SDS to the denatured proteins imparts a net negative charge 
to the proteins which when loaded on to a polyacrylamide gel are separated 
according to their molecular weight on applying electric current through the gel. 
A molecular weight marker dye is also loaded on to one of the lanes of the gel as 
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a guide to indicate the molecular weight of the separated proteins. The 
separated proteins are then transferred to nitrocellulose or polyvinylidene 
fluoride (PVDF) membrane and specific proteins can be identified by adding 
primary antibodies directed against them. This protein-antibody binding reaction 
can be amplified by addition of horse radish peroxidase (HRP) conjugated 
secondary antibody directed against the primary antibody, followed by addition 
of chemiluminescent substrate which emits a light signal that is captured with 
autoradiography. 
2.3.1 Materials 
NuPage MOPS running buffer    Invitrogen 
NuPage transfer buffer     Invitrogen 
NuPage SDS sample buffer     Invitrogen 
NuPage antioxidant      Invitrogen 
Ultrapure water      Millipore 
Dithiothreitol (DTT)      Sigma 
Novex X-Cell Sure-Lock minicell    Invitrogen 
Dri-Block heating block     Techne 
Whirlmixer vortex       Fisher 
Novex pre-cast polyacrylamide gels (4-12%, 10%) Invitrogen 
See-blue Plus 2 protein Standard    Invitrogen 
Running buffer      Refer appendix 1 
Transfer buffer      Refer appendix 1 
Blocking solution      Refer appendix 1 
Marvel milk powder      Premier foods, U.K 
Immobilin-P transfer membrane    Millipore 
3MM filter paper      Whatman International 
Antibodies – primary and secondary   Refer appendix 2 
Hulme Martin heat bag sealer    Jencons  
Rocking 4RT table       Luckham 
Rotatest R100 shaker     Luckham 
ECL Western detection reagent    Amersham Biosciences 
Fuji Super RX Medical X-ray Film    Fuji  
Hypercassette 18 x 24 cm      Amersham Biosciences 
X-OMAT 480 RA processor     Kodak 
 
 
2.3.2 SDS-PAGE 
The Novex mini-gel system was used for Western blotting. Proteins were 
separated according to their molecular weight using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) and analysed further by Western 
blotting. 100µg of protein extract, made up to volume of 65µL distilled water, 
was denatured and reduced by adding 25µL of NuPAGE (4X) SDS sample buffer 
Chapter 2   57 
and 10µL of DTT   followed by heating at 70ºC for 10 minutes.  Molecular weight 
marker (SeeBlue plus2 TM pre-stained standard) and 20µg of denatured protein 
sample were loaded to separates wells in NuPAGE polyacrylamide gel which was 
immersed in X-Cell Sure lock TM minicell tank filled with NuPAGE MOPS running 
buffer. The gradient of polyacrylamide gel was dependent on the molecular 
weight of proteins analysed and the commonly used gradients were 4-12% or 12% 
acrylamide gel. The gel tank was connected to a power pack and run at 200V for 
50 minutes at room temperature. 
2.3.3 Immunoblotting 
The proteins were transferred from the acrylamide gel to polyvinylidene fluoride 
(PVDF) microporous membrane (Immobilin-P TM transfer membrane) using semi-
dry electroblotting transfer method according to the manufacturer’s 
instructions. The transfer membrane was pre-wet in 100% methanol for 1-2 
minutes and then equilibrated with transfer buffer together with blotting paper 
and sponge pad. The gel and transfer membrane was sandwiched between the 
pre-wet blotting paper and sponge pads soaked in transfer buffer and, placed in 
a transfer unit. The transfer unit was then held vertically in a gel tank, with 
platinum electrodes, that was filled with transfer buffer and run at 30V for 1 
hour. This resulted in the transfer of negatively charged SDS-loaded protein from 
the gel to the transfer membrane.  The efficiency of the transfer was assessed 
by complete visualisation of the coloured bands of the molecular weight marker 
in the transfer membrane.  
2.3.4 Immunodetection of proteins 
Following transfer of proteins to transfer membrane, the unoccupied protein 
binding sites in the transfer membrane were blocked by gently agitating the 
transfer membrane in blocking buffer (Marvel plus Tween 20 in Tris buffered 
saline) at room temperature for 1 hour. The transfer membrane was then 
incubated overnight at 4ºC with primary antibody (with dilution as per appendix 
3), in sealed airtight plastic sleeve which was placed in an orbital shaker. The 
next day, the transfer membrane was rinsed and washed three times with 
washing buffer by gentle agitation in an orbital shaker for 10 minutes each. The 
transfer membrane was then incubated at room temperature for I hour, with 
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appropriate horse radish peroxidase conjugated secondary antibody which was 
diluted in blocking solution.  Following this process, the membrane was rinsed 
and washed three times as before with washing buffer. The visualisation of 
secondary antibody was enhanced by incubating the washed transfer membrane 
with Amersham ECL western blotting reagents for 1 minute and the light 
emission was detected by short exposure to blue light sensitive autoradiography 
film. The film was developed using Kodak X-OMAT 480 RA processor. 
2.4 Animal experiments 
2.4.1 Materials 
 
CD-1® athymic nude mice     Charles River 
25G needles       Becton Dickinson 
Syringes 1mL, 3mL      Becton Dickinson 
Balance       Mettler 
Vacutainer (EDTA bottles)     Becton Dickinson 
Small CO2 chamber      Vet Tech solution 
Calliper 
 
 
CD-1® athymic nude mice were obtained from Charles River laboratories. Mice 
were housed in a sterile environment in the biological services unit, Beatson 
Institute of Cancer Research. All the procedures were carried out under a UK 
Home office project licence.  
2.4.2 Development of subcutaneous xenografts 
2.4.2.1 Materials 
Routine tissue culture materials    Refer section 2.1.1 
Animal experiment materials     Refer section 2.4.1 
 
 
2.4.2.2 Method 
Cells were trypsinised, collected and centrifuged at 300g for 5 minutes. The 
supernatant was discarded the cell pellet was resuspended in sterile PBS to 
achieve  a concentration of 5-10 x 106 cells per 100µL. 100-200µL of the cell 
suspension was injected subcutaneously into the flank of immunodeficient nude 
mice using a 1mL syringe with 23G needle. Mice were inspected once every 2-3 
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days for general welfare and tumour growth. Once the mean diameter of the 
tumours had reached 5mm mice were used for experiments. Mice were 
randomised into groups of six and treated as specified in specific experiments. 
All handling and injections were carried out in a laminar flow hood under aseptic 
conditions. Mice were weight daily and tumour volumes determined by calliper 
measurements. The volume of the tumour was calculated using the formula (π/6 
X d2), where “d” is the mean of the two perpendicular diameters. 
2.5 Molecular Biology Techniques 
2.5.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR) 
Polymerase chain reaction is a useful tool to amplify specific DNA sequence. DNA 
of interest is denatured and annealed by subjecting to thermal cycles of heating 
and cooling. This denatured and annealed DNA when subjected to a reaction 
between appropriate combination of oligonucleotides, thermo stable Taq or DNA 
polymerase and Magnesium salts results in the exponential amplification of the 
DNA sequence of interest. The final product of PCR can be checked by agarose 
gel electrophoresis using ethidium bromide as DNA marker, which can be 
visualised by illumination under ultraviolet light. 
2.5.1.1 Materials 
Sterile water for injection     Braun 
Agarose       Bio-Rad 
TAE buffer       Refer appendix 1 
Ethidium bromide (0.625mg/mL)    NBS Biologicals 
Electrophoresis unit     Pharmacia, Biotech 
DNA ladder       Invitrogen 
Oligonucleotides      Promega 
Peltier Thermal Cycler DNA engine   Bio-Rad 
Agarose        Melford  
 
2.5.1.2 Method 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) was used to obtain 
the plasmids for recombination reaction by BIO-RAD tetrad peltier thermal 
cycle. Taq polymerase (0.5µL), primers (10µM), dNTP (10µM), MgCl2 (50µM) and 
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DNA (100nGµL) were mixed in a PCR tube and the machine was run at the 
following setting: 94ºC for 3 minutes, 94ºC for 45 seconds, 55ºC for 30 seconds, 
72ºC for 90 seconds, 72ºC for 10 minutes and finally cooled to 4ºC overnight.  
The final product from PCR was analysed with agarose gel electrophoresis (1.5% 
agarose gel with ethidium bromide, run at 50 volts for 45 minutes) and the DNA 
bands were visualised with UV transilluminator. 
2.5.2 Restriction digest 
2.5.2.1 Materials 
Restriction enzymes and buffers    Invitrogen 
RT-PCR materials      Refer section 2.5.1.1 
2.5.2.2 Method 
DNA was digested by mixing 1µL each of appropriate restriction digest enzyme 
and buffer along with 8µL of DNA in a vortex mixer and incubating at room 
temperature for 1 hour. The digested fragments were analysed by agarose gel 
electrophoresis (1.0% agarose gel with ethidium bromide, run at 100V for 45 
minutes). Electrophoresis gels were prepared by dissolving electrophoresis grade 
agarose in TAE buffer and boiling in microwave at full power for 1-2 minutes. 
Once the solution was cooled to 50ºC, 5µg/mL of ethidium bromide was added 
and gel was allowed to solidify in a gel former. 
The bands were assessed for the appropriate fragment size by correlating against 
the bands from the DNA ladder and were subsequently imaged with SYNGENE gel 
visualisation system. 
2.5.3 Bacterial Transformation 
2.5.3.1 Materials 
Transformation competent E.coli cells   Invitrogen 
SOC medium       Invitrogen  
LB broth       Central services, Beatson 
Rocking incubator      Innova 
Ampicillin       Sigma 
Kanamycin       Sigma 
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2.5.3.2 Method 
Bacterial transformation was performed using One Shot® Stbl3 TM chemically 
competent E.coli cells or other cells as specified by manufacturer. One vial of 
E.coli cells was thawed on ice and the DNA (prepared from recombination 
reaction) was added to the vial and mixed gently. The mixture was placed on ice 
for 30 minutes and the cells were then heat-shocked for 45 seconds at 42ºC. The 
vial was removed from the water bath and placed on ice for 2 minutes. 250µL of 
pre-warmed SOC medium was added to the vial. The vial was closed tightly and 
placed in a shaking incubator to be shaken horizontally at 225rpm for 1 hour at 
37ºC. The contents of the vial were streaked on pre-warmed selective agar plate 
with appropriate antibiotics (chosen according to the resistance cassette in the 
plasmid) and incubated overnight at 37ºC. The volume used for streaking varied 
from 25µL to 250µL according to the density of colony formed. The next day, 
colonies were picked and cultured overnight in LB medium, containing 
appropriate antibiotics, by agitating the medium in a shaking incubator at 37ºC. 
The broth was centrifuged at 1200g for 15 minutes at room temperature to 
obtain a bacterial pellet, which was used for DNA extraction as per 
manufacturer’s instruction (e.g. Qiagen). 
 
2.5.4 Extraction of DNA 
2.5.4.1 Materials 
DNA extraction kit       Qiagen 
Micro centrifuge tubes      Eppendorf 
Refrigerated centrifuge      Eppendorf 
 
 
2.5.4.2 Method  
Extraction of genomic DNA from cultured cancer cell lines was done accordance 
with the protocol from Qiagen. Briefly, cultured cells in exponential growth 
phase were trypsinised, resuspended in growth medium and centrifuged at 300g 
for 5 minutes. The supernatant was discarded and the pellet was resuspended in 
200µL of PBS to which 20µL of Proteinase K was added. 200µL of buffer AL was 
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then added, mixed thoroughly, and incubated at 56ºC for 10 minutes. 200µL of 
ethanol was added to the sample and mixed by vortexing to obtain a 
homogenous solution. The contents were pipetted into a DNeasy mini spin 
column placed in a 2mL collection tube and centrifuged at ≥6000g for 1 minute. 
The mini spin column was placed in a new collection tube and 500µL of buffer 
AW1 was added and centrifuged at ≥6000g for 1 minute. Subsequently 500µL of 
buffer AW2 was added to the mini spin column which was now placed in another 
fresh collection tube and centrifuged at ≥20,000g for 3 minutes, to dry the 
membrane. The mini spin column was placed in a clean 1.5mL micro centrifuge 
tube and 200µL of buffer AE was added. DNA was eluted by incubating the 
membrane for 1 minute at room temperature and then centrifuging for ≥6000g 
for 1 minute. The DNA was quantified as described below (section 2.5.5). 
2.5.5 Quantification of DNA  
2.5.5.1 Materials 
Spectrophotometer      Nanodrop 
Deionised water      Millipore 
 
 
2.5.5.2 Method 
DNA was quantified using Nanodrop™ ND1000 spectrophotometer based on its 
absorbance of UV light. 1-2µL of sample was placed on a fibre optic pedestal 
(sample arm) which forms a liquid column when in contact with another fibre 
optic pedestal (receiving arm). Light shone through the sample liquid column 
using a pulsed xenon flash lamp was analysed using a spectrophotometer, 
measures the DNA concentration of the sample using Beer’s law. The ratio of 
absorbance at 260nm and 280nm was calculated and A260/A280 ratio of 1.8 was 
the accepted standard for purity of DNA. Distilled water (1µL), used as a blank, 
was pipetted on to the sample pedestal which was wiped clean with tissue 
paper. The sampling arm was closed and the absorbance was measured. Once 
the measurement is complete, the surfaces were wiped clean and 1µL of 
samples were sequentially analysed.  
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2.5.6 Transfection with DNA 
2.5.6.1 Materials 
Routine tissue culture materials    Refer section 2.1.1 
LipofectamineTM 2000     Invitrogen 
Opti-MEM       Invitrogen 
 
 
2.5.6.2 Method 
Transfection of cells was done in accordance with Lipofectamine 2000TM 
protocol. Briefly, 7.5 - 10 x 105 cells were seeded in 6 well plates in growth 
medium without antibiotics aiming for 90-95% confluence after 24 hours of 
incubation in humidified incubator at 37ºC. On the day of transfection, the cells 
were fed with 2mL of fresh growth medium per well. The volume of the 
transfection reagent and the amount of the DNA per well could be scaled up or 
down according to the Lipofectamine 2000TM protocol. In the case of 6 well 
plates, 4µg of DNA per well was used to transfect the cells, which was diluted in 
240µL of serum free Opti-MEM. Similarly, 10µL of Lipofectamine transfection 
reagent was diluted with 240µL of serum free Opti-MEM. The diluted DNA and 
transfection reagent were mixed together and incubated at room temperature 
for 20 minutes, following which the DNA-transfection reagent complexes were 
added to the cells. The plates were left in humidified incubator with 95% 
atmospheric air and 5% CO2 at 37ºC. The medium in all the wells was changed 
after 6 hours and the incubation was allowed to continue for 24 hours, before 
checking for transgene expression. Stably transfection cell lines were then 
produced by propagating the cells in growth medium containing appropriate 
selection antibiotics. 
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3 Activity of cucurbituril encapsulated cisplatin in 
ovarian cancer  
3.1 Introduction  
Cisplatin is widely used in the treatment of variety of malignancies including 
testicular, lung, ovarian and gastric cancers both with curative and palliative 
intent. Ovarian cancer has a good overall response rate to treatment with 
cisplatin both in early and advanced stage. Unfortunately the response is not 
sustained and the tumour eventually becomes resistant to cisplatin (Ozols 2002; 
Hennessy, Coleman et al. 2009; Ledermann and Raja 2011). In contrast, 
treatment with a cisplatin based chemotherapy regimen is curative in 70% of 
patients with testicular cancer and in early stage testicular cancer nearly 100% 
of patients can be cured (Einhorn 2002; Jones and Vasey 2003). However, in the 
majority of tumour types the clinical activity of cisplatin is restricted by toxicity 
and drug resistance, both inherent and acquired. Cisplatin kills rapidly dividing 
cells. It is a low molecular weight molecule and once administered is distributed 
non-specifically to both malignant and normal tissues. The proliferating 
compartments of normal tissues such as the bone marrow and gut are damaged, 
resulting in intolerable toxicities which limit the clinical efficacy of cisplatin. 
The dose limiting toxicity of cisplatin is nephrotoxicity and other toxicities 
include nausea, vomiting, ototoxicity and neurotoxicity (Hartmann and Lipp 
2003; Kelland 2007). Aggressive hydration with 0.9% saline before and after the 
infusion of cisplatin has significantly reduced the nephrotoxicity of cisplatin 
(Cornelison and Reed 1993). Similarly the use of effective anti-emetics has 
attenuated the emetogenic side effects of cisplatin (Marty, Pouillart et al. 1990; 
Hesketh, Grunberg et al. 2003). However, the other toxicities like neurotoxicity 
still continue to hamper the clinical use of cisplatin and there is evidence that 
these toxicities persist even decades after treatment (Sprauten, Darrah et al. 
2012). Attempts to circumvent toxicity through the development of less toxic 
analogues have had limited success. To date, only carboplatin and oxaliplatin 
have been approved globally. The introduction of carboplatin resulted in a 
significant reduction in the nephrotoxicity associated with platinum based 
chemotherapy. By contrast, oxaliplatin has a different clinical profile compared 
to cisplatin in that it is active in colorectal cancer, a tumour type otherwise 
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resistant to platinum based chemotherapy (Sugasawa, Ng et al. 1998; Raymond, 
Faivre et al. 2002; Ibrahim, Hirschfeld et al. 2004). 
An alternative approach to the toxicity problem is to deliver the drug 
preferentially to the tumour. Drug delivery systems can protect the drug from 
degradation or alter the pharmacokinetics of the drug resulting in prolonged 
plasma/tissue half-life, reduced toxicities and enhanced anti-tumour efficacy. 
Drug delivery systems include polymer based drug carriers, lipid based carriers 
such as liposomes and micelles, dendrimers and gold nanoparticles. To date, no 
one system has been shown to be ideal. Liposomal drug delivery is hampered by 
lack of controlled release, rapid clearance by reticuloendothelial system and 
instability of the carrier resulting in opsonisation, a process by which liposomes 
are cleared from circulation by the Kupffer cells in the liver (Yan, Scherphof et 
al. 2005). Polymer-drug conjugates suffer from polymer-induced immunogenicity 
and toxicity, tight binding of polymer to the drug with resultant suboptimal 
release of drug and loose binding leading to premature drug release has limited 
the widespread use of these agents. Attempts to improve the delivery of 
cisplatin using drug delivery systems have involved conjugation with polymers or 
encapsulation within liposomes as discussed in chapter 1. The conjugation of 
platinum compound with HPMA co-polymer (AP5280) resulted in increased 
tumour delivery of platinum but did not translate to increased platinum-DNA 
adduct formation and there was no reduction in the nephrotoxic side effects of 
platinum (Lin, Zhang et al. 2004; Rademaker-Lakhai, Terret et al. 2004). 
Liposomal formulation of cisplatin, lipoplatin, demonstrated limited or absence 
of nephrotoxicity in mice bearing prostate cancer and although this drug has 
been evaluated in  early phase clinical trials, significant questions remain  about 
its pharmacokinetic profile and clinical efficacy (Jehn, Boulikas et al. 2007). 
Polymeric micelles incorporating cisplatin (NC-6004) have shown promising  pre-
clinical activity with increased anti-tumour activity and decreased 
nephrotoxicity in mice (Nishiyama, Okazaki et al. 2003). However in the phase I 
trial NC-6004 in patients with advanced cancer, there were increased incidence 
of nephrotoxicity and hypersensitivity reactions (Plummer, Wilson et al. 2011). 
These data indicate that drug delivery systems using cisplatin confer advantages 
namely increased plasma circulation time and increased platinum delivery to 
tumour but are limited by toxicities and/or absence of anti-tumour activity in 
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clinical trials. There is an unmet need to evaluate novel drug delivery systems to 
enhance the activity of cisplatin. 
3.1.1 Cucurbit[7]uril encapsulated cisplatin 
Many delivery systems are toxic and some show anti-tumour activity (Gabizon, 
Shmeeda et al. 2003). There are few if any studies that compare delivery 
systems in the same experimental model and it is, thus, difficult to select a drug 
delivery system that will suit the drug of interest. Cucurbiturils offered a novel 
drug delivery system that is commercially available but has not been exploited 
extensively. Cucurbiturils are not cytotoxic to cells in culture and are well 
tolerated in vivo (Wheate, personal communication). Besides encapsulating 
various organic compounds CB[7] and CB[8] can encapsulate platinum compounds 
including cisplatin and oxaliplatin (Wheate 2008; Walker, Oun et al. 2011). The 
cavity of cucurbit[7]uril is large enough to  encapsulate cisplatin to form an 
inclusion complex in a 1:1 ratio, and is the most soluble of all the CB homologues 
(Figure 1.5, chapter 1). These properties make CB[7]  a suitable drug delivery 
carrier for cisplatin. Cisplatin upon encapsulation within CB[7]  is completely 
within the cavity and when hydrolysed appears to be bound to the portals 
(Wheate 2008) . The complex is too small to exploit the EPR effect but could 
protect cisplatin from thiol degradation once in the circulation. The aim of this 
study was to determine whether cisplatin when incorporated within 
cucurbit[7]uril retained cytotoxicity in vitro in cancer cell lines and in vivo in a 
human tumour xenograft model. The human ovarian cancer cell line A2780 and 
two independently derived cisplatin resistant variants (A2780/cp70 and MCP1) 
were used since these are established in the department and have been well 
characterised for cisplatin sensitivity. Both A2780/cp70 and MCP1 lack a 
functional DNA mismatch repair mechanism due to methylation of the MLH1 
gene promoter and cisplatin resistance can be reversed by re-expression of MLH1 
(Plumb, Strathdee et al. 2000). The human colon cancer cell line HCT116 was 
included as a second tumour type since this cell line is resistant to cisplatin due 
the lack of a functional DNA mismatch repair system (Wheeler, Beck et al. 
1999). Cucurbit[7]uril cisplatin, herein after, will be referred to as 
CB[7]cisplatin. 
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3.2 Methods 
3.2.1 Synthesis of CB[7]cisplatin 
CB[7] was either obtained commercially or synthesised by Dr Nial Wheate 
(Strathclyde Institute of Pharmacy and Biomedical Sciences-SIBPS, University of 
Strathclyde). CB[7]cisplatin was synthesised by Dr Nial Wheate at SIBPS, 
University of Strathclyde by the addition of equimolar quantities of CB[7] and 
cisplatin in distilled water. The resultant solution was then freeze dried or 
rotary evaporated to dryness for 3 hours. Binding of cisplatin to CB[7] was 
confirmed by nuclear magnetic resonance (NMR) spectroscopy. CB[7] dissolved 
on its own in distilled water has a spike in the resonance at 5.6 ppm (parts per 
million), whereas, upon addition of cisplatin, there is a division of the peak 
resonance. The representative NMR spectrum of CB[7] alone and CB[7]cisplatin 
(which has been provided by Dr Nial Wheate’s group)  is illustrated in figure 3.1  
whereby the splitting of the resonances indicate that cisplatin is encapsulated 
within the cavity of CB[7] (Wheate 2008) . 
The molecular weight of the final product was analysed by mass spectrometry, 
from which the amount of water molecules was calculated. The molecular 
weight of the resultant CB[7]cisplatin was  dependent on the number of water 
molecules which could be controlled to be between 5 and 13 per batch. The 
molecular mass of CB[7] is 1162.4. Dependent on the method of preparation, the 
water content of CB[7] cisplatin can vary and the formula weight of 
CB[7]cisplatin was calculated according to each individual formulation to 
account for the number of water molecules. For in vitro and in vivo experiments 
in this thesis, the molecular mass of CB[7]cisplatin was calculated as 1697.2g 
since there were six water molecules in the  formulation of CB[7]cisplatin.  
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Figure 3.1: Representative NMR spectra of CB[7] cisplatin (A) and CB[7] in distilled water(B). 
The spike in the resonance at 5.6 ppm corresponds to CB[7] (B) which is split in to two upon 
addition of cisplatin to CB[7](A). 
 
3.2.2 Cytotoxicity of CB[7]cisplatin in vitro 
The cytotoxicity of CB[7]cisplatin was determined by the MTT based growth 
inhibition assay as described in section 2.2, chapter 2. CB[7]cisplatin was 
dissolved in PBS at a concentration of 10mM immediately before further dilution 
in culture medium and addition to the cells. Cells were exposed to drug for 24 
hours. CB[7]cisplatin when dissolved in PBS was shown to be  stable  based on 
the NMR studies done by our collaborators at University of Strathclyde. However 
in order to avoid any potential interactions due to the stability of CB[7]cisplatin 
was  freshly constituted in PBS  just  before  using  for in vitro or in vivo 
experiments. 
3.2.3 Induction of p53 and PARP inhibition 
A2780 cells were grown in T25 flasks to reach 70-80% confluence and were 
incubated with a range of concentrations of cisplatin and CB[7]cisplatin (0.04 to 
5µM) for 24 hours.  Cells were washed with ice cold PBS and lysed with protein 
lysis buffer and protein was extracted as described in section 2.2.2, chapter 2. 
Chapter 3   69 
Samples (20g protein) were analysed by Western blotting as described in 
section 2.1.5, chapter 2. The primary antibody was anti-p53, clone DO-1 or anti-
PARP. 
3.2.4 Activity of CB[7]cisplatin in vivo 
3.2.4.1 Drugs 
The clinical formulation of cisplatin at 1mg/ml was obtained from the pharmacy 
Beatson West of Scotland Cancer Centre (BWoSCC) for use in the animal 
experiments. It was diluted to 0.6mg/ml with sterile PBS such that injection of 
10µL/g body weight gave a dose of 6mg/kg which was selected as the maximum 
tolerated dose from previous experience (Plumb, personal communication). 
CB[7]cisplatin was administered at a dose of 34mg/kg which was equivalent to 
6mg/kg cisplatin. It was dissolved in sterile PBS at a concentration of 3.4mg/ml 
and administered at a rate of 10µL /g body weight. CB[7]  was administered at  
a dose of 250mg/kg which was known to be non-toxic (Wheate, personal 
communication). This dose of CB[7] is also   consistent with published literature 
indicating that the MTD of CB[7] is 250mg/kg when administered  intravenously 
(Uzunova, Cullinane et al. 2010). 
3.2.4.2 Human ovarian cancer xenografts 
Xenograft experiments were conducted in collaboration with Dr Jane Plumb. 
Subcutaneous human tumour xenografts were developed as described in section 
2.4.2, chapter 2. Briefly, 107 cells which were suspended in PBS were injected 
subcutaneously into the right flank of athymic nude mice and were monitored 
for tumour growth. Once the tumours reached a mean diameter of 5mm (day 0), 
mice were randomly divided into four groups of 5. They were treated by 
subcutaneous injection of either PBS (control), cucurbit[7]uril  (250mg/kg), 
cisplatin (6mg/kg body weight of mouse) or CB[7]cisplatin (34mg/kg, equivalent 
to cisplatin at 6mg/kg). Tumour volumes and body weight were measured daily 
for one week. Tumour volume and body weight on day 0 was equated to unity 
and change in tumour volume and body weight relative to day 0 was calculated 
to obtain relative tumour volume and body weight. 
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3.3 Results 
3.3.1  Cytotoxicity of CB[7]cisplatin in vitro 
The cytotoxicity of cisplatin and CB[7]cisplatin determined in vitro is shown in 
Table 3.1. All the experiments were performed in triplicates and were repeated 
at least three times. CB[7] alone at doses up to 1mM did not result in any growth 
inhibition for all the tested ovarian cancer cell lines. The cytotoxicity of 
cisplatin and CB[7]cisplatin was comparable for all four cell lines studied (Table 
3.1) and is clearly seen from the survival curves for A2780 and A2780/cp70 
shown in figure 3.2 and 3.3 respectively. Resistance factors (fold resistance) 
which is derived by dividing the IC50 of resistant cell lines (A2780/cp70 or MCP1) 
by the IC50 of sensitive cell line (A2780) were comparable for both cisplatin and 
CB[7]cisplatin. As shown in table 3.2, A2780/cp70 and MCP1 are 21 and 5.6-fold 
resistant to cisplatin and exhibit comparable resistance factors for CB[7]cisplatin 
which has a resistance factor of 23-fold and 4.6-fold  for A2780/cp70 and MCP1 
respectively. The cytotoxicity of cisplatin and CB[7]cisplatin was different for 
human colon cancer cell line HCT116 but this data still demonstrate that 
encapsulation of cisplatin within CB[7] has not resulted in any loss of 
cytotoxicity in these colon cancer cell lines.  
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Cell line 
IC50 (µM) 
Cisplatin CB[7]cisplatin 
A2780 0.10 ±  0.004 0.11 ±  0.006 
MCP1 0.56 ±  0.007 0.51 ±  0.16 
A2780/cp70 2.06 ±  0.07 2.13 ±  0.08 
HCT116 5.63 ±  0.58 2.52 ±  0.70 
Table 3.1: Cytotoxicity of cisplatin and CB[7]cisplatin in cell lines in vitro as determined by 
an MTT based growth inhibiton assay. Cells were exposed to drug for 24 hours and sensitivity 
is expressed as the concentration required to reduce cell survival by 50% (IC50). The results 
are mean ± S.E.M of three replicates. 
 
 
Cell line 
Resistance factors 
Cisplatin CB[7]cisplatin 
A2780/cp70 21 23 
MCP 1 5.6 4.6 
Table 3.2: Resistance factors of A2780/cp70 and MCP1 to cisplatin and CB[7]cisplatin  
relative to A2780 cells as calculated from MTT based growth inhibition assays.  
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Figure 3.2: MTT based growth inhibition assay for A2780 cells treated with cisplatin or 
CB[7]cisplatin. The results are mean of three replicates with the error bars representing 
S.E.M 
 
 
Figure 3.3:  MTT based growth inhibition assay for A2780/cp70 cells treated with cisplatin or 
CB[7]cisplatin. The results are mean of three replicates with the error bars representing 
S.E.M. 
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3.3.2 Induction of p53 
Expression of p53 in cell line A2780 determined by Western blotting following 
treatment of cells with either cisplatin or CB[7]cisplatin for 24 hours is shown in 
figure 3.4.  A2780 has low levels of expression of p53 and expression increases 
with increasing concentrations of cisplatin. A similar increase is observed after 
exposure to CB[7]cisplatin.   
3.3.3 PARP Expression 
Expression of PARP in cell line A2780 determined by Western blotting following 
treatment of cells with either cisplatin or CB[7]cisplatin for 24 hours is shown in 
figure 3.5. Intact PARP is observed as a band at 116kd in untreated A2780 cells. 
Treatment of cells with either cisplatin or CB[7]cisplatin results in cleavage of 
PARP as shown by the appearance of a cleavage product of 89kd. Cleavage is 
detected at a concentration of 1M for both treatments and is much more 
marked at 5M. 
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Figure 3.4: Induction of p53 expression by cisplatin (A) and CB[7]cisplatin (B) in A2780. Cells 
were incubated with a range of concentrations of cisplatin or CB[7]cisplatin for 24 hours and 
induction of p53 was detected by Western blotting. The position of molecular weight 
markers is shown. The results of one of two replicate experiments are shown. 
 
 
 
 
 
Figure 3.5: Induction of PARP cleavage by cisplatin (A) and CB[7]cisplatin(B) in A2780 cells. 
Cells were incubated with a range of concentrations of cisplatin or CB[7]cisplatin for 24 
hours and PARP cleavage was detected by Western blotting. The results of one of two 
replicate experiments are shown. 
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3.3.4 Activity of CB[7]cisplatin in A2780 xenografts 
The growth of xenografts of A2780 following treatment with cisplatin or 
CB[7]cisplatin is shown in figure 3.6 and table 3.3. The tumour doubling time of 
A2780 xenografts (controls) is 3.1 ± 0.1 days and CB[7] alone had no effect on 
the growth of the tumours (doubling time 2.9 ± 0.2 days, table 3.3).  A2780 
xenografts are sensitive to cisplatin and tumour doubling time was increased 
significantly to 4.9 ± 0.2 days (P=0.0036) following a single intraperitoneal 
injection of cisplatin (6mg/kg). Treatment with CB[7]cisplatin (34mg/kg, dose 
equivalent of 6mg/kg cisplatin) also showed a significant growth delay compared 
to the control group (6.3 ± 0.5 days vs. 3.1 ± 0.1 days, P=0.0042). The tumour 
growth delay following CB[7]cisplatin treatment (6.3 days) was slightly greater 
than that seen following cisplatin treatment (4.9 days) but this increase did not 
reach statistical significance (P = 0.19). All treatments were well tolerated and 
the mice did not show significant loss of body weight as shown in figure 3.7. 
3.3.5  Activity of CB[7]cisplatin in A2780/cp70 xenografts 
The growth of xenografts of A2780/cp70 following treatment with cisplatin or 
CB[7]cisplatin is shown in figure 3.8 and table 3.3. A2780/cp70 xenografts are 
resistant to the MTD of cisplatin (6mg/kg). The mean tumour doubling time for 
control untreated mice was 3.2 ± 0.1 days and was not significantly different for 
the cisplatin treated group (3.8 ± 0.6 days, P = 0.2). By contrast, treatment with 
CB[7]cisplatin (34mg/kg) resulted in a significant reduction in tumour growth as 
illustrated by the  increase in tumour doubling time to 5.3 ± 0.2 days (P=0.0015; 
Figure 3.8). Treatment with CB[7] alone had no effect on tumour growth and 
mice tolerated all treatment with no significant weight loss (Figure 3.9). 
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Figure 3.6: Growth of A2780 xenografts following single intraperitoneal injection of saline 
(●), CB[7] at 250mg/kg(  ), cisplatin at 6mg/kg (  ) and CB[7]cisplatin at 34mg/kg (   ).           
Results shown are mean ± SEM of 5 mice. 
.  
 
Figure 3.7:  Relative body weight of mice following single intraperitoneal injection of saline 
(●), CB[7] at 250mg/kg(  ), cisplatin at 6mg/kg (   ) and CB[7]cisplatin at 34mg/kg (   ). Results 
shown are mean ± SEM of 5 mice. 
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Figure 3.8:  Growth of A2780/cp70 xenografts following single intraperitoneal injection of 
saline (●), CB[7] at 250mg/kg(     ), cisplatin at 6mg/kg (  ) and CB[7]cisplatin at          
34mg/kg (   ). Results shown are mean ± SEM of 5 mice. 
 
 
Figure 3.9: Relative body weight of mice with A2780/cp70 xenografts following single 
intraperitoneal injection of saline (●), CB[7] at 250mg/kg (   ), cisplatin at 6mg/kg( ■ ) and 
CB[7]cisplatin at 34mg/kg  (   ). Results shown are mean ± SEM of 5 mice. 
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Treatment 
Tumour volume doubling time (days) 
A2780 A2780/cp70 
Control 3.1 ± 0.1 3.2 ± 0.1 
CB[7] 2.9 ± 0.2 3.4 ± 0.4 
Cisplatin             
(6mg/kg) 
4.9 ± 0.2 
P=0.0036 
3.8 ± 0.6 
P=0.19 
CB[7]cisplatin    
(34mg/kg) 
6.3 ± 0.5 
P=0.0042 
5.3 ± 0.2 
P=0.0015 
Table 3.3: Tumour doubling times for A2780 and A2780/cp70 xenografts following treatment 
with either saline (control), CB[7], cisplatin or CB[7]cisplatin. The results are mean ± S.E.M 
of 5 mice. P values indicate statistically significant differences compared to the control 
group. NS = not significant 
 
 
3.3.6 Activity of CB[7]cisplatin in HCT116 xenografts 
The growth of xenografts of HCT116 following treatment with cisplatin or 
CB[7]cisplatin is shown in figure 3.10. Xenografts of HCT116 are slow growing 
tumours with a doubling time of approximately 6 days. HCT116 xenografts are 
resistant to the MTD of cisplatin (6mg/kg). There is a clear tumour growth delay 
following treatment with CB[7]cisplatin but the duration of this experiment was 
too short to calculate tumour doubling times. As noted in mice with ovarian 
tumour xenografts, there was no significant loss of body weight (Figure 3.11). 
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Figure 3.10: Growth of HCT116 xenografts following single intraperitoneal injection of saline 
(●), cisplatin at 6mg/kg (■) or CB[7]cisplatin at 34mg/ kg (   ).  Results shown are mean ± SEM 
of 5 mice. 
 
Figure 3.11: Relative body weight of mice with HCT116 xenografts following single                
intraperitoneal injection of saline (●), cisplatin at 6mg/kg (■) or CB[7]cisplatin at 34mg/ kg    
(    ).  Results shown are mean ± SEM of 5 mice. 
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3.4 Discussion 
Encapsulation of cisplatin within CB[7] has no effect on the cytotoxicity of the 
drug in cell lines. The IC50 values for cisplatin and CB[7]cisplatin in the ovarian 
cell lines are comparable and encapsulation has no effect on the cellular 
resistance to cisplatin. In addition, encapsulation has no effect on the ability of 
cisplatin to induce p53 expression or cleavage of PARP.  By contrast, 
encapsulation of cisplatin results in enhanced anti-tumour activity such that 
significant growth inhibition is observed in xenografts of A2780/cp70 which are 
resistant to the maximum tolerated dose of free cisplatin. 
3.4.1 Activity of CB[7]cisplatin in vitro 
The growth inhibition assays demonstrate that the cytotoxic activity of 
CB[7]cisplatin is comparable to cisplatin and that the encapsulation of cisplatin 
within CB[7] does not reduce the cytotoxicity of cisplatin (Figures 3.2 and 3.3, 
Table 3.2).  These results are promising given that encapsulation of platinum 
compounds, in general, has been shown to result in loss of the cytotoxic activity. 
Jeon and colleagues reported  a 4-10 fold reduction in the in vitro cytotoxicity 
of oxaliplatin encapsulated within CB[7] in a variety of cell lines (Jin Jeon, Kim 
et al. 2005). Similarly, binding of cisplatin to PAMAM [poly(amidoamine)] 
dendrimers, resulted in 2-11 fold reduction in the in vitro cytotoxicity of 
cisplatin in both cisplatin sensitive and resistant ovarian cancer cell lines.  Of 
note, it was also demonstrated that the PAMAM bound cisplatin has  enhanced in 
vivo efficacy in mice bearing A2780 tumour xenograft (Kirkpatrick, Plumb et al. 
2011). 
A2780/cp70 cells are resistant to cisplatin and the cellular sensitivities 
determined in this study are comparable to published results (Plumb, Strathdee 
et al. 2000). However, CB[7]cisplatin is not able to circumvent drug resistance. 
Cell lines, A2780/cp70 and MCP1 are independently selected cisplatin resistant 
derivatives of A2780. Both have lost expression of MLH1 due to gene promoter 
methylation and A2780/cp70 has also lost functional regulation of p53 
(Strathdee, MacKean et al. 1999).  These cell lines A2780/cp70 and MCP1 are 21 
and 5.6 fold resistant to cisplatin respectively, and the resistance is not reduced 
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by treatment with encapsulated cisplatin (Figure 3.3). In addition, these results 
also confirm that cucurbit[7]uril  alone does not exhibit any cytotoxicity in vitro. 
Cisplatin induced DNA damage results in stabilisation and activation of p53 and 
induction of apoptosis (Wang and Lippard 2005). The ovarian cancer cell line 
A2780 is relatively sensitive to cisplatin. It has functional wild type p53 and 
expresses the MLH1 component of DNA mismatch repair pathway. This pathway 
has been shown to be involved in the recognition of cisplatin DNA adducts and 
induction of apoptosis (Anthoney, McIlwrath et al. 1996; Strathdee, MacKean et 
al. 1999). Induction of p53 expression and apoptosis as measured by PARP 
cleavage were determined by Western blotting. The degree of p53 induction and 
PARP cleavage was similar in cells treated with cisplatin and cells treated with 
CB[7]cisplatin (Figures 3.4 and 3.5).  These results suggest that the 
encapsulation of cisplatin within CB[7] does not prevent the interaction between 
cisplatin and DNA, resulting in apoptosis, which is consistent with the observed 
similarity in cytotoxicity. 
The results from the cell based assays suggest that CB[7]cisplatin is as effective 
as free cisplatin. This result is promising given that in some instances 
encapsulation of platinum drugs within different sized cucurbit[n]urils (n = 6, 7, 
8 or 10) led to large or complete loss of cytotoxicity in vitro (Jin Jeon, Kim et al. 
2005; Kirkpatrick, Plumb et al. 2011). Previously it has been speculated that the 
decrease in cytotoxicity in vitro of some platinum drugs upon encapsulation with 
cucurbit[n]urils was due to either decreased cell uptake or because the drugs 
were too strongly bound by the cucurbit[n]uril and could not go on to bind DNA 
at a sufficiently fast rate (Wheate 2008). In only a few instances has 
encapsulation by cucurbit[6]uril increased the cytotoxicity of platinum(II)-based 
DNA intercalator drugs (Kemp, Wheate et al. 2007; Wheate, Taleb et al. 2007). 
 
However, these results do not exclude the possibility that cisplatin dissociates 
from the CB[7] cavity whilst in the culture medium and that the activity that is 
noted is due to the free drug. A cucurbit[7]uril-acridine orange dye complex has 
been used to demonstrate that cucurbit[7]urils can cross the cell membrane 
(Montes-Navajas, Gonzalez-Bejar et al. 2009). It has been reported that the 
fluorescent properties of proflavine change when bound within CB[7] (Kemp, 
Wheate et al. 2007) and it was thought that this property, whereby the spectral 
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shift could be used to determine whether CB[7] can penetrate into the ovarian 
cancer cells.  However, no such change in fluorescence was observed when 
proflavine was encapsulated within CB[7] (data not shown). 
3.4.2 Activity of CB[7]cisplatin in vivo 
Xenografts of A2780 show a dose-dependent growth delay following treatment 
with cisplatin (Plumb, Strathdee et al. 2000). The tumour doubling time of 
A2780 was 3.1 days and this was delayed to 4.9 days when treated with the MTD 
of cisplatin (6mg/kg) (Figure 3.6). When treated with encapsulated cisplatin at a 
dose equivalent of 6mg/kg the growth delay for the cisplatin sensitive A2780 
xenografts (6.3 days) was equivalent if not greater than when mice were treated 
with the free drug (Figure 3.6, Table 3.3). Although this increased growth delay 
did not reach statistical significance, the fact that xenografts of A2780 show a 
dose dependent growth inhibition indicates that the encapsulation increases the 
activity of cisplatin. The cisplatin resistant derivative of A2780 (A2780/cp70) has 
a similar doubling time (3.2 days) to A2780. It is resistant to the maximum 
tolerated dose of cisplatin but showed a significant growth delay (doubling time 
delayed to 5.3 days) when mice were treated with CB[7] encapsulated cisplatin 
at 6mg/kg dose equivalent (Figure 3.8, Table 3.3). The CB[7] control by itself 
demonstrated no toxic side-effects in these mice, up to a dose of 250 mg/kg, 
which is consistent with previous studies of this macrocycle that have 
demonstrated that CB[7] at doses up to  250mg/kg  are non-toxic to mice 
(Wheate 2008; Uzunova, Cullinane et al. 2010). The CB[7] encapsulated cisplatin 
had no significant effect on the body weight of the mice suggesting that there is 
no increased toxicity associated with encapsulation (Figures 3.7 and 3.9). That 
CB[7]cisplatin was active in the drug resistant xenografts of A2780/cp70 suggest 
that the increased growth delay observed for A2780 xenografts is real. 
 
Since the cucurbiturils have no inherent anti-tumour activity, the observed 
growth delay for the drug resistant A2780/cp70 xenografts is most likely due to 
an increased exposure to cisplatin compared to the use of the free drug. This 
would also explain the slight increase in activity of CB[7]cisplatin in the A2780 
xenografts when compared with the free drug. Unfortunately encapsulation did 
not alter the MTD of cisplatin. The therapeutic index of CB[7]cisplatin  could   
have been widened if the safe delivery of higher dose equivalent of cisplatin is 
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possible. However the in vivo experiments with CB[7]cisplatin at dose of 
34mg/kg (equivalent to 6mg/kg  of cisplatin) demonstrated that toxicity profile 
of CB[7] cisplatin was similar to but not better than cisplatin. It could only be 
speculated that encapsulation of cisplatin within CB[7] did not change the MTD 
of cisplatin as higher doses of CB[7]cisplatin were not evaluated to avoid 
suffering to mice.  
 
The encapsulation of cisplatin was thought to protect cisplatin from thiol 
degradation whilst in the plasma. Partial encapsulation of oxaliplatin within 
CB[7] resulted in decreased platinum reactivity  with methionine and guanosine 
(Jin Jeon, Kim et al. 2005). NMR spectroscopy studies have also shown that that 
encapsulation of trans-dinuclear platinum within CB[7]  protects the platinum 
from reacting  with sulphur containing thiols, glutathione and methionine (Bali, 
Buck et al. 2006). It is also possible that degradation occurs within the tumour 
although increased glutathione levels are not a major mechanism of resistance in 
A2780/cp70 cells (Plumb, Strathdee et al. 2000). In order to determine whether 
the activity of CB[7] cisplatin was specific to the ovarian model a human colon 
tumour xenograft was included in the study. Human colon cancer cell line 
HCT116 is resistant to cisplatin due to loss of DNA mismatch repair resulting 
from a mutation in the gene for the MLH1 protein component (Wheeler, Beck et 
al. 1999). Whilst HCT116 xenografts were resistant to the MTD of cisplatin, a 
clear growth delay was observed when mice were treated with CB[7]cisplatin 
(Figure 3.10). This observation indicates that the activity of CB[7]cisplatin is not 
tumour type specific.  
 
3.5 Conclusion 
Encapsulation of cisplatin within CB[7] does not overcome cisplatin resistance at 
the molecular level but does enhance the anti-tumour activity in vivo without an 
associated increase in toxicity. This is an important observation since a general 
increase in plasma levels of cisplatin would be expected to increase toxicity as 
well as anti-tumour activity. Cucurbiturils are too small to exploit the enhanced 
permeability and retention (EPR) effect and lack a targeting moiety that would 
selectively deliver the drug to the tumour. It is also possible that the tumour 
microenvironment could favour CB[7]cisplatin. The most likely explanation for 
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the enhanced activity in the absence of increased toxicity is that encapsulation 
alters the plasma and tissue pharmacokinetics. Since toxicity is potentially 
related to the peak plasma levels of cisplatin it is possible that encapsulation 
delays the release of cisplatin such that overall exposure is maintained or 
enhanced without the increase in peak plasma concentration that would be seen 
with an increased dose of free cisplatin.  
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4 Pharmacokinetics of cucurbituril encapsulated 
cisplatin 
4.1 Introduction 
The xenografts experiments described in chapter 3 demonstrate that 
CB[7]cisplatin can overcome cisplatin resistance in A2780/cp70 xenografts. 
However, experiments in vitro with CB[7]cisplatin have shown that 
CB[7]cisplatin does not circumvent the molecular mechanism of resistance in the 
A2780/cp70 cells. It was concluded that the enhanced activity of CB[7]cisplatin 
in the xenografts is most likely due to a pharmacokinetic effect. The synthesis of 
CB[7]cisplatin was based on the hypothesis that the encapsulation would prevent 
thiol degradation in vivo and hence prolong the half-life of cisplatin in the 
circulation. 
The mechanism of action of cisplatin is not tumour-specific since the mechanism 
of action targets all dividing cells. As a result utility in vivo is limited by the 
therapeutic index of the drug as it is for many conventional chemotherapeutic 
agents. Provided that the tumour is more sensitive to the drug than is the 
normal tissue, growth inhibition can be achieved. Cisplatin was used at the 
maximum tolerated dose in vivo in the xenografts and this dose is sufficient to 
cause a growth delay in the parental A2780 xenografts but not in the A2780/cp70 
xenografts (Figure 3.6 and 3.8). Encapsulation of cisplatin has increased the 
therapeutic index of cisplatin such that activity is observed in the drug resistant 
xenografts. In order to understand the basis for the enhancement we examined 
the pharmacokinetics of encapsulated cisplatin in the mice. 
Pharmacokinetics is the study of the absorption, distribution, metabolism and 
excretion of the drug in the body. Each of these factors influences the overall 
exposure of the body organs and the tumour to the drug. In the mouse studies 
cisplatin was administered intraperitoneally and has to pass from the peritoneal 
cavity into the circulation. The amount that reaches the tumour depends on the 
efficiency of absorption, the volume of distribution and the rate of clearance 
from the circulation. Encapsulation, in addition to other changes in 
pharmacokinetics, could affect the rate of absorption, stability of the drug in 
the circulation and the rate of clearance. For some drugs toxicity is related to 
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the peak plasma levels (Cmax) achieved while for others it is the overall 
exposure to the drug that is important. Similarly, anti-tumour activity can be 
dependent on the peak plasma concentration, overall exposure or a combination 
of the two (Undevia, Gomez-Abuin et al. 2005). Overall exposure is quantified as 
the area under the plasma concentration/time plot (AUC). In the mice, cisplatin 
was administered as a bolus dose. Since cisplatin is readily absorbed into the 
circulation, the peak plasma concentration is directly related to the dose of 
cisplatin administered. The pharmacokinetics study was thus designed to 
measure the peak plasma concentration and the AUC of the free and 
encapsulated cisplatin. 
Evaluation of the pharmacokinetics of a drug ideally requires an assay capable of 
detecting small amounts of the drug, metabolites and break down products in 
biological samples.  However, there are only few reliable assays for the 
measurement of cisplatin in biological samples due to lack of a technique for 
detection of this small molecule.  Measurement of free platinum metal has been 
used to establish the pharmacokinetic properties of platinum compounds 
(Morrison, White et al. 2000). In particular,  in our group there was  paucity of  a 
reliable assay to measure the platinum levels in biological samples. 
4.2 Platinum analysis with Inductively Coupled Plasma–
Mass Spectrometry  
4.2.1 Basic principles of ICP-MS 
Inductively Coupled Plasma–Mass Spectrometry (ICP-MS) is an elemental analysis 
technique which is now widely used to quantitatively measure trace amounts of 
metal based anti-cancer agents like platinum in biological samples (Brouwers, 
Tibben et al. 2008). Earlier studies utilising atomic absorbance spectrometry 
(AAS) to estimate the platinum levels were limited by poor sensitivity and were 
not suitable to demonstrate the lesser magnitude yet pharmacologically 
significant difference in platinum levels between various newer formulations of 
platinum compounds (Tothill, Matheson et al. 1990). The use of ICP-MS in 
evaluating pharmacologically relevant elements has been extensively reviewed 
(Huang, Hu et al. 2006; Brouwers, Tibben et al. 2008). Briefly, ICP-MS relies on 
the ability of inductively coupled plasma (ICP) to convert the sample to 
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distinctly charged ions. These charged ions in turn can be detected by mass 
spectrometer based on their mass-charge ratio (m/z) which then translates the 
concentration of the analyte (platinum) in the sample to integrated counts per 
second.  
4.2.1.1 Advantages of ICP-MS 
Limited sample availability and low concentration of platinum in the plasma are 
the limiting factors in performing pharmacokinetics of platinum compounds in 
human plasma samples and animal models. The high sensitivity and wide linear 
dynamic range of ICP-MS helps to measure the platinum exposure in cellular 
samples and in various biological matrices including plasma, plasma ultra-filtrate 
(pUF) and tissues (tumour and organs).  
The signal intensity or the counts per second is not dependent on the chemical 
structure of the metal compound. This allows the measurement of elemental 
platinum in both the free and encapsulated cisplatin but does not allow 
measurement of drug metabolism and degradation. Unlike other bio-analytical 
assays, such as high-performance liquid chromatography (HPLC), a single 
validated method and sample preparation protocol can be used to analyse 
platinum levels in different biological matrices including plasma and tissues. The 
wide linear dynamic range of detection allows the measurement of platinum 
levels in plasma at both early and late time points without affecting the 
sensitivity in a single analytical experiment. The low detection limit aides the 
evaluation of clinically relevant difference in platinum levels relative to 
different platinum compounds even at levels as low as ng/L or parts per trillion 
(ppt).  
4.2.1.2 Practical limitations of ICP-MS 
The analysis of platinum levels using ICP-MS has some limitations which are 
inherent to ICP-MS but are not insurmountable. These are spectral interferences 
from isobaric interference and polyatomic ions. The three abundant isotopes of 
platinum are 194Pt, 195Pt and 196Pt with abundances of 33.0%, 33.8% and 25.2% 
respectively (E. E. M. Brouwers 2006). Of these three isotopes, 196Pt alone is 
subject to interference from mercury (196Hg) and this could be corrected by 
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monitoring the isotopic ratio of the three platinum isotopes. The interference 
from polyatomic ions namely Hafnium oxide was not a major concern as the 
background levels of platinum in our samples were greater than that of Hafnium 
oxide. There were significant issues from non-spectral interference arising from 
sample preparation and matrix interference which were dealt by optimising the 
sample preparation process. 
4.2.2 Study design: Validation of ICP-MS 
The analysis of platinum by ICP-MS was performed in collaboration with           
Prof Andrew Hursthouse in the Department of environmental geochemistry, 
University of the West of Scotland, Paisley. Although skilled in elemental 
analysis, his expertise did not include analysis of biological materials.  A method 
specific to analysis of platinum in biological samples was developed and 
validated. The validation of ICP-MS for analysis of platinum was carried out 
following the principles outlined by the United States FDA Centre for Drug 
Evaluation and Research (FDA 2001), published literature (Shah, Midha et al. 
2000; Miller, Bowsher et al. 2001) and in-house Analytical services unit (ASU) 
method development and validation protocols.  
Briefly, all the vital parameters that were required for validation of 
bioanalytical methods were tested including specificity, calibration curve and 
linearity, accuracy, precision, limit of detection and stability. The specificity 
was analysed by checking the levels of platinum in blank samples containing the 
biological matrix. Certified reference solution of platinum was purchased from 
Inorganic ventures, USA.  Lower limit of quantitation (LLOQ), the concentration 
that could be measured with confidence and limit of detection (LLOD), the 
lowest concentration of the analyte (platinum) that could be reliably 
differentiated from background levels were defined. The linearity was checked 
by plotting a calibration curve with minimum of 6 non-zero standards with a 
correlation co-efficient (r2) ≥ 0.95. Quality control (QC) samples, with a 
minimum of 5 concentrations, spanning the calibration with the appropriate 
biological matrix were used for ascertaining the accuracy and precision.  
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4.2.2.1 Accuracy and precision 
Accuracy is the closeness of the observed results determined by the assay 
(ICPMS) to the true value. Accuracy can be determined by analysing the samples 
with a known quantity of the analyte (quality control samples) and measuring 
the difference in the observed value. Accuracy (%) = [(expected-
observed)/expected] x 100. Accuracy should be tested with a minimum of five 
concentrations which would be in the range of expected concentrations in the 
sample and at least five replicates should be tested. Guidelines recommend that 
the accuracy should be within 15% of the expected concentration, barring the 
lower limit of quantitation where the accuracy can be within 20%.  
Precision could be considered as the reproducibility of the results from the 
method, when the analyte is measured repeatedly in the same homogenous 
volume. This is the closeness of the results within the same analytical run for 
the quality control samples. Similar to accuracy, five determinations per 
concentration should be performed and the concentrations should cover the 
expected range of concentration in the sample. Precision values of ≤15% for each 
concentration (20% for lower limit of quantitation) were acceptable according to 
the guidelines. For the purposes of platinum analysis using ICPMS, concentrations 
within range from 250ng/L (ppt) to 100µg/L (ppb) were used for determining 
precision and accuracy.  
4.2.2.2 Calibration curve and linearity 
Calibration curve and linearity is the relationship between the instrument 
response and actual known concentration of the analyte. The relation should be 
linear and a minimum of six standards need to be used. Quantitation was based 
on linear regression analysis and the correlation coefficient greater than 0.99        
(r > 0.99) was accepted for each standard curve. In our validation, a minimum of 
nine calibration standards ranging from 50ng/L to 500µg/L was used. 
4.2.2.3 Limit of detection 
Limit of detection (LOD) is defined as the lowest concentration that can be 
detected by the method with reasonable confidence that this is not due to 
contamination from background levels. Lower limit of detection should be more 
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than at least 5 times the response from the sample compared to blank response.  
This differs from lowest limits of quantitation (LLOQ) which is the lowest 
concentration of the analyte which can be determined with acceptable accuracy 
and precision.  
4.2.2.4 Stability 
The stability of platinum in biological matrices was evaluated both for short 
term stability (run time: 1-2 days) and also in medium term to deal with the 
freeze-thaw cycle. The analyte is accepted to be stable when 95%-105% of the 
original concentration was attained in the stored samples. 
The assay was then tested in a small study of drug uptake in cell lines. Once a 
reliable assay was established the plasma and tissue pharmacokinetics of free 
and encapsulated cisplatin was determined in tumour bearing mice. 
4.2.3 Materials 
Platinum(1000 μg/mL) in 10% (v/v) hydrochloric acid and Indium(1000 μg/mL) in 
2%(v/v)  hydrochloric acid were purchased  from Inorganic Ventures, Lakewood, 
New Jersey, USA. Nitric acid (Fisher OptimaTM trace metal grade, product code 
N/2275) was obtained from Fischer Scientific, U.K. Nalgene® volumetric flasks 
(Thermo Fisher, U.K) and Polypropylene (transport) tubes (Elkay Laboratories, 
UK) were used for the volumetric analysis and transport of standards and 
samples respectively. Cisplatin was a kind donation from pharmacy at the 
Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, U.K and CB[7] 
cisplatin was synthesised as described in chapter 3. Materials required for 
cellular and animal experiments were sourced from suppliers as mentioned in 
appendix 2. 
Thermo Electron Corporation X-Series II quadrupole ICP-MS was used for the 
analysis of platinum. 
4.2.4 Methods 
The Thermo Electron Corporation X-Series II quadrupole ICP-MS uses a concentric 
nebuliser with a Peltier cooled (to 3oC) conical single-pass spray chamber with 
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impact bead and has an integral peristaltic pump for sample uptake from a 
Cetac ASX-520 auto-sampler. The instrument is situated in a temperature and 
humidity controlled environment to minimise drift. Each run was supervised to 
ensure quality control, although the instrument could analyse samples through 
an automated process. Unexpected isobaric interferences were monitored by 
measuring the 194pt/195pt and the 196pt/195pt isotopic ratios which were 
consistent throughout. After analysis of each sample, the ICP-MS instrument was 
flushed with 1% nitric acid to clean the system thoroughly, such that the 
background analyte (platinum) levels came down to that of blank sample, to 
avoid carry over effect from previous samples. The Thermo X-Series II provides a 
monitored sample flush time option. This enabled efficient use of analysis time 
versus low to zero carry over between standards and between samples. A 
maximum flush time of 240 seconds was used, while the minimum counts per 
second allowed before measuring the next sample was set to around the level of 
the calibration blank. This could be varied depending on the conditions required. 
The high organic content of the samples by virtue of their biological origin 
resulted in signal suppression. In addition, there was a risk that these organic 
particles could block the sample introduction system and interface. Matrix 
interference was also noted due to high organic content of the sample. This 
problem was overcome by diluting the samples which resulted in adequate 
mineralisation without affecting the specificity. In addition, the sampling tubes 
were regularly changed to avoid cross-over contamination and flow variation due 
to wear and tear. The sampler and skimmer cones were also regularly inspected 
and thoroughly cleaned to reduce the non-spectral interferences. Indium (1μg/L) 
was used as the internal standard which acted as a control for flow variation and 
matrix interference. The calibration standards were run prior to each analysis 
and up to 100 samples were analysed as a single batch. 
4.2.4.1 Preparation of standards  
Chloroplatinic acid containing platinum (1000µg/mL) in 10% hydrochloric acid 
and Indium (1000µg/mL) in 2% nitric acid was used for the preparation of 
calibration and internal standards respectively. Initially calibration standards 
with concentration ranging from 50 ppt (parts per trillion) to 100 ppb (parts per 
billion) were prepared with 1% nitric acid in ultrahigh pure deionised water. The 
typical concentrations used for the calibration were 50ppt, 250ppt, 500ppt, 
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1ppb, 5ppb, 10ppb, 25ppb, 100ppb and 500ppb. A stock solution of 1 µg/mL 
(part per million-ppm) was prepared from the main stock which was then diluted 
with 1% nitric acid in ultrahigh pure deionised water (Milli-Q) to obtain the 
calibration standards. 1% nitric acid in ultrahigh pure deionised water was used 
as a blank control.  The minimum volume of each calibration standard was 50mL 
which was accurately measured with the volumetric flasks (Nalgene) and then 
transferred to 50mL polypropylene transport tubes. All the standards were 
analysed thrice in the ICP-MS and the blank was analysed for 7 times. Similarly 
serial dilution of the stock of Indium was performed with 1% nitric acid in 
ultrahigh pure deionised water to obtain the final concentration of 1 µg/mL 
(1ppb). All the volumetric flasks used for preparation of calibration standards 
were washed thrice with 1% nitric acid in ultrahigh pure deionised water. The 
pipette tips and polypropylene transport tubes were discarded after single use. 
Quality control samples were prepared by diluting the chloroplatinic acid stock 
solution with 1% nitric acid in ultrahigh pure deionised water and the 
concentration of the quality control samples used were 250ppt, 1ppb, 2.5ppb, 
10ppb and 100ppb of platinum. In addition, to study the effect of interference 
from the organic materials in the mouse plasma and tumour tissue, two different 
solutions were made. 
1. Mouse plasma was heat digested at 65oC with concentrated nitric acid 
(68% Optima grade, from Fisher Scientific) and diluted to 1% plasma and 
1% nitric acid with ultrahigh pure deionised water, the biological matrix 
herein after referred to as “1% plasma in 1% nitric acid”.    
2. The quality control samples were prepared by diluting the chloroplatinic 
acid stock solution with 1% plasma in 1% nitric acid. This biological matrix 
herein after will be referred to as “quality control samples in 1% plasma”. 
Preparing calibration standard solution with 1% plasma in 1% nitric acid would 
involve sacrificing and collecting blood from large group of mice. However the 
aim of the ICP-MS was to analyse the platinum levels in the mouse plasma and 
published guidelines suggest that the matrix used for calibration and test 
samples need to be similar. To strike a balance, 1% plasma in 1% nitric acid was 
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used for preparing the quality control samples but the calibration samples were 
prepared using 1% nitric acid in ultrahigh pure deionised water.  
To summarise, the validation of ICP-MS assay was done with three different 
solutions namely, 
a) Both calibration and quality control standards prepared in 1% plasma in 1% 
nitric acid. 
b) Calibration standards prepared in 1% nitric acid in ultrahigh pure 
deionised water and quality control samples in 1% plasma in 1% nitric 
acid. 
c) Both calibration and quality control standards prepared in 1% nitric acid in 
ultrahigh pure deionised water. 
4.2.4.2 Preparation of cellular samples 
The method used to measure platinum uptake in cells was adapted from Samimi 
and colleagues (Samimi and Howell 2006). Drug uptake was carried out with cell 
monolayers at 60-80% confluence. Cells (A2780, A2780/cp70) were plated out at 
a density of 105 - 106 cells/well in 3mL of medium in 6 well plates and incubated 
overnight at 37oC in a humidified atmosphere of 5% CO2 in air. The medium was 
then replaced with fresh medium alone or with medium containing cisplatin or 
CB[7]cisplatin at a range of concentrations. Triplicate wells were harvested at 
various times. The medium was then removed and cells washed with ice cold PBS 
and the cells lysed by addition of 215L of nitric acid (68% Optima grade, Fisher 
Scientific, U.K) to each well. Plates were left at room temperature for 30 
minutes. The cells were then collected into microfuge tubes and incubated 
overnight at 65oC in a heating block. Three further wells were used to estimate 
the number of cells per well. The cell lysates were diluted in ultrahigh pure 
deionised water containing Triton-X (0.1%) to give a final nitric acid 
concentration of 1%    (volume /volume).  
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4.2.4.3 Calculation of cellular platinum content 
Typically 50L of nitric acid containing the digested cells was diluted with 
4950L of de-ionised water containing 0.1% Triton-X to achieve a final volume of 
5mL.  The platinum content of samples was determined by ICP-MS which gives 
the value of platinum (x) in ppb (ng/L) which would be equivalent to the 
platinum content in 50L of digested cells. The total platinum content of the 
digested cells in each well was derived by multiplying by a factor 4.3 (i.e. 215L 
/50L). The platinum uptake in each cell was then obtained by dividing the total 
platinum contents in the 215L of digested cells by the total cell count. Finally, 
the cellular platinum uptake was expressed as picomoles (pmol) of drug per 106 
cells by dividing the final value by 195 (molecular weight of platinum). Results 
are the mean ± SEM of drug uptake in 3 wells. 
 
For the purpose of comparing the cellular platinum uptake, cells were incubated 
with cisplatin or CB[7]cisplatin (5µM), which was chosen based on the time 
course and drug dose finding experiments that were conducted for validating 
ICP-MS.  
 
4.3 Pharmacokinetics of cucurbit[7]uril cisplatin 
Human tumour xenografts were established as described in section 2.4.2, 
chapter 2. Groups of 3 mice were treated with a single intra-peritoneal injection 
of cisplatin (6mg/kg body weight) or CB[7]cisplatin (34 mg/kg,  dose equivalent 
to cisplatin 6mg/kg) and  sacrificed at specified time points. Blood was collected 
by cardiac puncture and stored in ethylene diammine tetra acetic acid (EDTA) 
tubes, which were placed on ice and plasma was separated as soon as possible to 
minimise the loss of platinum due to binding with erythrocytes. The plasma was 
separated by centrifuging the blood samples at 1500g for 10 minutes. The 
supernatant plasma was separated, collected and stored at -20oC until further 
analysis. Tissues (tumour, kidney and liver) were harvested, snap frozen and 
stored at -70oC until further analysis. 
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4.3.1 Preparation of tissue samples 
Various methods have been described for the analysis of platinum in biological 
matrices including plasma (Tothill, Matheson et al. 1990; Morrison, White et al. 
2000), plasma ultra-filtrate (E. E. M. Brouwers 2006) and tissues (Jandial, Messer 
et al. 2009) with their own limitations.  
Sample preparation is a vital step in the development of the assay. Inadequate 
de-mineralisation can lead to contamination and subsequent blockage of the ICP-
MS sample introduction system. Conversely use of large quantity of nitric acid to 
digest the sample could result in higher dilution of the sample and thereby 
decrease the sensitivity of the assay. Hence it is pertinent to find a balance 
between adequate demineralisation and dilution of the sample 
A variety of methods were evaluated to prepare the tissues for analysis of 
platinum. Tissues were snap frozen in liquid nitrogen and subsequently ground to 
fine pieces using a mortar and pestle. Although this process allowed the tissues 
to be stored in aliquots, there was considerable amount of tissue that was stuck 
to the pestle which could not be recovered. Other methods of sample 
preparation were explored.  Tissue samples were weighed and then homogenised 
with PBS using a Dounce homogeniser. The tissue homogenate was nitrolysed by 
adding nitric acid (68%, Optima grade, Fisher Scientific, U.K) and digested by 
placing on a heat block at 65oC. The Dounce homogeniser was rinsed thoroughly 
with 1% nitric acid in ultrahigh pure deionised water between each use. However 
there was still a possibility of carry over effect from previous sample and hence 
this method was also abandoned. 
Tissue digestion was finally optimised by adding varying volumes of nitric acid 
and heat digesting for varying time periods to obtain the best results. Addition 
of nitric acid at ratio of 1:10 (weight:volume) of tissue and heat digestion at 
65oC in a water bath for 24 hours achieved the optimum digestion of the tissue. 
The nitrolysed samples were subsequently diluted 50 to 100 fold 
(volume/volume) with 0.1% Triton–X in ultrahigh pure deionised water prior to 
analysis to reduce the matrix effect and contamination of sampler introduction 
system. Triton-X was used as an emulsifier and to denature proteins. In 
principle, a combination of acid digestion and dilution method was used to 
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prepare the samples. Typically 5mL of the solution containing 1% tissue 
homogenate in 1% nitric acid was prepared for the platinum analysis. 
4.3.2 Preparation of plasma samples 
Preparation of plasma was adapted from a method published by Jandial and 
colleagues (Jandial, Messer et al. 2009). Briefly, plasma was nitrolysed by adding 
equal volumes of plasma and nitric acid (68%, Optima grade, Fisher Scientific, 
U.K) and digesting overnight at 65oC. Typically 50 μL each of plasma and nitric 
acid was used. The acid digested plasma was then diluted with 0.1% Triton–X in 
ultrahigh pure deionised water to obtain a volume of 5mL or 10mL solution 
containing 1% plasma in 1% nitric acid. Therefore the final dilution was 100 fold 
when 50μL of digested plasma was added to 4950μL solution containing 1% 
plasma in 1% nitric acid. 
The solution was transported in polypropylene transport tubes and analysed 
using ICP-MS. The plastic pipette tips and transport tubes were discarded after 
single use to avoid carry-over of platinum. The values of platinum were given in 
parts per billion (ppb) which were converted to mg/mL by multiplying by a 
factor of 100 (to correct for the initial dilution of plasma to 1%) to obtain values 
of platinum at ng/mL. The resultant values were then divided by 1000 to derive 
the platinum values in plasma at µg/mL.  Since the human pharmacokinetic 
studies have expressed the platinum levels µg/mL (Plummer, Wilson et al. 2011), 
the plasma platinum values are expressed as µg/mL and not in molar terms. 
4.3.3 Data analysis 
Pharmacokinetic parameters were determined by non-compartmental analysis 
(WinNonLin Version 4.0 software, Pharsight, Mountain View, USA). Statistical 
analyses were performed with Sigma Plot 8.0 and t-test was used to evaluate 
statistical significance.  
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4.4 Results: Method development and validation of ICP-
MS 
4.4.1 Linearity  
Linear relationship was demonstrated between integrated counts per second 
(ICPS) and platinum concentration of the calibration standards for all the three 
isotopes of platinum (194pt, 195pt and 196pt) with correlation coefficient, r>0.999 
when 1% nitric acid in ultrahigh pure deionised water was used to prepare the 
calibration and quality control standards (Figure 4.1). This linear relationship 
was also maintained between the platinum levels expressed as ICPS and the 
concentration of the calibration standards when the calibration standards were 
prepared with a solution containing 1% plasma in 1% nitric acid (Figure 4.2). 
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Figure 4.1: Detection of the 3 platinum isotopes when prepared in a matrix of 1% nitric acid 
in ultrahigh pure deionised water as measured by ICP-MS. Each point represents the mean of 
three measurements. 
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Figure 4.2: Detection of the 3 platinum isotopes when calibration standards and quality 
control samples were prepared with 1% plasma in 1% nitric acid as measured by ICP-MS. Each 
point represents the mean of three measurements. 
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4.4.2 Accuracy and precision 
The accuracy and precision were evaluated using five concentrations of quality 
control samples containing 250ppt, 1ppb, 2.5ppb, 10ppb and 100ppb of 
platinum. These values were chosen based on pilot runs that demonstrated the 
possible spread of the platinum concentration in the tissue and plasma samples. 
The accuracy and precision when 1% plasma in 1% nitric acid was used as the 
biological matrix to prepare both the calibration and quality control samples is 
illustrated in table 4.1. 
 
Analyte value 
 
250 ppt 1 ppb 2.5 ppb 10ppb 100 ppb 
Run 1 0.09 0.85 2.31 10.12 96.27 
Run 2 0.08 0.84 2.39 9.97 97.08 
Run 3 0.08 0.87 2.37 10.19 97.30 
Run 4 0.09 0.84 2.34 9.96 96.43 
Run 5 0.08 0.84 2.39 10.02 94.98 
Mean 0.08 0.85 2.36 10.05 96.41 
Accuracy 68% 15% 7% 0.5% 3.5% 
Precision 6.3% 1.5% 1.5% 1.0% 0.9% 
Table 4.1: Accuracy and precision of ICP-MS with both the  calibration standards and quality 
control samples prepared in 1% plasma in 1% nitric acid solution. 
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The accuracy and precision of the assay, when calibration standards were 
prepared with 1% nitric acid in ultrapure deionised water and quality control 
samples with the biological matrix of 1% plasma in 1% nitric acid is given in table 
4.2. The accuracy was within acceptable standards (<15%) in concentration 
ranging from 1ppb to 100ppb. 
 
Analyte value 
 
250 ppt 1 ppb 2.5 ppb 10ppb 100 ppb 
Run 1 0.44 1.1487 2.86 10.75 102.20 
Run 2 0.44 1.1447 2.89 10.85 101.40 
Run 3 0.43 1.1423 2.85 10.80 101.23 
Run 4 0.43 1.1413 2.79 10.77 102.53 
Run 5 0.41 1.1449 2.84 10.81 102.47 
Mean 0.430 1.144 2.85 10.80 101.97 
Accuracy 92% 14% 14% 8% 2% 
Precision 2.30% 0.25% 1.40% 0.37% 0.60% 
Table 4.2: Accuracy and precision of ICP-MS with calibration standards made from 1% nitric 
acid in ultrahigh pure deionised water and quality control samples prepared in 1% plasma in 
1% nitric acid solution. 
  
The accuracy and precision when 1% nitric acid in ultrahigh pure deionised water 
was used as the background matrix for both the calibration and quality control 
samples is given in table 4.3.  
 
Analyte value 
 
250 ppt 1 ppb 2.5 ppb 10ppb 100 ppb 
Run 1  0.239 0.926 2.325 9.340 97.123 
Run 2 0.237 0.914 2.283 9.385 96.440 
Run 3 0.239 0.918 2.294 9.278 95.763 
Run 4 0.235 0.879 2.213 9.249 96.097 
Run 5 0.238 0.904 2.231 9.353 95.553 
Mean 0.238   0.908   2.269   9.321   96.19   
Accuracy 5% 9% 9% 7% 4% 
Precision 0.75% 1.99% 2.03% 0.6% 0.64% 
Table 4.3:  Accuracy and precision of ICP-MS using 1% nitric acid in ultrahigh pure deionised 
water based matrix for calibration and quality control samples. 
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4.4.3 Level of Quantitation 
The lower limit of detection of platinum, when 1% plasma in 1% nitric acid was 
used as the biological matrix, was 1μg/L. However when 1% nitric acid in ultra-
high pure, deionised water was used in calibration standard, the limit of 
detection improved and was in the range of 0.1 – 0.25 μg/L. 
4.4.4 Stability 
The stability of the platinum in various biological matrices was evaluated by 
measuring the platinum values in the samples which were maintained at room 
temperature for short term and at 4oC in refrigerator for longer term. There was 
no significant deviation from the baseline and it was less than 2% from the 
baseline in sample analysed within 3 days and 3% in samples analysed after 4 
weeks. The stability of platinum (195pt) between days 1 and 4 is illustrated in 
figure 4.3  
 
Figure 4.3: Stability of platinum isotope in a matrix containing 1% plasma in 1% nitric acid 
when  measured on days 1 and 4. 
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4.5 Results: Validation of ICP-MS in cellular samples 
The uptake of platinum by A2780  cells incubated for 4 hours with a range of 
concentrations of cisplatin (0.5µM to 50µM) is shown in figure 4.3. The 
intracellular accumulation of platinum was proportional to the concentration of 
cisplatin as illustrated in figure 4.4. The numerical results of uptake of platinum 
by cells are given in table 4.4. 
 
 
Figure 4.4: Uptake of platinum by A2780 cells with increasing concentrations of cisplatin. 
Each point represents the platinum content of the cells treated with increasing doses of 
cisplatin. Values are the mean ± S.E.M of 3 replicates. 
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Cisplatin (µM) Pt content (pmol)/10
6 
cells 
control 1.3 ± 0.4 
0.5 2.7 ± 0.1 
5 22.2± 2.5 
10 77.2 ± 7.6 
15 64.6 ± 5.4 
50 194.7 ± 19.3 
Table 4.4: Platinum accumulation in A2780 cells with increasing doses of cisplatin. Results 
are the mean ± SEM of three replicates. 
 
4.5.1 Optimum duration of drug exposure 
On the basis of the dose finding experiments, the dose of 5μM was chosen for 
time course experiments and results of the time course experiment with 5μM are 
illustrated in figure 4.5 which demonstrates that the intracellular accumulation 
of platinum increases with  time of exposure. 
 
Figure 4.5: Platinum uptake by A2780 cells incubated with 5μM of cisplatin at increasing 
time. Each point represents the platinum content of the cells measured at corresponding 
time period. Values are mean ± S.E.M of 3 replicates. 
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4.5.2 Platinum uptake by A2780 cells with CB[7]cisplatin 
The platinum content of A2780 cells when treated with 5μM of either cisplatin or 
CB[7]cisplatin and incubated  for 15 minutes, 1, 4 and 24 hours is as shown in 
figure 4.6. 
 
Figure 4.6: Platinum uptake by A2780 cells when incubated with cisplatin (black bars) or 
CB[7]cisplatin (clear bars) for varying time interval. Values are the mean ± S.E.M of 3 
samples. 
 
 
4.6 Results: Plasma pharmacokinetics of CB[7]cisplatin 
Plasma platinum concentrations measured at various times after a single 
intraperitoneal dose of either cisplatin (6mg/kg) or CB[7]cisplatin (34mg/kg) are 
shown in table 4.5 and figure 4.6. The pharmacokinetic parameters of cisplatin 
and CB[7]cisplatin determined by non-compartmental analysis are given in table 
4.6. The peak plasma level of platinum was observed 5 minutes after injection 
and this peak plasma platinum level was  higher following injection of free 
cisplatin than for CB[7]cisplatin (Figure 4.7 and Table 4.6) with Cmax of  
cisplatin 17.5μg/mL compared with 10.2μg/mL for CB[7]cisplatin. This 
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difference in Cmax, however, did not reach statistical significance (P=0.09). 
Plasma platinum levels decreased rapidly but the decline was slower for 
CB[7]cisplatin such that after 15 minutes, plasma levels of platinum were higher 
following injection of CB[7]cisplatin. This difference was maintained for up to 48 
hours. The AUC for cisplatin and CB[7]cisplatin is similar over the first hour after 
injection but is higher for the encapsulated cisplatin at all subsequent times 
(Table 4.6). 
Time 
Plasma platinum concentration (µg/mL) 
Cisplatin CB[7]cisplatin 
Control 0.003 ± 0.0001 0.003 ± 0.0001 
3 minutes 10.08  ± 1.62 8.48  ± 1.44 
5 minutes 17.45  ± 0.85 10.43  ± 2.74 
7 minutes 11.78 ± 0.69 8.29 ± 0.38 
15 minutes 5.49 ± 0.51 6.92 ± 0.54 
30 minutes 2.10 ± 0.12 4.01 ± 0.39 
1 hour 0.84 ± 0.07 1.92 ± 0.22 
2 hours 0.76 ± 0.06 1.56 ± 0.14 
4 hours 0.66 ± 0.05 1.66 ± 0.26 
6 hours 0.49 ± 0.03 0.95 ± 0.03 
24 hours 0.35 ± 0.03 0.64 ± 0.06 
48 hours 0.19 ± 0.02 0.40 ± 0.010 
Table 4.5: Plasma platinum levels in mice treated with cisplatin (6mg/kg) or CB[7]cisplatin 
(34mg/kg, equivalent to cisplatin at 6mg/kg) at various time points. Values are the mean ± 
S.E.M of at least 3 samples. 
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Figure 4.7: Plasma platinum concentration measured at various times after a single 
intraperitoneal dose of either cisplatin at 6mg/kg (●) or CB[7]cisplatin at 34mg/kg (  ). 
Results are the mean ± SEM of triplicate measurements and are shown with either a linear 
(A) or log (B) time scale. 
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PK Parameter Cisplatin 6mg/kg CB[7]cisplatin (34m/kg) 
Cmax (μg/mL) 17.5 10.2 
Tmax (minutes) 5 5 
AUC0-1(hr.μg/mL) 4.0 4.8 
AUC0-4(hr.μg/mL) 6.4 10.3 
AUC0-6(hr.μg/mL) 7.6 13.2 
AUC0-24(hr.μg/mL) 16.3 28.8 
Table 4.6: Pharmacokinetic parameters for cisplatin and CB[7]cisplatin when administered as 
single intraperitoneal injection in nude mice. 
  
It could be argued that the increased plasma platinum concentrations can be 
achieved by simply increasing the dose of the administered cisplatin. 
Subsequently, to test the hypothesis that increased platinum exposure could be 
obtained by simply increasing the dose of cisplatin, the pharmacokinetics of 
CB[7]cisplatin with a higher dose of cisplatin of 8mg/kg was examined. 
Previously it has been established that the maximum tolerated doses of cisplatin 
in mice is 6mg/kg (Dr Jane Plumb, personal communication)(Plumb, Strathdee et 
al. 2000). Doses beyond 6mg/kg of cisplatin are toxic to mice and hence cannot 
be tolerated in longer term. However, since the mice were sacrificed after 8 
hours these experiments were explored wherein mice were administered single 
intraperitoneal injection of cisplatin at 2 different doses namely 6mg/kg and 
8mg/kg. The time course of platinum in plasma of mice treated with single 
intraperitoneal injection of cisplatin at two different doses, 6mg/kg and 8mg/kg 
or CB[7]cisplatin  is shown in figure 4.8. Intraperitoneal injection of cisplatin at 
8mg/kg resulted in a higher peak plasma level compared to that for cisplatin at 
6mg/kg dose (Figure 4.8, Table 4.7). The AUC for the first hour after injection 
(AUC0-1hr) was 4.2hr.μg/mL for cisplatin at 6mg/kg and increased to 4.9hr.μg/mL 
for cisplatin at 8mg/kg which was similar to that obtained for CB[7]cisplatin   
(4.8hr.μg/mL). The AUC over the first 6 hours after injection was higher for 
CB[7]cisplatin (13.2hr.μg/mL) than for cisplatin at either 6mg/kg (7.6 hr.μg/mL) 
or 8mg/kg (10.6hr.μg/mL) (Table 4.7). 
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Figure 4.8: Plasma platinum concentration measured at various times after a single 
intraperitoneal dose of either cisplatin (6mg/kg,   or 8mg/kg,    ) or CB[7]cisplatin (34mg/kg, 
●). Results are the mean ± SEM of triplicate measurements and are shown with either a 
linear (A) or log (B) time scale. 
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PK parameter Cisplatin 6mg/kg CB[7]cisplatin 
(34mg/kg) 
Cisplatin 8mg/kg 
Cmax (μg/mL) 17.5 10.4 19.3 
Tmax (minutes) 5 5 3 
AUC0-1(hr.μg/mL) 4.0 4.8 4.9 
AUC0-4(hr.μg/mL) 6.4 10.3 8.4 
AUC0-6(hr.μg/mL) 7.6 13.2 10.6 
Table 4.7: Pharmacokinetic parameters of cisplatin 6mg/kg, 8mg/kg and CB[7]cisplatin when 
administered as single intraperitoneal injection in nude mouse. 
 
4.7  Results: Tumour and tissue platinum levels 
The platinum levels in A2780 and A2780/cp70 xenografts are as shown in figure 
4.9, table 4.8 and 4.9. Tumour platinum levels were higher after treatment with 
CB[7]cisplatin  at the dose of 34mg/kg which is equivalent to  the dose of 
cisplatin at 6mg/kg than with free cisplatin in both the cisplatin sensitive 
(A2780) and cisplatin resistant (A2780/cp70) xenografts. There was a statistically 
significant difference in tumour platinum levels at 4 hours, favouring 
CB[7]cisplatin,  in both A2780 xenografts (cisplatin 134 ± 13 ng Pt/gm tissue, 
compared to 187 ± 15ng Pt/gm tissue for CB[7]cisplatin, P=0.03) and A2780/cp70 
xenografts (cisplatin 107 ± 16 ng Pt/gm tissue  compared with 178 ± 32 ng Pt/gm 
for CB[7]cisplatin, P=0.04) (Table 4.8 and 4.9). Similar trend favouring 
CB[7]cisplatin was also noted at 1 hour after drug treatment. 
The deposition of platinum in kidney and liver measured at similar time points as 
the tumours are given in table 4.10 and illustrated in figure 4.9.  At 4 hours, the 
platinum levels in kidney of the mice treated with CB[7]cisplatin  was higher   
compared to cisplatin (1332 ± 39  ng Pt/gm tissue for CB[7]cisplatin versus 878 ± 
67 ng Pt/gm tissue for cisplatin, P=0.004. 
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Figure 4.9: Platinum levels in A2780 (left) and A2780/cp70 (right) xenografts measured 
following single intraperitoneal injection of cisplatin 6mg/kg (black bars) or CB[7]cisplatin 
34mg/kg, equivalent dose of cisplatin 6mg/kg (grey bars).Values are mean ± SEM of 6 mice. 
 
 
Figure 4.10: Platinum levels in liver (right) and kidney (left) of mice treated with single 
intraperitoneal injection of cisplatin at 6mg/kg (black bars) or CB[7]cisplatin at  34mg/kg, 
equivalent dose of cisplatin 6mg/kg (grey bars).Values are mean ± SEM of 6 mice. 
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Time(hours) 
Pt levels in A2780 xenografts (ng of Pt/gm tissue) 
Cisplatin 6mg/kg CB[7]cisplatin 
0 (control) 13 ± 7 13 ± 7 
1 151 ± 25 198 ± 19   (P=0.18) 
4 134 ± 13 187 ± 15   (P=0.03) 
Table 4.8: Platinum content in A2780 xenografts after single intraperitoneal administration 
of cisplatin at 6mg/kg or CB[7]cisplatin at 34mg/kg (dose equivalent of cisplatin at 6mg/kg). 
Results are mean ± S.E.M of 6 samples. 
 
Time(hours) 
Platinum levels in A2780/cp70 xenografts 
(ng of Pt/gm tissue) 
Cisplatin 6mg/kg CB[7]cisplatin(34mg/kg) 
0 (control) 11 ± 2 11 ± 2 
1 124 ± 20 193 ± 33   (P=0.09) 
4   107 ± 16 178 ± 32     (P=0.04) 
Table 4.9: Platinum content in A2780/cp70 xenografts after single intraperitoneal 
administration of cisplatin at 6mg/kg or CB[7]cisplatin at 34mg/kg (dose equivalent of 
cisplatin at 6mg/kg). Results are mean ± S.E.M of 6 samples. 
 
Time 
(hours) 
Kidney (ng of Pt/gm tissue) Liver (ng of Pt/gm tissue) 
Cisplatin 
6mg/kg 
CB[7]cisplatin 
(34mg/kg) 
Cisplatin 
6mg/kg 
CB[7]cisplatin 
(34mg/kg) 
0 (control) 8 ± 2 8 ± 2 6 ± 2 6 ± 2 
1 
761 ± 244 1206 ± 37  
(P=0.15) 
539 ± 177 926 ± 45   
(P=0.11) 
4 
878 ± 67 1332 ± 39  
(P=0.004) 
649 ± 83 719 ± 94   
(P=0.61) 
Table 4.10: Values of platinum deposited in kidney and liver of mice treated with single 
intraperitoneal administration of cisplatin at 6mg/kg or CB[7]cisplatin at 34mg/kg (dose 
equivalent of cisplatin at 6mg/kg). Results are mean ± S.E.M of 3 samples. 
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4.8 Discussion 
These results demonstrate that the method developed to evaluate platinum 
levels in biological samples using ICP-MS is reliable and detection limits of ICP-
MS are within the acceptable range for bioanalytical assays. This method with 
ICP-MS was suitable for measuring low levels of platinum obtained in the cellular 
drug uptake studies. The pharmacokinetic experiments in tumour bearing mice 
demonstrate that CB[7]cisplatin has a favourable and distinct pharmacokinetic 
profile compared to cisplatin which results in  increased systemic exposure (both 
plasma and tumour) of platinum. 
4.8.1 Validation of ICP-MS 
These experiments confirm that ICP-MS can be used as a reliable and 
reproducible method to analyse platinum compounds in biological matrices. ICP-
MS has a wide dynamic linear range and can detect analytes in the range of ng/L 
or ppt. Clearly, the Thermo Electron Corporation X-Series II quadrupole ICP-MS 
used in our analyses has a remarkable sensitivity for platinum with a detection 
limit in the region of 35ng/L. However, this level of sensitivity is difficult to 
achieve in whole plasma due to inherent high background levels of platinum, 
interference due to high organic contents of unfiltered plasma and variation 
between samples. Hence the lower limit of detection according to this assay was 
established as 1.0μg/L which provides a wide safety net and it is likely that the 
levels of detection are better than the indicated value of 1.0μg/L.  The tests to 
check the stability of platinum in the biological matrices have confirmed that 
the deviation of platinum values in the stored samples was less than 5% from the 
initial value even when samples were stored for more than a month. 
Nevertheless, potential problems with stability were avoided since both the 
calibration standards and the test samples were freshly prepared prior to each 
analysis. 
There is a clear linear correlation between the platinum levels expressed as ICPS 
and the concentration of the calibration standards. The correlation regression 
coefficient(r) was greater than 0.9999 for all the three isotopes of platinum, 
irrespective of the matrix used, which conforms to the acceptable levels of        
r > 0.95 for bioanalytical assays. There were high background levels of platinum, 
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when 1% plasma in 1% nitric acid was used as the biological matrix for calibration 
and quality control standards  as evident by the high intercept  value in figure 
4.2 (range: 3550-4571). This is notably higher (Intercept value: 76–105) in 
comparison to the calibration using 1% nitric acid in ultrapure, deionised water 
as shown in figure 4.1. This could be explained by the matrix interference and 
signal noise from high organic content in plasma based biological matrix. 
The within-day accuracy was in the range of 2%-14% and the precision was 0.9% 
to 1.5% for platinum concentrations ranging from 2.5μg/L to 100μg/L when      
1% plasma in 1% nitric acid was used to prepare the quality control samples     
(Table 4.1). The deviation of the observed from the expected results was less 
than 15% for concentration ranging from 1.0μg/L to 100μg/L and the accuracy 
improved with higher concentrations. The between-day precision and accuracy 
were also measured and did not vary significantly (results not shown). These 
results adhere to  published criteria for validation of bio-analytical methods 
(Shah, Midha et al. 2000). It is generally advocated that matrix based calibration 
should be used for bioanalytical assays. Typically with meticulous care, 1mL of 
blood could be obtained by cardiac puncture from each mouse from which 
plasma can be separated by centrifugation. However, preparing calibration 
standards with plasma derived from mice would involve sacrificing a large 
number of mice. In keeping with principle of “refine, reduce and recycle” in 
performing animal experiments, the calibration standards were prepared with 1% 
nitric acid in ultrahigh pure deionised water but the quality control samples 
were prepared with plasma based matrix (1% plasma in 1% nitric acid). As shown 
in table 4.2, both the accuracy and precision were notably better (compared 
with plasma based calibration) and were within acceptable limits in the 
concentration ranging from 1.0μg/L to 100μg/L.  
The cellular platinum uptake experiment confirms the validity of ICP-MS as tool 
to analyse platinum at low concentrations. Cisplatin enters the cells primarily by 
passive diffusion and this process is not saturable when cancer cells are exposed 
to cisplatin at doses up to at least 100μM (Andrews, Velury et al. 1988). The 
dose of 5μM was chosen to evaluate the platinum content of cells with increasing 
time as this was a dose at which the levels of platinum could be reliably 
detected using ICP-MS and was not toxic to cells within the duration of the 
experiment. As shown in figures 4.3 and 4.4, the cellular accumulation of 
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platinum increases proportionally with increasing dose and incubation time. The 
experiments demonstrate that the uptake of platinum is proportional to dose of 
cisplatin and time of exposure to cisplatin, in keeping with the published 
literature (Yoshida, Khokhar et al. 1994; Siddik 2003; Ghezzi, Aceto et al. 2004).   
Following the validation of the method described above, ICP-MS was used to 
evaluate the platinum uptake in cancer cell lines treated with a novel drug 
delivery system of platinum (gold nanoparticle containing active component of 
oxaliplatin) that was developed by Dr Nial Wheate and this has been published 
(Brown, Nativo et al. 2010).  
4.8.2 Cellular pharmacokinetics of CB[7]cisplatin 
The cellular platinum uptake experiments demonstrate that the encapsulation of 
cisplatin does not affect the intracellular accumulation of platinum  with 
comparable levels of  platinum  content in the A2780 cells treated with 
CB[7]cisplatin or cisplatin (Figure 4.6). The platinum uptake in the cisplatin 
sensitive ovarian cancer cell line, A2780 is identical for cisplatin compared with 
CB[7]cisplatin at both early and delayed time points. The cellular platinum 
uptake experiment is consistent with the observations made in the experiments 
described in chapter 3 (Figures 3.2 and 3.3) that there is no difference in the in 
vitro cytotoxicity between free and encapsulated cisplatin. 
Of note, the uptake and retention of platinum has been suggested as a 
mechanism of resistance to cisplatin (Siddik 2003). In these experiments, there 
was no difference in the cellular platinum accumulation between cisplatin or 
CB[7]cisplatin treated cells which further strengthens the results presented in 
chapter 3,  that CB[7] encapsulation does not play a role in modulating cellular 
platinum resistance. 
4.8.3 Plasma pharmacokinetics of CB[7]cisplatin 
The results of the pharmacokinetic experiments in xenografts reliably 
demonstrate that CB[7]cisplatin has a favourable and distinct pharmacokinetic 
profile compared to cisplatin which results in  increased systemic exposure of 
platinum. The maximum plasma concentration of the drug is higher for cisplatin 
than CB[7]cisplatin (Cmax 17.5μg/mL for cisplatin versus 10.4μg/mL for 
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CB[7]cisplatin, P=0.09). However Tmax, the time taken to attain the Cmax is 
identical at 5 minutes for both cisplatin and CB[7]cisplatin. These 
pharmacokinetic  parameters for cisplatin are comparable to published  data for 
cisplatin in mice which further validates the method used for platinum analysis 
(Johnsson, Olsson et al. 1995).  
Of note, the platinum values measured in the plasma pharmacokinetics 
experiments were well within the range of standard curve which covered 
concentrations ranging from 0 to 50μg/mL. 
The xenograft experiments with cisplatin and CB[7]cisplatin have demonstrated 
that the tumour growth delay by CB[7]cisplatin in comparison with cisplatin was 
pronounced in the first 48 hours  and this tumour growth delay was maintained 
for the entire duration of the experiment. Early clinical studies with cisplatin 
have established that the initial half-life of cisplatin is 14-30 minutes  and the 
terminal half-life could vary from 24 hours to 7 days (DeConti, Toftness et al. 
1973). Hence the plasma pharmacokinetic analysis in this study was primarily 
focused towards the initial 48 hours. 
The key difference in the pharmacokinetics between the two platinum 
compounds was noted in AUC. The AUC of CB[7]cisplatin is consistently higher 
across early time point when compared with cisplatin (AUC0-1: 4.8 hr.μg/mL for 
cisplatin vs. 4.0 hr.μg/mL for CB[7]cisplatin), mid-time point (AUC0-6: 13.2 
hr.μg/mL for cisplatin vs. 7.6 hr.μg/mL for CB[7]cisplatin) and at later time 
point (AUC0-24: 28.8 hr.μg/mL for cisplatin vs. 16.3 hr.μg/mL for CB[7]cisplatin). 
This data clearly show that with CB[7]cisplatin, there is prolonged retention of 
platinum in the plasma which has resulted in increased platinum delivery to 
tumour with a corresponding  increase in anti-tumour activity.  
As with any chemotherapeutic agent, it is possible to achieve higher 
concentrations of platinum in plasma by increasing the dose of cisplatin 
administered but this would result in unacceptable toxicities. Cisplatin produces  
dose proportional attenuation of tumour growth at doses ranging from 4 to 
8mg/kg  but cisplatin at dose of 8mg/kg is poorly tolerated with increased 
weight loss which is more pronounced after 2-3 days (Dr Jane Plumb, Personal 
communication)(Plumb, Strathdee et al. 2000).  To test the hypothesis that the 
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higher plasma platinum concentration attained with CB[7]cisplatin could be 
achieved by merely increasing the dose of cisplatin, the plasma 
pharmacokinetics of CB[7]cisplatin was compared with cisplatin at dose of 
8mg/kg (Figure 4.8). It needs to be emphasised that our group has established 
that this dose (cisplatin at 8mg/kg) is intolerable to mice. The mice treated at 
8mg/kg were monitored for general welfare and distress and were sacrificed 
within 6 hours in order to avoid any distress which could be caused by the 
increased dose of cisplatin. Ideally the pharmacokinetic analysis could have been 
conducted for the entire time spanning 24 hours and this could be considered as 
a limitation of this pharmacokinetic experiment. 
The pharmacokinetic parameters shown in table 4.7 demonstrate that Cmax for 
cisplatin at 8mg/kg was 19.3 μg/mL which is significantly higher than the Cmax 
of CB[7]cisplatin which was 10.6 μg/mL, P=0.0005.  However the AUC at the 
mid-time points was not higher for cisplatin at the higher dose of 8mg/kg 
compared with CB[7]cisplatin. There was a suggestion that the AUC of 
CB[7]cisplatin is marginally higher than the AUC of cisplatin at  8mg/kg       
(AUC0-4: 10.3 hr.μg/mL vs. 8.4 hr.μg/mL and AUC0-6: 13.2 hr.μg/mL  vs. 10.6 
hr.μg/mL for CB[7]cisplatin and cisplatin at 8mg/kg respectively). Together this 
data suggest that increasing the dose of cisplatin increases the peak plasma 
platinum concentration resulting in intolerable side effects without an 
associated significant increase in systemic platinum exposure. There is evidence 
to indicate that nephrotoxicity of cisplatin is potentially associated with the 
peak plasma concentration (Nagai, Kinoshita et al. 1996; Erdlenbruch, Nier et al. 
2001). CB[7]cisplatin, in contrast, did not result in higher Cmax but resulted in  
higher AUC even in comparison with cisplatin at 8mg/kg.   
Since it is only the elemental platinum that could be measured here with ICP-MS, 
it is not clear if the platinum in the tissue and plasma is free as cisplatin or still 
encapsulated within CB[7] cavity. Nevertheless, in the absence of significant 
toxicity as shown in the xenografts studies and the different pharmacokinetic 
profiles of these two compounds it could be speculated that cisplatin is still 
within the CB[7]cavity in plasma. There are ways to measure the free cisplatin in 
the plasma and one such method could be radionuclide labelling of cisplatin. The 
difference the radioactive signals emitted by free cisplatin and cisplatin 
encapsulated within CB[7] cisplatin could be measured by a radioactive camera. 
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In addition to measuring the free cisplatin, such radionuclide tagging could also 
help to ascertain the tissue deposition characteristic of CB[7]cisplatin. It could 
also be hypothesised that the encapsulation of cisplatin within CB[7] protects  
cisplatin from bio-degradation and metabolism resulting in prolonged circulation 
of platinum in the plasma. 
4.8.4 Choice of biological matrix 
Mouse plasma and tissues were chosen as the biological matrix to investigate the 
pharmacokinetics of CB[7]cisplatin. It is widely accepted that the platinum 
levels in the plasma ultra-filtrate represent the pharmacologically active 
component of administered platinum as platinum bound to plasma protein is not 
thought to be pharmacologically active. The  fact that cisplatin and oxaliplatin  
have shorter initial distribution phase and a long terminal elimination phase 
(Johnsson, Olsson et al. 1995; Graham, Lockwood et al. 2000) suggests that the 
platinum bound to plasma protein could be released in later stages and could 
contribute to the pharmacological actions of these compounds. Studies in 
patients on renal dialysis who receive cisplatin have demonstrated that the 
plasma cisplatin levels increase soon after dialysis even in patients where 
cisplatin was administered prior to dialysis. This indicates that there is degree 
interplay between free and bound cisplatin (Prestayko, Luft et al. 1978; 
Watanabe, Takiguchi et al. 2003). Published data indicate  a close equilibrium 
between  platinum in  plasma and plasma ultra-filtrate and it is possible that the 
protein binding of platinum is not completely  irreversible (Gamelin, Allain et al. 
1995). Besides, platinum could be measured in patients even 10 years after their 
treatment with cisplatin and there is now a growing body of evidence to suggest 
that long term retention of platinum correlates  with the toxicities e.g. 
neurotoxicity (Gietema, Meinardi et al. 2000; Sprauten, Darrah et al. 2012). It is 
also plausible that the magnitude of difference in platinum levels in plasma 
ultra-filtrate between the two platinum compounds (cisplatin and CB[7]cisplatin) 
could  be smaller in comparison with platinum levels in whole plasma and 
measuring the platinum levels in plasma ultra-filtrate could underestimate a 
smaller yet clinically meaningful difference in the platinum levels. The plasma 
protein binding of CB[7]cisplatin is not known and given its atomic mass unit is 
approximately 1kDa (Dr Nial Wheate, personal communication), any anti-tumour 
effect that could potentially be attributed to the plasma-protein bound 
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CB[7]cisplatin could have been overlooked. Preliminary in vitro experiments 
evaluating the albumin binding of CB[7]cisplatin or cisplatin were inconclusive. 
For these reasons, levels of platinum in whole plasma were measured. 
4.8.5 Tissue pharmacokinetics of CB[7]cisplatin 
The tissue pharmacokinetic data indicate that treatment with CB[7]cisplatin 
results in increased platinum delivery to tumours both in cisplatin sensitive 
(A2780) and cisplatin-resistant (A2780/cp70) human ovarian cancer xenografts. 
In A2780 xenografts, the platinum content in tumour, measured 4 hours after 
administration of the drug, was significantly higher with CB[7]cisplatin in 
comparison with cisplatin. Platinum levels were 134 ± 13 ng Pt/gm tissue  for 
cisplatin vs. 187 ± 15 ng Pt/gm tissue  for CB[7]cisplatin, P=0.03 and there was 
numerical difference favouring CB[7]cisplatin at 1 hour time point although this 
difference did not reach statistical significance with P=0.18 (Table 4.8). 
A similar difference was also noticed in A2780/cp70 xenografts with higher 
tumour platinum levels in CB[7]cisplatin treated mice. This observation merits 
further discussion as A2780/cp70 xenografts are not sensitive to treatment with 
cisplatin and in vitro experiments have shown that the cytotoxicity of 
CB[7]cisplatin is similar to cisplatin in these ovarian cancer cell lines. At 4 hours’ 
time point, the platinum content in  A2780/cp70 tumours was 107 ± 16 ng Pt/gm 
tissue  and 178 ± 32 ng Pt/gm tissue  for cisplatin and CB[7]cisplatin 
respectively, P=0.04 (Table 4.9). Similar to A2780 xenografts, the platinum 
content in A2780/cp70 tumours measured 1 hour following administration of 
CB[7]cisplatin was higher than tumours treated with cisplatin (124 ± 20 ng Pt/gm 
tissue  for cisplatin and 193 ± 33 ng Pt/gm tissue for CB[7]cisplatin),  although 
the difference was not statistically significant (P=0.60). It is more than likely 
that this increased delivery of platinum to A2780/cp70 tumour by CB[7]cisplatin 
has overcome cisplatin resistance exhibited by these tumours. This enhanced 
anti-tumour activity does not come at the expense of increased toxicity. This 
hypothesis could also explain the increased anti-tumour activity demonstrated 
by CB[7]cisplatin in human colon cancer xenografts, HCT116 (Figure 3.10, 
Chapter 3). 
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It could be debated if statistically significance of the tumour platinum levels 
would result in a meaningful difference. More often a statistically significant 
result does not always result in clinically meaningful difference. For example in 
the phase III trial comparing  gemcitabine  versus the combination of erlotinib 
and gemcitabine in advance pancreatic cancer resulted in statistically significant 
improvement in overall survival (6.21 months for the combination group versus 
5.9 months for gemcitabine) but a difference of mere 10 days cannot be 
accepted as clinically meaningful (Moore, Goldstein et al. 2007). However, the 
in vivo experiments in chapter 3 have demonstrated that there is a significant 
difference in the tumour doubling time in both the A2780 and A2780/cp70 
xenografts. Taken in conjunction with the data from the in vivo experiments, 
these statistically significant differences in tissue platinum values are 
meaningful and relevant. 
Contrary to the hope of tumour targeted drug delivery, the increased delivery of 
platinum is not specifically targeted towards the tumour tissue alone as the 
platinum levels were higher in both liver and kidney of mice treated 
CB[7]cisplatin when compared with cisplatin. This effectively reflects that the 
increased plasma platinum concentration due to CB[7]cisplatin treatment has 
resulted in increased, non-specific  tissue exposure to platinum. Although the 
platinum deposition was higher upon CB[7]cisplatin administration particularly in 
kidneys  (878 ± 67ng Pt/gm tissue with cisplatin  and 1332 ± 39ng Pt/gm tissue 
with CB[7]cisplatin at 4 hours, P=0.004)  (Table 4.10 and Figure 4.10), this was 
not associated with increased toxicity as evident by the absence of loss of body 
weight in these mice. Clearly this increased deposition of platinum in kidneys of 
mice treated with CB[7]cisplatin is considerably higher when compared to the 
platinum content in the tumour xenograft. The information about the stability of 
CB[7]cisplatin would be the key determinant in explaining the absence of  
significant toxicities despite the increased platinum deposition in these organs. 
It is evident from these experiments that the toxicity of cisplatin is influenced 
by the Cmax than AUC. Cisplatin at 8mg/kg resulted in a Cmax which is 
significantly higher than the Cmax of CB[7]cisplatin and a similar trend was also 
noted with cisplatin at 6mg/kg. The AUC of cisplatin at 8mg/kg however, 
appears to be equal if not lesser when compared with CB[7]cisplatin. Of note, 
cisplatin at 8mg/kg was not tolerated by the mice whereas all the mice 
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tolerated CB[7]cisplatin well as evident by absence of loss of body weight. This 
indicates that Cmax is responsible for the toxicity than AUC. Since CB[7]cisplatin 
has a lesser Cmax  and larger AUC than cisplatin, it was well tolerated by mice 
and there was enhanced  tumour growth attenuation with CB[7]cisplatin. This 
increased toxicity due to Cmax of platinum is also noted in another platinum 
analogue, oxaliplatin. Patients treated with oxaliplatin can experience laryngo-
pharyngeal dysaesthesia or laryngeal spasm, a significant toxicity of oxaliplatin 
and this is related to Cmax of oxaliplatin. In patients who experience laryngeal 
spasm, increasing the duration of infusion to 6 hours reduces the Cmax by 
approximately 50% when compared to one hour infusion and results in lesser 
occurrence of such spasm (Graham, Lockwood et al. 2000).  
In addition, as hypothesised for the plasma pharmacokinetics, it is plausible that 
encapsulation of cisplatin within CB[7], besides protecting  the platinum from 
biodegradation, also controls the  release of cisplatin  dependent on the tumour 
microenvironment. It is likely that the acidic pH at the tumour interstitium 
facilitates the release of cisplatin from CB[7] whereas cisplatin  still remains 
encapsulated in the renal and hepatic  tissues which are well vascularised and 
oxygenated. As discussed in the introduction chapter, the fundamental principle 
of macromolecular drug delivery is that these drug delivery systems enhance 
drug delivery through exploiting the principle of enhanced permeability and 
retention in tumours. However, although CB[7] is a macrocycle, the size of 
CB[7]cisplatin is approximately 1nm (nanometre) and this size is not large 
enough for CB[7]cisplatin to be trapped in the permeable vasculature of 
tumours. Hence it possible that the altered microenvironment in the tumour 
facilitates the release of cisplatin from CB[7]cisplatin but this phenomenon  
could not have happened in organs with normal vascularisation and  perfusion. 
4.9 Conclusion 
The observations noted in this chapter confirm the validity of ICP-MS as a 
suitable bio-analytical assay to evaluate platinum levels in cell, plasma and 
tissue samples. To conclude, the experiments in chapter 3 and 4 have shown 
that CB[7]cisplatin could overcome cisplatin resistance and this is due the 
distinct pharmacokinetic properties of the encapsulated cisplatin which results 
in increased tissue exposure of platinum as measured by AUC. These 
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experiments are proof of principle that cucurbit[7]uril can be an effective drug 
delivery system for cisplatin. In addition, it could also be hypothesised that 
encapsulation of cisplatin hinders the degradation of cisplatin by the sulphur 
containing thiols, thereby resulting in enhanced cytotoxic activity. In the 
following chapters, the effect of cucurbit[7]uril cisplatin in a disseminated 
ovarian cancer model will be explored using bioluminescence imaging as a 
pharmacodynamic marker for response to treatment. In addition, the activity of 
subcutaneously administered CB[7]cisplatin will also be evaluated to ascertain 
the relationship between the route administration of the drug and its cytotoxic 
activity
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5 Activity of Cucurbituril encapsulated cisplatin in 
disseminated model of ovarian cancer 
5.1 Introduction 
Epithelial ovarian cancer is the most lethal gynaecological cancer in part, due to 
advanced stage at presentation  and in 2010 was the 4th most common cause of 
female cancer deaths in the UK (CancerResearchUK 2012; Konstantinopoulos Pa 
2012). Advanced stage ovarian cancer presents with widespread peritoneal 
dissemination and ascites. Treatment primarily involves aggressive cytoreductive 
surgery, modern combination chemotherapy (platinum analogues and paclitaxel) 
and/or i.p. cisplatin based-chemotherapy (Armstrong, Bundy et al. 2006; 
Guarneri, Piacentini et al. 2010; Ledermann and Kristeleit 2010). Difficulty in 
early cancer detection due to vague non-specific symptoms and  lack of reliable 
screening tests  resulting in advanced stage presentation, and the rapid 
progression to chemo-resistance have prevented an appreciable improvement in 
the five year survival rate of patients with ovarian cancer (Hennessy, Coleman et 
al. 2009; Schorge, Modesitt et al. 2010; Buys, Partridge et al. 2011). 
Dissemination of single tumour cells into the peritoneal cavity is the major cause 
of tumour recurrence even after complete resection of the primary solid tumour 
(Scott, Holdsworth et al. 2000; Lim, Song et al. 2010). Despite the advent of 
targeted therapy, there is no effective treatment for peritoneal recurrence 
(Guarneri, Piacentini et al. 2010; Burger, Brady et al. 2011) and there is a clear 
need for the development of new therapies. 
 
Animal models of cancer are essential in the preclinical evaluation of anti-
cancer agents. Potential new drugs are usually identified from studies in vitro. 
These studies range from random screen of compounds for activity in cell lines 
(Shoemaker 2006) to more detailed studies involving drug design and target 
specificity. Whilst studies in vitro with cancer cell lines can answer a number of 
mechanistic questions they do not address selectivity for tumour compared to 
normal tissues and do not take account of the physiological and pharmacological 
properties of the compound. These properties are of critical importance to 
studies of drug delivery since they can be exploited to ensure tumour specific 
delivery. Human tumour xenograft models, produced by transplantation of 
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human cancer cell lines or tumour biopsies in to immunodeficient mice play a 
vital role in drug development (Morton and Houghton 2007). Ovarian cancer cell 
lines derived from ascites or primary ovarian tumours have been used 
extensively and can be very effective for studying the processes controlling 
growth regulation and chemosensitivity (Ingersoll, Yue et al. 2009). Many of 
these studies of human tumour growth in vivo are based on subcutaneous 
xenografts where growth is measured by changes in tumour volume which is 
estimated by calliper measurements. This works well for rapidly growing 
tumours such as those derived from the human ovarian cancer cell line A2780 
and, where the aim is to demonstrate growth inhibition in response to drug 
treatment. However, calliper measurements do not give a true estimate of 
viable tumour mass and can underestimate the treatment efficacy(Rehemtulla, 
Stegman et al. 2000). Growth of subcutaneous xenografts depends on the blood 
supply derived from either the skin or the body wall. The vasculature tends to 
predominate round the periphery of the tumour with poor penetration in to the 
tumour mass such that the central region becomes necrotic. Furthermore, 
subcutaneous xenografts can be criticised as lacking an appropriate tumour 
microenvironment and the ability to spontaneously metastasise to clinically 
relevant sites. It should be stressed, however, that almost all the conventional 
chemotherapeutic agents that are now in clinical use have demonstrated notable 
preclinical activity in these models (Sharpless and DePinho 2006). However, as 
stressed above the ability to kill tumour cells is not the only requirement of a 
drug delivery system since the tumour microenvironment can have a major 
impact on the efficacy of delivery systems. 
 
One approach to address these criticisms has been the development of 
orthotopic tumours, whereby tumour cells are injected into the tissue or organ 
of origin. Examples of these models are the injection of breast cancer cells in to 
the mammary pad of fat or of pancreatic cancer cells into the pancreas.  These 
tumour models can reproduce the tumour micro-environment to a certain degree 
and have been used to monitor drug activity (Kim, Evans et al. 2009). 
Development of such models frequently requires surgical implantation and is 
technically challenging. Besides, tumour development is not easy to monitor 
without sacrifice of the animal. Other animal models of disseminated ovarian 
cancer include spontaneous ovarian carcinoma in experimental animals 
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(Vanderhyden, Shaw et al. 2003; Connolly and Hensley 2009) or genetically 
modified animals (Dinulescu, Ince et al. 2005; Hensley, Quinn et al. 2007).  
However, the generation of these models is time-consuming, involves large 
animal cohorts and tumour growth is difficult to monitor and they are thus not 
ideal for the evaluation of novel drugs. 
5.2 Biophotonic imaging 
The development of new tools that can non-invasively assess the molecular and 
cellular events leading to the generation and proliferation of transformed cells, 
and their response to anti-cancer agents, would overcome many of the 
drawbacks of the existing pre-clinical models used in developing anti-cancer 
therapies. Several advanced imaging strategies that utilise fluorescence imaging, 
magnetic resonance imaging (MRI) and positron emission tomography (PET) have 
been described for studying cancer (Tjuvajev, Finn et al. 1996; Chenevert, 
McKeever et al. 1997; Uehara, Miyagawa et al. 1997; Bogdanov Jr and Weissleder 
1998; Ross, Zhao et al. 1998; Tjuvajev, Avril et al. 1998; Galons, Altbach et al. 
1999; Gambhir, Barrio et al. 1999; Gambhir, Barrio et al. 1999; Jacobs, Dubrovin 
et al. 1999; Weissleder, Tung et al. 1999). However there are many biological 
processes that cannot be externally monitored with non-invasive scanning 
techniques such as computed tomography (CT), ultrasound and MRI because key 
molecules in these processes are not distinguishable even in the presence of 
contrast dyes or radioactive tracers, although methods for acquiring functional 
data and analysis of transgene expression have been developed with MRI 
(Weissleder, Moore et al. 2000). However, MRI requires long scan times and 
expensive instrumentation. PET imaging provides metabolic information and 
some reporter genes that contain radionuclides are available (Tjuvajev, Finn et 
al. 1996; Tjuvajev, Avril et al. 1998; Gambhir, Barrio et al. 1999; Gambhir, 
Barrio et al. 1999). PET is also limited by the requirement of radioactive tracers 
with relatively short half-lives.  
 
Photoproteins such as luciferase from the firefly, Photinus pyralis, have been 
used as reporter genes in both in vitro and ex vivo assays (Wood 1995; Hastings 
1996). This luciferase has been used to study gene expression in cancer cells in 
culture (Chen, Biel et al. 1997; Willard, Faught et al. 1997) and to tag tumour 
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cells for the purpose of monitoring growth and response to therapy in animal 
models of human disease (Zhang, Hellstrom et al. 1994; Takakuwa, Fujita et al. 
1997). However, analysis of cell proliferation in vivo in these studies was 
performed using an ex vivo assay. Analysis of reporter gene expression following 
removal of tumour tissues is limited by the loss both of the contextual influences 
of intact organ systems, and most of the temporal information. The goal of real-
time analysis of biological events in intact living animals has now been realised 
(Contag, Contag et al. 1995) by biophotonic imaging. Biological sources of light 
are sufficiently intense such that the light generated within a mammal can be 
detected externally and either endogenous or exogenous substrate can be made 
available to bioluminescent reporters in living mammals (Contag, Contag et al. 
1995). Among the many strengths of bioluminescence as a reporter in living 
mammals is the inherent low background of bioluminescent markers as 
compared with fluorescent or colorimetric reporters. This makes luciferase a 
superior reporter in vivo compared to fluorescent reporters where 
autofluorescence of tissues results in significant background, and already poor 
signal-to-noise ratios can further be reduced by photobleaching. Furthermore 
the rate of luciferase enzyme turnover in the presence of substrate allows for 
real-time measurements as this reporter does not accumulate to the extent of 
other reporters in cells (Contag, Olomu et al. 1998).  
 
Sensitive detection devices have been designed to visualise and quantify 
bioluminescent light by detecting photons that are transmitted through 
mammalian tissue from internal sources (Contag, Contag et al. 1995). 
Technology such as the IVISTM imaging system from Perkin Elmer use a charge 
coupled device (CCD) camera (with liquid nitrogen cooling and micro-channel 
plate intensifier to reduce background and increase signal), a dark imaging 
chamber to reduce incident light, and software to quantify the results. The 
number of photons transmitted through mouse tissues is sufficient to detect 1 x 
103 cells in the peritoneal cavity, 1 x 104 cells at subcutaneous sites, and 1 x 106 
circulating cells immediately following injection of the substrate (luciferin) 
suggesting that this approach may be applicable in evaluating agents in minimal 
disease states (Edinger, Sweeney et al. 1999). A quantitative comparison of 
bioluminescence imaging with serial MRI measurements of orthotopic rat brain 
tumours treated with the alkylating agent, carmustine (BCNU) demonstrated an 
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excellent correlation between detected photons and tumour volume with 
statistically similar cell kill values for the two imaging modalities (Rehemtulla, 
Stegman et al. 2000). 
 
5.3 Assessment of tumour growth in vivo by 
bioluminescence imaging 
An IVIS50 imaging system (Parkin Elmer) was available in the department but 
there was only very limited experience of the application of this technology to 
evaluate tumour growth in mice. Previous studies by the research group aimed 
to validate the use of bioluminescence imaging by comparing the technique with 
calliper measurements to monitor the growth and response to cisplatin of the 
ovarian cancer cell line A2780. Attempts to transfect the ovarian cancer cell 
lines A2780 and A2780/cp70 with the luciferase gene linked to the CMV promoter 
resulted in heterogeneous expression of luciferase. Selection of clones with high 
expression of the reporter often resulted in poor tumour uptake in mice. It was 
also noted that intraperitoneal injection of luciferin did not always provide a 
signal and that frequent anaesthesia, even for the short time required for 
imaging was not ideal. 
 
These problems are addressed in the initial studies described in this chapter. 
The manufacturers of the IVIS 50 were aware of the problems with transfection 
of tumour cell lines and had developed a panel of tumour cell lines expressing 
the luciferase gene. In order to increase the efficiency of gene transfer, they 
used a lentiviral system for infection and linked the gene to the human ubiquitin 
C promoter to ensure high expression. One of these lines, HCT116Luc, was 
compared with the A2780/cp70CMVLuc cells developed “in house” for the initial 
validation study. 
The aim of the validation studies was to be able to develop a disseminated 
model of ovarian cancer and to use bioluminescence imaging to monitor tumour 
growth and response to treatment. This chapter also describes development of a 
disseminated model by a colleague (Dr Gomez-Roman) and a study, carried out 
in collaboration with Dr Gomez-Roman, of the activity of encapsulated cisplatin 
in this model. 
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5.4 Rab25 model of disseminated ovarian cancer 
Many genes have been identified, both from cell lines and tumour samples, 
which are associated with enhanced tumour growth and invasiveness. Cheng and 
colleagues identified a region located on chromosome 1q22 which was amplified 
in 54% of ovarian cancer who failed to respond to chemotherapy (Cheng, Lahad 
et al. 2004). Subsequently Rab25, a member of the RAS oncoprotein superfamily, 
was identified as the oncogene associated with amplification of chromosome 
1q22. Rab25 is a member of the Rab11 subfamily which control trafficking events 
from late endosomes to the plasma membrane (Peter, Nuoffer et al. 1994). 
Rab25 expression is up-regulated in around 80% of ovarian cancer samples 
compared to normal ovarian epithelium (Cheng, Lahad et al. 2004). Much of our 
understanding of the role of Rab25 in tumour growth and invasion has come from 
the work of Prof Jim Norman and colleagues in the Beatson Institute for Cancer 
Research, Glasgow. They showed that Rab25 contributes to tumour progression 
by enabling the tumour cells to invade the extracellular matrix by altering the 
trafficking of integrin (Caswell, Spence et al. 2007). Rab25 associates with the 
α5β1 integrin through the cytoplasmic tail of the β1 integrin (Caswell, Spence et 
al. 2007). α5β1 integrin is known to have a key role in tumour cell proliferation 
and metastasis (Sawada, Mitra et al. 2008; Mitra, Sawada et al. 2011).  Rab25 
driven invasiveness is due to Rab25 dependent localisation and recycling of α5β1 
integrin vesicles at the pseudopodial tips of the cell and this invasiveness is 
strongly dependent on association of Rab25 with β1 integrin and ligation of 
fibronectin by α5β1 (Caswell, Spence et al. 2007). 
 
Over-expression of Rab25 in the human ovarian cancer cell line A2780 has been 
shown to confer invasive properties both in vitro and in vivo (Cheng, Lahad et 
al. 2004).  Furthermore expression of Rab25 in ovarian and breast cancer cell 
lines increased cell survival through reduced apoptosis after multiple stress 
conditions including UV radiation and paclitaxel. These results suggest that 
Rab25 expression might regulate resistance to chemotherapy. Since A2780 is well 
characterised as a subcutaneous xenograft this model of disseminated cancer 
was chosen for these studies. Before the advent of biophotonic imaging 
techniques, the in vivo assessment of the growth of disseminated ovarian cancer 
models was primarily done by monitoring the abdominal distension. Given that 
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peritoneal disease contains cells and ascitic fluid this was a crude assessment of 
tumour burden.  
 
For routine clinical use cisplatin is given by an intravenous infusion. This route is 
not practical in mice and the intraperitoneal route is often used since the 
pharmacokinetics parameters are closer to an intravenous infusion than those 
obtained by a bolus intravenous dose. It could be argued that intraperitoneal 
administration of drug when the tumour is located in the peritoneal cavity (as in 
the case of disseminated ovarian cancer model) is inappropriate. In order to 
address this issue subcutaneous drug administration was also investigated. 
 
5.5 Methods 
5.5.1 Bioluminescence imaging of animals  
The IVIS 50 imaging system was housed within a laminar flow work station in 
order to maintain sterility and was controlled and images analysed by Living 
Image 2.50.2 software (Perkin Elmer). The camera was initialised about 15 
minutes before imaging commenced to allow the camera to cool. Mice were 
brought into the work station in filter top cages and all subsequent steps were 
carried out within the work station. Mice bearing human tumour xenografts 
(established as described in section 2.4.2, chapter 2) were injected either 
intraperitoneally or subcutaneously, just below the back of the neck, with 100L 
of a sterile solution of D-luciferin (30mg/mL in PBS, Perkin Elmer). They were 
then placed in the chamber of the Xenogen GGI-8 gas anaesthesia system and 
anaesthetised according to the manufacturer’s instructions. The system delivers 
oxygen and vapourised isoflurane gas (3% isoflurane and 1 litre/min oxygen) to 
the induction chamber and to the imaging chamber through a 3 port anaesthesia 
manifold. In addition, it also contains activated charcoal evacuation filters which 
absorb the waste isoflurane from the induction chamber, thereby protecting the 
handlers from the effects of anaesthesia. The stopcock controlling the supply of 
isoflurane to the nose cone in the imaging chamber was turned on, to maintain 
the anaesthesia for the mice when they were placed in the imaging chamber. 
After 2-3 minutes, once the mice were anaesthetised they were placed in the 
imaging chamber. The chamber contained a manifold with 3 nose cones allowing 
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three mice to be imaged together. Mice were placed with their noses in the cone 
to maintain anaesthesia throughout the imaging procedure. Initially a black and 
white image of the mice was captured. The bioluminescent image was then 
captured. The duration of image capture varied depending on the intensity of 
the signal with an average capture time of 1 to 2 minutes. The intensity is 
proportional to time such that the duration of capture is not critical for 
comparisons but it is important not to let the signal saturate which can happen if 
the signal is intense. On completion of the imaging, mice were placed back in 
the cage and monitored for recovery which occurred within 1-2 minutes. 
5.5.2 Development of A2780-Rab25Luc 
A2780 cells stably expressing Rab25 were produced by transfecting A2780 cells 
with plasmids pcDNA3-Rab25 using Lipofectamine 2000 as described in section 
2.5.6, chapter 2. Geneticin (0.5mg/mL) was used as the selection agent. The 
cells were then evaluated for expression of Rab25 using Western blotting with a 
primary antibody developed “in house” by Prof Jim Norman’s research group, 
(antibody dilution 1:4000). A2780Rab25 cell line expressing the firefly luciferase 
gene under the control of Ubiquitin C promoter was constructed using a 
commercially available lentiviral gene delivery system. The luciferase gene was 
amplified from Pgl4-CMVLuc vector obtained from Promega with the aid the 
primers outlined below: Forward-5’ CACCATGGAAGACGCCAAA; Reverse-5’ 
AAACACGGCGATCTTTCCG. Virapower promoterless lentiviral gateway kit 
(described in detail in chapter 6) was used to clone the luciferase product into 
pENTR gene. Plasmid containing Ubiquitin C promoter (UbCp) was supplied in the 
kit. Lentiviral constructs were produced by recombination of pENTR/UbC 
promoter, the cloned pENTR luciferase and pLenti6/R4R2/V5-DEST. The 
resultant plasmid was then used to transfect HEK293FT cells (supplied in the kit) 
as per the Lipofectamine 2000 protocol described in section 2.5.6, chapter 2. 
Supernatant medium containing virus was harvested 72 hours post-transfection 
into a 15mL sterile capped, conical tube. This was then centrifuged and filtered 
through 0.45µm PVDF filter (Millipore, Bedford, MA) and resuspended in fresh 
medium. Determination of lentiviral titre was performed using A2780 cells and 
the lentiviral stocks were stored at -80oC.   
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Transduction of lentiviral constructs containing luciferase gene into A2780 and 
A2780Rab25cells was performed by plating the cells in a 6 well plate at a density 
of 5 x107 cells/well. After 24 hours, the supernatant medium was removed and 
2mL of lentivirus in culture medium was added along with 2 µg/mL of 
hexadimethrine bromide (Polybrene®). The next day (day 2), virus  was removed 
and fresh medium was added  and on the following day (day 3), culture medium 
containing blasticidin (2.5 µg/mL, A2780 and A2780-Rab25Luc)  and geneticin 
(0.5mg/mL, A2780-Rab25 only) as a selection agent was added for selecting cells 
stably expressing luciferase and Rab25. Expression of both genes was confirmed 
by Western blotting and bioluminescence imaging as above. These cells were 
labelled as A2780-Luc and A2780-Rab25Luc and their chemosensitivity to 
platinum based compounds was determined as described in section 2.2, chapter 
2.  
5.5.3 Growth and drug sensitivity of A2780-Rab25Luc in vivo 
For i.p. xenografts (disseminated ovarian cancer model), about 5x107 cells of 
either A2780-Luc or A2780-Rab25Luc were injected into the peritoneal cavity of 
mice. Mice were imaged weekly until the appearance of bioluminescent signal 
and the signal was greater than 8x105photons/second (around three to four 
weeks). Mice were treated (day 1) with PBS, cisplatin (6mg/kg) or CB[7]cisplatin 
(34mg/kg) and both drugs were given either intraperitoneally or subcutaneously. 
They were then imaged on days 4, 7 and 14. Analysis of the bioluminescent 
images was performed by defining a set region of interest to be used in all 
animals and for the disseminated model the signal over the entire abdomen of 
the mouse was analysed. 
 
5.6 Results 
5.6.1 Route of administration of luciferin 
Luciferin was administered as a bolus dose either intraperitoneally or 
subcutaneously to mice bearing HCT116Luc tumours and mice were imaged at 
intervals of 1 minute for 14 minutes (Figure 5.1). Initially the flux, which is the 
measure of bioluminescent signal emitted, increased with time. It reached a 
plateau after which the signal decreased. The shape of the curve was 
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independent of the size of the tumour (signal intensity) and of the route of 
administration. The plateau was achieved slightly earlier following subcutaneous 
administration but the duration of the plateau phase was similar for the two 
routes of administration. 
 
 
Figure 5.1: Bioluminescent signal (flux) obtained at various times after administration of        
D-luciferin to HCT116Luc tumour bearing mice. D-luciferin (3mg/mouse in 100µL PBS) was 
administered either intraperitoneally (A) or subcutaneously (B). The lines represent the 
signal from each of three mice used for each route of administration and maximum flux for 
each mouse is related to the size of the tumour. 
 
5.6.2 Sensitivity of bioluminescence measurement in vivo 
Mice were injected intravenously with cells at different concentration ranging 
from 104-106/mL, and bioluminescent imaging was done after 10 minutes as 
explained in section 5.5.1. The bioluminescent signal measured after about 10 
minutes and a rectangular field was placed over the mice (after BLI)  to measure 
the total flux from each of the mice (Figure 5.2 and Table 5.1). The cells used 
were either HCT116Luc or A2780/cp70 that had been transfected with a 
luciferase reporter (A2780/cp70CMVLuc). Cells were detected in the lungs of all 
mice although the signal was much greater for HCT116Luc cells than for 
A2780/cp70CMVLuc cells. 
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Figure 5.2: Bioluminescent signal measured 10 minutes after intravenous injection of cells at 
the densities shown. For comparison the colour bar has been set to the same range for the 
two images. 
 
 Total Flux 
(photons x 10-6/sec) 
Cell line / cell number 104 105 106 
A2780/cp70CMVLuc 0.5 2.0 18.7 
HCT116Luc 10.2 27.0 195.7 
Table 5.1  Quantitation of the bioluminescent signal (total flux) for the mice shown in figure 
5.2. 
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5.6.3 Effect of seeding density on tumour growth 
HCT116Luc cells were injected subcutaneously into mice at a range of seeding 
densities (2.5x105 to 2x106cells/injection) and the bioluminescent signal, 
measured at various times, is shown in figure 5.3. Tumours were visible by eye 
after 5 days in mice injected with 1x106 and 2x106 cells but were only detectable 
by bioluminescence at the lower densities. Only one mouse injected with 2.5x105 
cells had a visible tumour by day 15 and the bioluminescent signal showed only a 
very small increase by day 15 in the other mice in the group. At the higher 
densities (1 and 2x106) the bioluminescent signal increased with time up to day 
12 but there was no further increase at day 15 although the tumour size was 
smaller than could be measured by callipers (5mm). At a seeding density of 
5x105 all mice had visible tumours by day 15 and the bioluminescent signal 
showed a gradual increase with time. 
 
 
Figure 5.3: Bioluminescent signal (flux) measured in mice at various times following 
subcutaneous injection of HCT116Luc cells at a range of seeding densities. Results are the 
mean ± SEM of 6 mice. 
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5.6.4 Quantitation of tumour growth 
A group of six mice was injected subcutaneously on Day 0 with HCT116Luc cells 
(5 x 105cells/mouse) and tumour growth for individual mice as measured by 
bioluminescence is shown in figure 5.4A. All mice developed tumours and an 
exponential increase in flux with time was observed. The size of the tumours, 
indicated by the total flux, differed markedly between mice. When the flux was 
related to the initial flux measured on Day 0, a consistent growth rate was 
observed as seen by the small error bars in the mean plot (Figure 5.4B). 
 
Figure 5.4: Tumour growth measured by bioluminescence following subcutaneous injection 
of HCT116Luc cells (5 x 105cells/mouse). The flux measurement for each mouse was 
standardised relative to that measured on Day 1 and the mean ± SEM of the relative flux 
(relative tumour growth) is shown in (B). 
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5.6.5 Effect of subcutaneous administration of cisplatin on 
tumour growth 
Subcutaneous xenografts of A2780 are sensitive to cisplatin and the growth delay 
is not affected by the route of administration of the drug (Figure 5.5A). The 
subcutaneous route of administration is not toxic to the mice as seen by the 
maintenance of body weight (Figure 5.5B). 
 
Figure 5.5: Growth of A2780 xenografts following treatment on Day 0 with PBS (●) or 
cisplatin (6mg/kg i.p.▲ or subcutaneous ■). Values are mean ± SEM of 6 mice in each cohort. 
Also shown is the body weight of the mice (B). 
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5.6.6 Cisplatin sensitivity of A2780-Rab25Luc in vitro 
The cisplatin sensitivity of A2780, A2780-Luc and A2780-Rab25Luc is shown in 
Table 5.2. Infection of A2780 with the control plasmid containing just the 
luciferase gene (A2780-Luc) had no effect on the cisplatin sensitivity of the 
cells. However, infection with Rab25 resulted in a four-fold decrease in cisplatin 
sensitivity when compared with A2780-Luc cells (P < 0.001). Similar results were 
obtained when the encapsulated cisplatin (CB[7]cisplatin) was used.   
Cell line 
IC50 (µM) 
Cisplatin CB[7]cisplatin 
A2780 0.13 ± 0.02 0.14 ± 0.03 
A2780-Luc 0.12 ± 0.01 0.13 ± 0.008 
A2780-Rab25Luc 0.46 ± 0.04 0.42 ± 0.02 
Table 5.2: Sensitivity to cisplatin and CB[7]cisplatin of the parental ovarian cancer cell line 
A2780 and the two derivatives that express luciferase (A2780-Luc) and Rab25 and luciferase 
(A2780-Rab25Luc). Drug sensitivity was determined by the MTT based assay and cells were 
exposed to drug for 24 hours. Results are the mean  SEM of three replicates within one 
experiment.  
 
 
5.6.7 Growth of A2780-Rab25 in mice 
A2780-Luc and A2780-Rab25Luc cells were injected intraperitoneally into mice 
and they were imaged weekly for 5 weeks and the results are shown in figure 
5.6. After 1 week cells are present in all four A2780-Rab25Luc mice and in 3 out 
of 4 A2780Luc mice. By week 2 there is very little signal from the A2780-Luc 
mice and only one mouse shows evidence of viable tumour cells by week 5. All 
four A2780-Rab25Luc mice show a marked increase in the bioluminescent signal 
throughout the experiment. This difference is clear when the bioluminescent 
signal is quantified and plotted against time (Figure 5.6B). There was no 
apparent distension of the abdomen until week 5. 
 
 
Chapter 5   138 
 
Figure 5.6: Growth of A2780-Luc and A2780-Rab25Luc in the peritoneal cavity of mice. Cells 
(5x107) were injected intraperitoneally and mice were imaged after 1 week and then weekly 
for 5 weeks. Mice were identified by ear tags and sequential bioluminescent overlay images 
are shown for 4 mice in each group (A). The bioluminescent signal was quantified with Living 
Image 2.50.2 software with the area of measurement defined by a rectangle, drawn to cover 
the entire abdomen, and the same area was used for all mice and all measurements. For 
each mouse the signal at week 1 was defined as 100 and all subsequent measurements were 
related to this initial signal. The change in signal with time is also shown (B).  
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5.6.8 Cisplatin sensitivity of A2780-Rab25Luc in vivo 
Growth of A2780-Rab25Luc in the peritoneal cavity of mice following treatment 
with cisplatin and CB[7]cisplatin is shown in figure 5.7 and quantified in table 
5.3. A2780-Rab25Luc is less sensitive to cisplatin but the growth delay is only 
just significant by Day 14. Growth delay is enhanced when mice are treated with 
the encapsulated form of cisplatin (CB[7]cisplatin) given either intraperitoneally 
(P<0.001) or subcutaneously (P<0.002). None of the treatments had a significant 
effect on the body weight of the mice (Figure 5.8).  
 
Figure 5.7: Growth of A2780-Rab25Luc as a disseminated tumour in mice following 
treatment on day 1 with PBS (i.p. ●), cisplatin (6 mg/kg    ), CB[7]-cisplatin (34 mg/kg i.p ■, or 
subcutaneously   ). Values are mean ± SEM of 6 mice. 
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Figure 5.8: Body weight of mice bearing A2780-Rab25Luc disseminated tumours after 
treatment on day 1 with PBS (i.p. ●) cisplatin (i.p. 6 mg/kg    ) or CB[7]cisplatin (34 mg/kg    
i.p    ,or subcutaneous    ). Values are mean ± SEM of 6 mice. 
  
Days Control Cisplatin (6m/kg) CB[7]cisplatin 
(34mg/kg) i.p 
CB[7]cisplatin 
(34mg/kg) s.c 
1 1 1 1 1 
4 2.88 ± 1.88 2.43 ± 0.70 
NS 
1.44 ± 0.22 
P<0.05 
2.22 ± 0.75 
NS 
7 5.21 ± 0.85 3.36 ± 0.93 
NS 
2.66 ± 0.61 
P<0.05 
3.67 ± 1.77 
NS 
14 17.1 ± 0.34 9.78 ± 3.19 
P<0.05 
2.66 ± 0.9 
P<0.001 
5.01 ± 2.92 
P<0.002 
Table 5.3: Increase in bioluminescent signal relative to that measured on day 1 (day of 
treatment) of A2780-Rab25Luc. Values are the mean ± SEM of 6 mice. Statistically significant 
differences when compared with the control untreated tumours are also shown. NS = not 
significant 
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5.7 Discussion 
These results clearly show that bioluminescence can be used to measure tumour 
growth in mice in vivo. The bioluminescent signal relies on the presence of 
luciferin as a substrate for the light emitting reaction and the subcutaneous 
route of administration was shown to be more consistent than intraperitoneal 
administration. The level of luciferase expression by the tumour cells not only 
determines the sensitivity in terms of the number of cells that can be detected 
but also determines the total tumour burden that can be measured without 
saturation of the camera. Expression of luciferase in A2780-Rab25Luc cells 
allowed measurement of tumour growth in the peritoneal cavity of mice at an 
early stage when no visible distention of the abdomen was present. Treatment 
of A2780-rab25Luc tumour bearing mice with cisplatin resulted in small growth 
delay which was only just significant by Day14. This was consistent with the 
observation that A2780-Rab25Luc cells were 4 fold resistant to cisplatin in vitro 
when compared with parental A2780 cells. However, treatment with the 
encapsulated form of cisplatin (CB[7]cisplatin) resulted in a significant growth 
delay regardless of the route of administration of the drug. 
5.7.1 Route of administration  
For bioluminescence imaging luciferin can be injected intraperitoneally, 
subcutaneously or intravenously since luciferin permeates tissues including 
blood-brain and placental barrier easily. However, the kinetics of light emission 
varies significantly with the route of administration. On intraperitoneal 
administration of luciferin the peak bioluminescent signal was obtained at 6-8 
minutes after injection following which the intensity of the signals plateau and 
eventually taper (Figure 5.1A). This gives a narrow window of time to capture 
the bioluminescent signal from the luciferase expressing cells. The 
intraperitoneal administration of luciferin is error prone due to risk of injecting 
into the bowel or bowel wall which results in suppression or loss of 
bioluminescent signal (Contero, Richer et al. 2009). Besides, i.p  administration 
of luciferin in disseminated ovarian tumour models can result in overestimation 
of signals due to  direct diffusion of D-luciferin, in addition to the systemic 
absorption (Inoue, Kiryu et al. 2009). For these reasons, the subcutaneous route 
of administration of luciferin was evaluated. The risk of injection failure is 
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virtually absent with subcutaneous administration as allows the direct 
visualisation of the injection which is evident by a transient swelling at the site 
of injection.  As shown in figure 5.1B, with subcutaneous administration, the 
peak intensity of bioluminescent signal was attained relatively earlier but with 
similar plateau phase compared to i.p administration and this allows slightly 
broader window of time for imaging.  
There is an apparent variability in the intensity of the bioluminescent signal 
emitted by each of the xenografts which is explained by the variable sizes of the 
xenografts. However, in the drug efficacy experiments the mice with xenografts 
of uniform sizes were chosen to minimise gross variability.   
The primary aims of preclinical evaluation of drugs in animals, in addition to 
checking the anti-tumour activity, are to evaluate the pharmacokinetics and 
toxicities. The experiments described in chapter 3 and 4 demonstrated that 
CB[7]cisplatin administered intraperitoneally in mice bearing subcutaneous 
ovarian cancer xenografts exerted enhanced anti-tumour activity over that of  
cisplatin. This was due to the favourable pharmacokinetic properties of 
CB[7]cisplatin and established that drug delivery could overcome  tumour drug-
resistance. However, intraperitoneal administration of CB[7]cisplatin in the 
disseminated ovarian cancer model described in this chapter is questionable. 
This could be compared to tissue culture where the cultured cells are directly 
exposed to the drugs without the need for drug delivery mechanisms. Hence 
both subcutaneous and intraperitoneal route of drug administration was 
explored. CB[7] cisplatin exerted anti-tumour activity irrespective of the route 
of  drug administration (Figure 5.7). Of note, cisplatin exerted similar growth 
reduction of subcutaneous A2780 xenografts either with subcutaneous or 
intraperitoneal route of administration (Figure 5.5A) without a significant 
change in body weight between the cohorts of mice (Figure 5.5B). 
5.7.2 Sensitivity of bioluminescence imaging  
Initial experiments to transfect A2780 and A2780/cp70 cell lines with luciferase 
expressing plasmids (pd2CMVLuc) were largely unsuccessful. The development of 
subcutaneous xenografts with transfected cells was unpredictable and the 
bioluminescent signal intensity was suboptimal. Hence bioluminescent 
Chapter 5   143 
experiments were performed using HCT116Luc cell line that was obtained from 
Caliper Life sciences, which was shown to express high signal intensity. Mice 
were administered intravenous injection (through tail vein) of either HCT116Luc 
or A2780/cp70CMVLuc to compare the bioluminescence expression and the 
sensitivity. The injected cells were predominantly deposited in the lungs. As 
shown in figure 5.2, bioluminescent signal was not seen in mice injected with 
104 and 105 A2780/cp70CMVLuc cells whereas strong bioluminescent signal was 
noted in mice injected with same number of HCT116Luc cells. There was at least 
a 10-fold difference in the bioluminescent signal between these two cell lines 
(Table 5.1).  On the basis of this promising result, subcutaneous xenografts of 
HCT116Luc cells were developed with seeding density of 107 cells/mouse as 
described in section 2.4.2, chapter 2. The increased bioluminescent signal from 
HCT116Luc allowed earlier detection of the tumour compared to external 
measurements (with callipers). However, these signals reached the saturation 
limits of camera despite reducing the imaging time to 10 seconds (compared to 
conventional 1-2 minutes) and were not suitable for longitudinal studies of 
tumour growth. To strike a balance between signal saturation and optimum 
seeding density required for establishing the xenografts, experiment was 
performed to optimise the seeding density and imaging time (Figure 5.3). 
HCT116Luc cells at 5 x 105cells/mouse was chosen as the optimum seeding 
density as it allowed measurement of tumour growth (with callipers) and also 
using bioluminescence imaging over 22 days. In this experiment as illustrated in 
figure 5.4A, all the 6 mice exhibited tumour growth and the bioluminescent 
signal increased exponentially with time. Although the signals varied between 
each of the mice there was a consistent growth in tumour size with time (Figure 
5.4B). This illustrates that the optimum seeding density that is required for 
meaningful bioluminescent experiment is lesser than that required for 
conventional measurement with callipers and with lower seeding density the 
issues with saturation of signal could be overcome. 
5.7.3 Development of A2780-Rab25Luc model 
A disseminated ovarian tumour model was developed with A2780-Rab25Luc cells 
to evaluate the efficacy of CB[7]cisplatin using bioluminescence imaging. A2780 
is a well-established ovarian cancer cell line and its chemo-sensitivity has been 
well characterised by our research group both in vitro and in vivo (Strathdee, 
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MacKean et al. 1999; Plumb, Strathdee et al. 2000). Both A2780 and its cisplatin 
resistant derivative A2780/cp70 were sourced originally from Dr R Ozols (Fox 
Chase cancer centre, Pennsylvania, USA) who derived these cells from ovarian 
cancer patients. Although A2780-Rab25 cell lines were readily available from 
Prof Jim Norman’s group, to avoid risking the variability between cell lines 
sourced from different laboratories and groups, transfection of A2780 with 
Rab25 was done de novo.  A2780-Rab25 cell lines were successfully established 
by transfecting with pcDNA3-Rab25 vectors. However, the subsequent 
transfection of A2780-Rab25 with luciferase genes was difficult and the stable 
expression of luciferase in the A2780 cells already transfected with Rab25 was 
not achievable. A2780 cells were not able to retain both the luciferase and 
Rab25 genes and there was loss expression of either of the two genes. Hence 
gene transfer was done with lentiviral vectors given the promising 
bioluminescent signal with HCT116Luc cells which were transfected with 
lentiviral vectors. A2780 cells were transfected with pcDNA3-Rab25 vectors using 
Lipofectamine 2000 and then transduction of lentiviral constructs containing 
luciferase gene was done which resulted in the successful establishment of 
A2780-Rab25Luc cell line. The expression of Rab25 in this cell line was confirmed 
through Western blotting and the luciferase expression through bioluminescence 
imaging. 
A2780-Rab25Luc cells were injected intraperitoneally into mice and their growth 
was compared with A2780-Luc by monitoring the intensity of bioluminescent 
signal. Mice injected with A2780-Rab25Luc cells had clear bioluminescent signal 
which increased with time indicating establishment and growth of peritoneal 
tumour deposits (Figure 5.6). A2780-Luc cells on the other hand did not have 
such increase in bioluminescent signal indicating lack of peritoneal tumours. This 
strengthens the case that the forced expression of Rab25 has resulted in an 
invasive phenotype. Consistent with published literature (Cheng, Lahad et al. 
2004), tumour was evident in 100% of mice injected with A2780-Rab25Luc cells 
even before the clinical evidence of ascites (abdominal distension). The 
consistent uptake of tumour in all the mice injected with A2780-Rab25Luc and 
the associated emission of bioluminescent signal indicate that this disseminated 
ovarian cancer model of A2780-Rab25Luc is suitable to measure drug effects.   
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5.7.4 Cisplatin sensitivity of A2780-Rab25Luc 
A2780-Rab25Luc cells exhibit 4-fold resistance to cisplatin compared with 
A2780Luc cells (IC50: 0.13 ± 0.02 µM   for A2780 versus 0.46 ± 0.04 µM for A2780-
Rab25Luc, P<0.001) (Table 5.2). Expression of Rab25 in A2780 has resulted in the 
chemo-resistance to cisplatin which is consistent with published literature. 
Chang and colleagues reported that overexpression of Rab25 down-regulates the 
expression of pro-apoptotic Bcl2 family members and also increases proliferation 
through anchorage independent growth (Cheng, Lahad et al. 2004). These 
properties are likely to have contributed to cisplatin resistance in vitro. Mice 
with A2780-Rab25Luc xenografts are less sensitive to cisplatin and reduction in 
the bioluminescent signal just reached statistical significance on day 14 (Figure 
5.7). This is the first evidence of Rab25 induced decreased sensitivity to cisplatin 
in vivo.  These data further confirm the role of Rab25 in the aggressiveness of 
ovarian cancer and also that Rab25 could be a prognostic marker and 
therapeutic target.  
5.7.5 Effect of CB[7]cisplatin on growth of A2780-Rab25 in vivo 
Treatment with CB[7]cisplatin resulted in significant growth delay in A2780-
Rab25Luc xenografts  when compared with controls both by intraperitoneal or 
subcutaneous  route of administration (Figure 5.7 & Table 5.3). Treatment with 
CB[7]cisplatin also resulted in tumour growth delay when compared with 
cisplatin at later stages of  the experiment although this was not statistically 
significant. On day 14, the bioluminescent signal  from CB[7]cisplatin treated 
mice was only 15.6± 5% of that in control mice compared with 57.2 ± 21% to that 
of control mice in the cisplatin treated cohort (Table 5.3). 
This tumour growth delay in the Rab25 models produced by CB[7]cisplatin 
irrespective of the route of administration is likely due to the distinct 
pharmacokinetic profile of CB[7]cisplatin which results in prolonged tissue 
exposure of platinum. The experiments described in chapter 3 demonstrated 
that CB[7]cisplatin  exerted anti-tumor activity even in the cisplatin resistant 
A2780/cp70 xenografts. Together, these observations suggest that drug delivery 
of cisplatin with CB[7] could be used to circumvent platinum resistance. 
However, it is debatable if the disseminated ovarian tumor model (with 
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Rab25Luc) is a suitable model to evaluate drug delivery of drugs that are 
administered intraperitoneally since the drug is physically delivered almost 
directly to the tumour. Parallel pharmacokinetic studies of intra-peritoneal 
administration of CB[7]cisplatin was not performed and this is a limitation of this 
section. Intraperitoneal delivery of chemotherapy in patients with peritoneal 
disease can result in increased diffusion of drug into the tumour compared with 
systemic delivery (Ceelen and Flessner 2010). Nevertheless it was a reasonable 
approach to evaluate the in vivo activity of CB[7]cisplatin in this model as 
CB[7]cisplatin exerts its enhanced anti-cancer activity due to its favourable 
pharmacokinetic profile  rather than by exploiting the enhanced permeability 
and retention (EPR) effect. The disseminated ovarian tumor model described in 
this chapter could be used for evaluating drug delivery system which relies on 
tumour microenvironment and also for active targeting where the target may be 
better expressed by the intraperitoneal model.  
5.8 Conclusion 
The experiments described in this chapter illustrate the advantages of 
biophotonic imaging. Conventional measurement of tumour with external 
callipers is based on assumption that tumours have spherical configurations. This 
assumption, however, is not always true as tumours are of variable shapes. 
Besides, the calliper measurements are subject to error due to variability in 
thickness of skin and subcutaneous pad of fat. Observer subjectivity and 
differences in the compressibility of the tumour can easily lead to increased 
errors in measurements (Jensen, Jorgensen et al. 2008). In addition, since the 
vascular supply of the xenografts is primarily derived from the skin and tumour 
bed, the centre of the tumour could be hypo-perfused. It is well established that 
subcutaneous xenografts are known to develop necrotic centre, and this results 
in the underestimation of the value of drug effect (Black, Shetty et al. 2010). 
Bioluminescence imaging, although time consuming, overcomes most of the 
problems outlined above once the method is standardised. The key parameters 
of bioluminescence imaging include efficient administration of luciferin and 
establishing the precise time for imaging, both of which could be easily 
standardised. Bioluminescence imaging does not have high background (in 
contrast to fluorescence) and since viable cells are required for the generation 
of bioluminescent signal, it gives a reliable and reproducible estimate of the 
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functional/biological activity of the tumour.  Of note, bioluminescence imaging 
is not subject to inter-observer and operator variability and the quantitation of 
the signal intensity could be re-analysed at any given time.  Importantly 
bioluminescence imaging could also assist to probe the key molecular pathways 
in tumourigenesis and their response to drug treatment by acting as reporters 
and this will be described in the next chapter.  
 
148 
6 Development of a pharmacodynamic marker of 
drug activity  
6.1 Introduction 
The rational development of novel therapies based on our increased 
understanding of the molecular basis of cancer is likely to place greater 
emphasis on the biological effectiveness of the therapeutic strategy in addition 
to the conventional endpoints of toxicity and objective tumour responses 
(Caponigro and Sellers 2011). This, in turn, will have implications for designing 
the optimal animal models for pre-clinical evaluation in vivo and the 
mechanisms of evaluating biological endpoints in these models. 
 
Several potential animal models exist for the pre-clinical evaluation of novel 
anti-cancer agents including xenograft mouse models, orthotopic models and 
gene-modified animals (e.g. transgenic oncomice) and the optimal model will 
depend on a number of factors including the putative mechanism of action of 
the agent undergoing evaluation. The advantages and disadvantages of each of 
these models have been extensively reviewed (Sausville and Burger 2006; Frese 
and Tuveson 2007; Kung 2007). However all of these potential models have the 
disadvantage of assaying endpoints which give limited information on the 
biological effects of the agent on specific processes within the tumour. The 
development of new tools that can non-invasively assess the molecular and 
cellular events involved in the response of tumour cells to anti-cancer agents, 
would overcome many of the drawbacks of the existing pre-clinical models used 
in developing anti-cancer therapies. 
 
Development of pharmacodynamic biomarkers of drug activity is now an integral 
part of preclinical drug development. Thus the optimal dose and schedule of an 
active agent can be determined based on biological (i.e. pharmacodynamic) 
endpoints and any correlation of biological activity with pharmacokinetic 
parameters can be explored. This approach will also be useful in designing drug 
delivery systems since biological endpoints could be used to determine if and 
when the drug reaches the tumour even if not in sufficient amounts to cause 
tumour growth delay. 
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The studies described in the previous chapter clearly demonstrated the value of 
bioluminescence imaging in studies of tumour growth in vivo. The technique is 
sensitive and reproducible and can detect a signal originating from within the 
body cavity. For the tumour growth studies, cancer cells were manipulated such 
that the luciferase gene was expressed under the control of a constitutively 
active promoter. As a result the signal was proportional to the number of viable 
cells present within the tumour. Reporter assays, where cells are transiently 
transfected with the luciferase reporter gene linked to a promoter or 
transcription response element (TRE) of interest, are widely used in cell studies.  
These in vitro assays rely on the short half-life of the luciferase gene product   
(< 1 hour). The advent of the technology to enable bioluminescence imaging in 
vivo allows the transfer of this approach to animal studies (Kang and Chung 
2008; Kimbrel, Davis et al. 2009; O'Neill, Lyons et al. 2010). Reporter assays are 
very sensitive since the product is an enzyme, luciferase, which results in 
amplification of the signal.  
 
The aim of the studies described in this chapter was to develop a dynamic real-
time marker of drug activity. Nearly all cytotoxic drugs including cisplatin and 
paclitaxel activate the transcription factor p53 (Vogelstein, Lane et al. 2000). A 
p53 luciferase reporter system was therefore chosen for this study. For this 
approach to work, it is important to ensure that the luciferase gene expression is 
regulated by p53 binding to the TRE and not due to non-specific effects. The 
codon optimised Luc2 luciferase gene (Promega) was used in the lentiviral vector 
system, described in the previous chapter, in order to obtain stable and specific 
expression of the vector in A2780 cells which have wild type p53. Initially, 
transfected cells were characterised for p53 response in vitro both by 
bioluminescence imaging and by Western blotting.  Cells were then grown as 
xenografts in vivo and expression of p53 was determined by bioluminescence 
imaging. The results obtained from the application of bioluminescence imaging 
were compared with a more traditional technique, immunohistochemistry, for 
the detection of p53 expression in vivo.  
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6.2 Methods 
6.2.1 Construction of the plasmid 
Invitrogen Virapower™ promoterless Lentiviral Gateway kit® (Invitrogen, 
catalogue number: L5910-00) was used to clone p53 promoter and Luciferase 
(Luc2) gene into lentiviral vector (pLenti6/R4R2/V5-DEST) to be expressed in 
A2780 cell lines.  The process involved three vital steps namely, cloning the 
promoter (p53) into the pENTR-TOPO vector (supplied in the kit) to produce the 
promoter entry clone, cloning the gene of interest (Luc2) into p-ENTR vector to 
produce the gene entry clones  and finally constructing  pLenti6p53Luc2 gene  
through the recombination reaction of the two entry clones with 
pLenti6/R4R2/V5-DEST vector. This pLenti6p53Luc2 gene was then used for 
transfecting A2780 and A2780-Rab25 cell lines. A schematic representation of 
this  process is illustrated in figure 6.1. 
 
Figure 6.1: Schematic representation of development of bioluminescent reporter containing 
p53 reporter using lentiviral derived plasmid. 
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6.2.1.1 Development of entry clones with p53 gene 
pENTR 5’-TOPO® cloning kit, supplied  with  the Invitrogen Virapower™ 
promoterless Lentiviral Gateway kit®, contained the  pENTR 5’-TOPO®  vector 
which was able to clone p53. Polymerase chain reaction (PCR) was performed 
using Taq polymerase to produce a PCR product containing p53 and also a 
negative control which contained minimal TATA element (without any active 
gene of interest). PCR was conducted as outlined in section 2.5.1, chapter 2 and 
with specific reference to this experiment, 100 nanograms of DNA of both p53 
and control were used.  Other calculations used were as follows: 
Taq polymerase: 0.5mL 
DNA(100ng/µL): 1µL 
10µM dNTP: 1mL 
50 µM MgCl2: 1.5mL 
Primer 1 (10µM): 5mL 
Primer 2 (10µM): 5mL 
 
The mixture was thoroughly mixed in vortex and was run using Bio-Rad tetrad 
Peltier thermal cycle.  The following day, the PCR products were checked using 
DNA gel electrophoresis to confirm the presence of DNA. Subsequently the bands 
of gel containing the DNA (checked using UV transilluminator) were cut and 
weighed. DNA was extracted from the gel using QIAEX II gel extraction kit. In 
brief, 10µL of QIAEX II buffer was added to gel, vortexed for 30 seconds, left at 
50ºC for 2 minutes and vortexed every 2 minutes till the solution turned yellow. 
The sample was then centrifuged at 12000g for 30 seconds at room temperature 
and the supernatant was aspirated. The DNA pellet was washed with 500µL of 
QIAEX buffer, vortexed and centrifuged for 30 seconds and the supernatant was 
aspirated. This step was repeated twice and the DNA was air-dried for 10 
minutes. 20µL of distilled water was added to the air-dried pellet and incubated 
for 5 minutes at room temperature. Finally the supernatant containing the DNA 
was collected and stored in Eppendorf tubes at 4ºC in a refrigerator. 
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6.2.1.2 TOPO® cloning reaction 
The final product of the PCR was cloned into pENTR 5’-TOPO® vector by  ligase 
reaction. 2µL of PCR product, 1µL of salt solution (supplied with the kit), 1µL 
pENTR 5’-TOPO® vector and 2µL of sterile water was mixed and incubated at 
room temperature for 5 minutes. The resultant product was transformed into 
chemically competent E.coli supplied with the kit by bacterial transformation as 
per the method described in section 2.5.3, chapter 2. Kanamycin was used as 
the selection antibiotic. The extracted DNA was sequenced using the DNA 
sequencing services at the Beatson labs and the alignment was cross examined. 
The sequence of p53 gene used in the entry vector is given below: 
TACAGAACATGTCTAAGCATGCTGTGCCTTGCCTGGACTTGCCTGGCCTTGCCTTGGG. 
Subsequently large samples of the entry clone containing p53 gene and negative 
control was prepared using maxi-prep of DNA  and quantified  as described in 
sections 2.5.4 & 2.5.5, chapter 2. This entry clone containing the gene of 
interest (p53) will be hereafter named as pENTR TOPOp53. Similarly entry clones 
containing Luc2 gene (hereafter referred to as pENTR TOPOLuc2) and negative 
control containing minimal TATA alone (hereafter referred as pENTR TOPO 
control) was also constructed and all the above analyses were conducted. The 
DNA content of all the entry clones and destination vector was the calculated (in 
ng) to facilitate the recombination reaction. The final concentrations of the 
plasmids were as given below: 
pENTR TOPO p53:1660ng/µL 
pENTR TOPO Luc2: 1166ng/µL 
pENTR TOPO control: 973ng/µL 
The concentration of the pLenti6/R4R2/V5-DESTvector was 1100ng/µL 
6.2.1.3 LR Recombination Reaction 
The two entry clones containing p53 gene and Luc2 reporter were added to final 
destination vector, pLenti6/R4R2/V5-DEST, by means of  Multisite Gateway® LR 
recombination reaction. LR clonase II Plus enzyme used for the recombination 
reaction was supplied in the kit. The required amount of plasmid DNA was 10 
femtomoles (fmoles) for both the entry clones and 20 fmoles for 
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pLenti6/R4R2/V5-DEST. The number of basepairs (bp) in the entry clone, pENTR 
TOPOp53 was 2808bp (2680bp for the pENTR 5’-TOPO® vector and 128bp for the 
p53reporter). Similarly the number of basepairs in the entry clones pENTR TOPO 
Luc2 and pENTR TOPO control was 4351bp and 2760bp respectively. Since the LR 
recombination reaction stipulated that the concentration of plasmid DNA to be 
in fmoles, the following formula (given in the manual) was used for the 
conversion from nanograms to femtomoles. 
Nanograms (ng) = (x fmoles) (N) [660fg/fmoles] [1 ng /106 fg], where “x” is the 
number of fmoles and “N” is the size of the DNA in bp. 
One µL each of pLenti6/R4R2/V5-DEST vector, pENTRTOPOp53 and pENTR 
TOPOLuc2 plasmid containing the required concentration of DNA (in fmoles) was 
mixed with 2µL of LR clonase II plus enzyme,  made up to a final  volume of 10µL 
with TE buffer and incubated  overnight at 21ºC. Proteinase K solution (2µg/µL) 
was added to resultant product and incubated at 37ºC for 10 minutes. Following 
this step, 10µL of the resultant solution from the recombination reaction was 
used for the bacterial transformation reaction using One Shot® competent as per 
the method described in section 2.5.3, chapter 2. Ampicillin and blasticidin were 
the selection antibiotics used to streak the agar plates. 
 
Colonies were isolated after 24 hours and DNA was extracted and quantified as 
described in section 2.5.4 and 2.5.5, chapter 2. The final construct containing 
the p53 response element (p53RE) promoter was named as pLenti6p53RELuc2 
and the negative control containing TATA sequence alone was named as 
pLenti6TATALuc2. The sequencing of both these final constructs was done 
indirectly by confirming the sequence of the p53 and Luc2 gene. Prior to 
expression of the pLenti6p53RELuc2 plasmid, restriction digest was performed to 
check the correct alignment and length of the construct. Restriction digest     
was performed as described in section 2.5.2, chapter 2. ECor V enzyme was used    
for the digestion which resulted in two DNA fragments each of 6974bp and          
1713bp which was verified using Hyperladder™ I (Bioline). The plasmids 
(pLenti6p53RELuc2 and pLentiTATALuc2) were then used to transfect A2780 
cells. 
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6.2.2 Transfection 
A2780 cells were transfected with the plasmids, pLenti6p53RELuc2 and 
pLentiTATALuc2 using Lipofectamine 2000 as described in section 2.5.6,    
chapter 2. In addition, the plasmid containing luciferase gene alone without the 
promoter, pLenti6TATALuc2 was also used to transfect cells which acted as a 
negative control.  For this experiment A2780 cells were plated in 6 well plates 
and upon 90-95% confluence, the transfection was performed.  4µg of plasmid 
DNA was used to transfect the cells and the rest of the procedure was done as 
per section 2.5.6, chapter 2. The cells were sub-cultured into two separate 
flasks and allowed to grow for 24-48 hours. At 60-80% confluence, cells in each 
of the replicate flasks were checked for transgene expression by incubating with 
cisplatin (0.1µM) for 24 hours to induce p53. The transiently transfected cells 
were then checked for luciferase expression using bioluminescence imaging by 
adding D-Luciferin (30mg/ml). Once the gene expression was confirmed, stable 
cell lines were generated by propagating the cells in the presence of blasticidin 
(2.5mg/mL) as the selection antibiotic. 
6.3 Cytotoxic drug treatment 
6.3.1 Bioluminescence  
A2780pLentip53RELuc2 cells were plated in 24 well Iwaki™ plates at a density of 
300 cells/well and allowed to attach and grow in a humidified incubator at 37oC 
equilibrated with 5% CO2 for 24 hours. Upon 90% confluence, the cells were 
treated with a range of concentrations of cisplatin, doxorubicin or paclitaxel for 
24 hours. These three drugs were chosen to cover a spectrum of 
chemotherapeutic agents with different mechanisms of action. The drug 
containing medium was replaced with fresh medium containing D-Luciferin 
(30mg/mL) and plates imaged immediately with the IVIS 50 imaging system. 
After imaging, the cells were trypsinised and counted. 
6.3.2 Western blotting  
A2780pLenti6p53RELuc2 and A2780 cells were plated at a density of 106cells/ml 
in 6 well plates and allowed to attach and grow in a humidified incubator at 370C 
equilibrated with 5% CO2 for 24 hours. Cells were treated with a range of 
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concentrations of cisplatin, doxorubicin or paclitaxel for 24 hours. Protein was 
then extracted and quantified as described in section 2.1.5 and 2.1.6, chapter 2, 
respectively. Western blotting was performed as described in section 2.3, 
chapter 2. The primary antibody was anti-p53 (Novocastra clone D-01 from Leica 
Biosystems Ltd) at a dilution of 1:1000. 
6.3.3 Human tumour xenografts 
Monolayer cultures of A2780pLenti6p53RELuc2 cells were harvested with 
trypsin/EDTA and resuspended in PBS. About 107 cells were injected 
subcutaneously into both the left and right flank of athymic nude mice (CD1 
nu/nu mice from Charles River). After 7 to 10 days when the mean tumour 
diameter was at ≥ 0.5 cm3 the baseline bioluminescent signal was measured (see 
chapter 5). Mice were then allowed to recover from the anaesthetic for 4 hours 
following which they were treated with either PBS or cisplatin (6mg/kg i.p.). 
After 24 hours, p53 induced bioluminescence was measured.  
6.3.4 Immunohistochemistry 
Monolayer cultures of A2780 were harvested with trypsin/EDTA and resuspended 
in PBS. About 107 cells were injected subcutaneously into the right and left flank 
of athymic nude mice (CD1 nu/nu mice from Charles River). Once tumours had 
reached a mean diameter of about 1cm, mice were treated with either PBS, 
cisplatin (6mg/kg) or CB[7]cisplatin (34mg/kg, dose equivalent of cisplatin at 
6mg/kg). After 24 hours, tumours were harvested and fixed in neutral buffered 
formalin. Samples were processed, sectioned and mounted on glass slides by 
Histology Services, Beatson Institute for Cancer Research. 
Sections were dewaxed in xylene for 5 minutes. They were then hydrated by 
immersing the sections in 100% ethanol for one minute thrice, 70% ethanol for 1 
minute and then immersed in tap water.  Antigen retrieval was performed using 
heat induced epitope retrieval (HIER) technique. Sodium citrate buffer with pH 
6.0 (Thermo scientific) was used for antigen retrieval which was preheated in a 
pressure cooker that was placed in a microwave. The slides were immersed in 
the pre-heated sodium citrate buffer, left in the pressure cooker which was 
sealed and heated to maximum pressure for 10 minutes. The pressure cooker 
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was allowed to cool under cold tap water. The slides were removed from the 
sodium citrate buffer and placed in wash buffer made of TBS-Tween 20 (TBS-
Tween 20x, diluted 20 fold with distilled water). Besides the HIER using pressure 
cooker, pre-treatment (PT™) module (Thermo scientific) was also used for 
antigen retrieval. In PT module, PT module buffer (100x citrate buffer, pH:6 
diluted with distilled water) was preheated in the PT module chamber for 90 
minutes and slides were placed in the chamber and heated at 98oC for 20 
minutes.  The final results were comparable for both these antigen retrieval 
techniques. Following antigen retrieval, the slides were washed twice for 5 
minutes with TBS-Tween and the tissue margins were delineated with DAKO 
marker. 100µL of peroxidase blocking solution was added to the tissues mounted 
on the slide and incubated at room temperature in a humidified chamber.  
The slides were then washed twice with TBS-Tween for 5 minutes each, after 
which 150µL of mouse anti-human p53 antibody (Leica microsystem, DO-6) 
(diluted 100 fold) was added and incubated for 45-60 minutes. The washing steps 
were repeated and the slides were incubated with secondary antibody, anti-
rabbit p53 (DAKO) at room temperature for 45-60 minutes. The slides were 
washed with PBS-Tween and 150µL of DAB solution with its substrate was added 
to the tissue section. The sections were monitored for uptake of the stain after 
which point the reaction was terminated by adding water.  The sections were 
stained with Mayers haematoxylin stain for 2 minutes, washed with Scotts tap 
water and distilled water for two alternate cycles. The sections were 
dehydrated by immersing in ethanol and xylene sequentially after which they 
were mounted. 
6.4 Results 
6.4.1 Confirmation of the construct sequence 
The final construct containing the p53 response element (p53RE) promoter 
(pLenti6p53RELuc2) and the negative control containing TATA sequence alone 
(pLenti6TATALuc2) were digested with the ECor V enzyme to confirm the 
sequence of the p53 and Luc2 gene. The expected two digestion products of 
6974bp and 1713bp were present for both constructs (Figure 6.2). 
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Figure 6.2: Restriction fragment of plasmid DNA using Ecor V. Left Panel (A) indicates two 
replicates (1) and (2) of pLentip53RELuc2 plasmid DNA and right panel (B) indicates two 
replicates (3) and (4) of pLenti6TATALuc2 plasmid DNA. The DNA ladder is shown on both 
sides. 
 
6.4.2 Confirmation of transfection 
A2780 cells transfected with pLenti6p53RELuc2 or pLenti6TATALuc2 and parental 
A2780 cells were treated with cisplatin (0.1µM) for 24 hours and the 
bioluminescence measured. The results are shown in figure 6.3 and table 6.1. 
The left column indicates the cells that were transfected with 
pLenti6p53RELuc2, the centre column indicates the cells transfected with 
pLenti6TATALuc2 and the right column indicates parental A2780 cells. The top 
row contains cells that were incubated with cisplatin (0.1µM) and the cells in 
bottom row were treated with DMSO(0.1µM) only. A2780 cells transfected with 
the control vector (pLenti6TATALuc2) and parental A2780 cells show background 
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bioluminescence only. A2780 cells transfected with the p53 reporter 
(A2780pLenti6p53RELuc2) show a small increase in bioluminescence when 
treated with DMSO as compared to those transfected with the control vector 
(A2780pLenti6TATALuc2). Only the cells transfected with p53 reporter show a 
significant increase in bioluminescence (7 fold) when treated with cisplatin in 
comparison with the cells transfected with control vector (Table 6.1 and Figure 
6.3). 
 
Figure 6.3: Bioluminescence imaging of cells parental A2780 cells (right column), A2780 cells 
transfected with pLentip53RELuc2 (left column) and pLentiTATALuc2(centre column). The 
cells on the top row (A) were treated with cisplatin (0.1µM) and bottom row (B) were treated 
with DMSO (0.1µM). 
 
Cell line 
Total Flux(photons/second)/well 
Cisplatin DMSO 
A2780p53RELuc2 2.365 x 108 6.06 x 107 
A2780TATALuc 3.351 x 106 5.48 x 106 
A2780 5.54 x 105 4.56 x 105 
Table 6.1: Bioluminescent signal (flux) emitted by the cells in each well upon treatment with 
cisplatin (0.1µM) or DMSO (0.1µM) for 24 hours. 
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6.4.3 Induction of p53 in vitro  
A2780pLenti6p53RELuc2 cells were treated with cisplatin, doxorubicin or 
paclitaxel at a range of doses for 24 hours and the p53 expression was 
determined by bioluminescence and confirmed by Western blotting.  Expression 
of p53 determined by Western blotting for the reporter cells and parental A2780 
cells upon treatment by the three drugs is shown in figure 6.4. There is a clear 
induction of expression of p53 by all the three drugs (cisplatin, paclitaxel and 
doxorubicin). 
 
Figure 6.4: Induction of p53 in A2780pLenti6p53RELuc2 cells (left panel A) and A2780       
cells (right panel B) upon treatment with paclitaxel (40nM), doxorubicin (400nM) and 
cisplatin (1µM). The molecular size markers are shown.  
 
 
Induction of p53 as measured by bioluminescence imaging is shown in figure 6.5. 
In the absence of drug treatment, the bioluminescent signal is at background 
levels. However, treatment with the cytotoxic drugs at doses around the IC50 
concentration shows a marked increase in the flux. The flux was measured, 
quantified and expressed relative to cell numbers and a clear dose response was 
seen for all three cytotoxic drugs (Figure 6.5). 
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Figure 6.5: Bioluminescent images of the induction of luciferase gene expression in 
A2780pLenti6p53RELuc2 cells 24hours after treatment with increasing doses (from left to 
right) of cisplatin (top panel), doxorubicin (middle panel) and paclitaxel (bottom panel). The 
first column of each plate contains untreated cells. Luciferase gene expression measured in 
flux per million A2780pLenti6p53RELuc2 cells is also shown. Bioluminescence for each well 
was quantified and the results, expressed as flux per 10 million cells (mean  SEM of 4 
wells), are shown as a histogram on the right. 
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6.4.4 Induction of p53 in vivo 
A2780pLenti6p53RELuc2 cells were grown as xenografts in nude mice and were 
imaged before and 24 hours after treatment with cisplatin. Results are shown as 
images and as the quantified flux in figure 6.6. Significant bioluminescent signal  
was obtained in the tumours before treatment (Figure 6.6A left panel & B). After 
24 hours there was a small increase in the signal obtained from the control, PBS 
treated, mice (Figure 6.6A right panel & C). This increase in bioluminescent 
signal was not statistically significant (P > 1, t-test). However, when mice were 
treated with cisplatin (6mg/kg, i.p) there was a significant increase (2.8 fold, P 
< 0.001) in the bioluminescent signal when compared with the pre-treatment 
signal (Figure 6.6B right panel & C). 
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Figure 6.6: Induction of p53 in vivo in mice bearing A2780pLenti6p53RELuc2 tumours. Mice 
were imaged (left) and then treated with either PBS (A) or cisplatin (6mg/kg i.p., B) and 
imaged again after 24 hours (right). The bioluminescent signal was quantified and the post-
treatment signals (grey bars) expressed relative to the pre-treatment signal are shown (black 
bars). Results are the mean ± SEM of 5 mice. 
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6.4.5 Detection of p53 expression by IHC 
Expression of p53 determined by immunohistochemistry of A2780 tumours taken 
from mice 24 hours after treatment with a single intraperitoneal injection of 
PBS,  cisplatin (6mg/kg) or CB[7]cisplatin (34mg/kg) are shown in figures  6.7, 
6.8 and 6.9 respectively. There were four mice in each treatment group and 
each of the images corresponds to the representative section of each of the 
mice in the cohort. p53 protein is present at low levels in tumours taken from 
the control PBS treated mice (Figure 6.7). However, expression is much greater 
in tumours taken from mice that were treated with cisplatin (Figure 6.8) or 
CB[7]cisplatin (Figure 6.9). 
 
Figure 6.7: Expression of p53 determined by immunohistochemistry. Mice bearing A2780 
tumours were treated with PBS and the tumours removed after 24 hours. They were then 
fixed and stained for p53 protein. Representative section from the cohort of 4 mice is 
shown. 
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Figure 6.8: Expression of p53 determined by immunohistochemistry. Mice bearing A2780 
tumours were treated with cisplatin (6mg/kg, i.p.) and the tumours removed after 24 hours. 
They were then fixed and stained for p53 protein. Representative section from the cohort of 
4 mice is shown. 
 
 
Figure 6.9: Expression of p53 determined by immunohistochemistry. Mice bearing A2780 
tumours were treated with CB[7]cisplatin (34mg/kg, i.p) and the tumours removed after 24 
hours. They were then fixed and stained for p53 protein. Representative section from the 
cohort of 4 mice is shown.   
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6.5 Discussion 
A2780 cells were successfully transfected with a plasmid designed to link the 
TRE site of p53 responsive genes to the luciferase gene. This construct allowed 
the detection of p53 induction in both cells in culture and in the cells when 
grown as xenografts in mice. For cells in culture, the bioluminescent signal was 
clearly related to the dose of drug used to induce p53 expression, with higher 
concentrations of the cytotoxic drug inducing around an eight fold increase in 
the flux measurement. The expression of p53 as measured by bioluminescence 
was very low in the control untreated cells and this was confirmed by Western 
blotting. However, the baseline bioluminescent signal detected in vivo in control 
untreated tumours was relatively high and even at the maximum tolerated dose 
of cisplatin the increase in signal was only 2.8 fold compared to baseline. A 
significant expression of p53 was also detected in the control (PBS treated) 
tumours by immunohistochemistry. As with bioluminescence imaging, there was 
a demonstrable increase in p53 expression in tumours taken from cisplatin or 
CB[7]cisplatin treated mice on immunohistochemical analysis. 
6.5.1 The plasmid 
The reporter used in the experiments described in this chapter contains 
luciferase gene under the control of transcriptional response elements (TRE) 
induced by p53. p53 was chosen as the promoter of interest since p53 is  
ubiquitously induced by a variety of  genotoxic stressors  including chemotherapy 
and radiotherapy (Wang and El-Deiry 2003). In addition, induction of p53 is the 
the key mechanism through which cisplatin and other platinum compounds exert 
their cytotoxic action and induction of p53 culminates in apoptosis (Lowe and Lin 
2000; Wang and Lippard 2005).  
Lipid based transfection, although simple and quick, does not always result in 
stable transgene expression. As demonstrated in figure 5.2, chapter 5 the 
transgene expression of A2780/cp70CMVLuc cell lines which were generated by 
transfecting A2780/cp70 cell lines with pd2CMVLuc plasmid by Lipofectamine 
was not successful. Hence gene delivery was attempted using lentiviral vectors. 
Use of lentiviral vectors for gene delivery generates cell lines with stable  and 
long term transgene expression, without affecting the normal function of the 
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host genome (Cockrell and Kafri 2007). Lentiviral vectors used in the 
experiments described in this chapter were easy to develop as per 
manufacturer’s instructions. This lentiviral vector was also used for the 
development of disseminated ovarian cancer model described in chapter 5. 
6.5.2 Characterisation of  p53 reporter in vitro 
Ovarian cancer cell line A2780 is one of the widely used cell lines to evaluate 
specific molecular pathways and chemosensitivity. A2780 cell line is 
characterised by the presence of wild type p53 (Brown, Clugston et al. 1993)  
and this is also shown in the Western blotting experiments in chapter 3 whereby 
treatment with cisplatin resulted in a clear dose response with incremental 
induction of p53 with increasing doses of the drug (Figure 3.4, chapter 3). 
Construction of a bioluminescent p53 reporter, wherein the expression of 
luciferase enzyme is controlled downstream of p53 response elements, enables 
to reliably monitor and quantify the induction of p53. In the in vitro 
bioluminescence imaging experiments with A2780 cells transfected with p53 
reporter, up to an 8 fold increase in the bioluminescent signal was noted 
depending on the dose and type of cytotoxic drug used (Figure 6.5). The 
induction of p53 demonstrated by bioluminescent reporter cell lines was 
confirmed with Western blotting to check for p53 induction upon treatment with 
similar doses of the drugs (Figure 6.4). The background bioluminescent signal 
noted in untreated bioluminescent reporters was very low and there was no 
evidence of p53 induction in untreated cells when assessed by western blotting.  
Clearly this would indicate that the increase (up to 8 fold) in bioluminescent 
signal is specifically due to the induction of p53.  An ideal reporter would also 
require negative control, i.e. treatment which would not result in p53 induction. 
However there is no clear negative control for p53 (Dr Diane Crighton, Personal 
communication).  
The p53 reporter described in these experiments give readout of the p53 
induction that has been brought on by a variety of cytotoxic drugs, thereby 
indicating that this reporter would serve a suitable tool-box for evaluating the 
efficacy of drugs and molecular pathways through which the drug exerts their 
cytotoxic activity. Paclitaxel which exerts its anti-tumour activity by disrupting 
the mitotic spindle can also induce p53 in a cell dependent manner and the 
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results of these experiments are in keeping with such observation (Giannakakou, 
Robey et al. 2001). 
Bioluminescent reporters have facilitated the drug development process and 
evaluation of a specific molecular pathway in tumourigenesis and serve as a 
pharmacodynamic marker of target activity. Unlike conventional Western 
blotting, use of reporter cell lines is less time consuming and simple. In addition, 
serial measurements and observer-independent quantification of target 
activation is possible with the bioluminescent reporters. Ubiquitin luciferase 
reporters were used to assess the function of proteasomes in animals and have 
enabled the preclinical evaluation of proteasome inhibitor, bortezomib.  Luker 
and colleagues developed ubiquitin reporter by fusing luciferase to ubiquitin, 
which emitted bioluminescent signal upon treatment with proteasome inhibitor, 
bortezomib (Luker, Pica et al. 2003). Here they demonstrated that 
bioluminescent activity was noticed in mouse tumour models within 30 minutes 
after treatment with bortezomib and returned to baseline at 46 hours indicating 
rapid inhibition of proteasome. Similarly, the transcriptional activity of hypoxia 
inducible factor response elements (HIF-RE) can be monitored using luciferase 
reporters (Kung, Zabludoff et al. 2004). These studies indicate that the drug 
activity could be reliably monitored with the help of a robustly established 
luciferase reporter. Clearly the lenti-viral vector used for gene delivery in our 
experiments has resulted in stable transgene expression. Results from study with 
cells indicate that the p53 reporter developed with lentiviral vectors is sensitive 
to drug dose and should be suitable for animal studies. 
6.5.3 Characterisation of p53 reporter in vivo 
Xenografts of A2780 cells with the luciferase reporters (A2780pLentip53RELuc2) 
and empty vectors (A2780pLentiTATALuc2) were developed to characterise the 
p53 luciferase reporter in vivo. In contrast to the in vitro experiments where the 
untreated cells did not exhibit notable bioluminescent signal, there was 
significant bioluminescent signal even from the untreated xenografts (Figure 
6.6A, left panel). This relatively high background bioluminescence could be due 
to the sensitivity of the reporter. The defective vasculature in tumours results in 
hypo-perfused area where the cells are exposed to hypoxic stress. It is well 
established that hypoxia induces p53 (Vousden and Ryan 2009) and this 
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underlying induction of p53 accounts  for the  high background bioluminescent 
signal. In contrast, cultured cells grown in vitro are adequately fed and well 
oxygenated and hence not under hypoxic stress that could induce p53 and hence 
the background bioluminescence was not high (Figure 6.5). Despite the 
background bioluminescent signal, as shown in figure 6.6, there was a 2.8 fold 
increase in bioluminescent signal in cisplatin-treated p53 luciferase xenografts 
compared with controls (untreated xenografts). This 2.8 fold increase in signal in 
the xenografts is lesser than the 8 fold increase noticed in vitro questioning the 
sensitivity of the reporter. The p53 luciferase reporter, however, is sensitive to 
p53 induction since the dose of cisplatin required to induce p53 in the in vitro 
experiments were closer to IC50 doses (Figure 6.5). This is in contrast to the PARP 
cleavage (Figure 3.5, chapter 3) which showed that doses as high as 5µM-25µM 
were required to induce PARP cleavage that could be monitored using Western 
blotting. The differential fold response between in vitro and in vivo experiments 
could be due to the heterogeneity of transfected A2780 cells, which result in the 
inevitable selection of a subpopulation of cells with variable degree of transgene 
expression. This also explains the challenges with establishing xenografts with 
transfected cells (Zeamari, Rumping et al. 2004). Gene transfer through 
lentiviral infection and selection of clones could potentially overcome this 
handicap and this could be considered in future.  
The induction of p53 in the xenografts was also correlated with conventional 
immunohistochemistry. As shown in figure 6.7, there was induction of p53 in the 
untreated xenografts which corresponds to the background bioluminescent signal 
noted in reporter assays (Figure 6.6). This indicates that the background 
bioluminescent signal noted in untreated control is genuine and not artefactual. 
There was a demonstrable increase in p53 staining in the A2780 tumours treated 
with cisplatin compared with control (Figure 6.8). However this increase in p53 
induction did not significantly differ between cisplatin and CB[7]cisplatin treated 
xenografts  and the intensity  and distribution of p53 staining were not dissimilar 
between these two groups (Figure 6.8 and 6.9).  Various semi-quantitative and 
automated methods have been described to standardise the 
immunohistochemistry reporting. This includes H-scores and Allred score which 
essentially measure the intensity and reactivity of the cells and the percentage 
of cells which are stained (Walker 2006). Despite the guidelines to standardise 
Chapter 6   169 
the procedures involved in immunohistochemical analysis there are still 
significant issues with sensitivity and specificity of this valuable technique 
(Hammond, Hayes et al. 2010). On the other hand, the bioluminescent signal 
emitted in vivo could be easily quantified and is independent of observer bias. 
Bioluminescent luciferase reporters allow sequential and repetitive 
measurement of the drug activity which is particularly useful in in vivo 
experiments. 
6.6 Conclusion 
The results of in vitro and in vivo experiments demonstrate that the  
 p53 luciferase reporter enables repetitive analysis of p53 activity and could be 
used to investigate target hit activity in drug development process. 
Bioluminescence is a good tool for studies with cell lines. The bioluminescent 
p53 reporter works in vivo but is not sensitive enough and there is scope to 
improve the sensitivity in vivo. 
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7 General Discussion 
The aims of this thesis, on the whole, have been achieved. Although this is not 
the first study of a drug delivery system for cisplatin the results demonstrate 
clearly that encapsulation of cisplatin increases the plasma and tumour 
concentration of platinum without an associated increase in toxicity. The 
delivery system is non-toxic, has no inherent anti-tumour activity and shows 
promise for further development. The lack of suitable tumour models for studies 
of drug delivery in vivo was addressed and biophotonic imaging is shown to allow 
estimation of growth and drug sensitivity of a disseminated model of human 
ovarian cancer. The results also demonstrate that biophotonic imaging can be 
used to monitor induction of p53 in real time in vivo. 
 
The results have been discussed in detail in each chapter and only the main 
points will be discussed in the final chapter. 
 
7.1 Cucurbituril encapsulated cisplatin 
Many drug delivery systems show promising preclinical activity but fail to 
reproduce this activity when tested in patients. There are many reasons for this 
but as for any preclinical drug discovery programme the choice of model system 
for evaluation of activity is critical. Cucurbituril encapsulated cisplatin was, 
therefore, evaluated in a well characterised model of human ovarian cancer. 
The parental A2780 cell line has wild type p53 and is relatively sensitive to 
cisplatin. By contrast, the drug resistant derivative, A2780/cp70 shows loss of 
regulation of p53 and has lost a functional DNA mismatch repair pathway which 
is known to be associated with cisplatin resistance (Plumb, Strathdee et al. 
2000). Both mechanisms of resistance are known to be relevant to patient 
tumours and the demonstration that CB[7]cisplatin can inhibit growth of the 
drug resistant tumour when grown in vivo as a xenograft suggests that the 
delivery system has potential for use in the clinic. Cucurbiturils are relatively 
small delivery systems ( ~ 1m) and thus would not be expected to be trapped in 
the tumour as a result of the enhance permeability and retention properties of 
tumours (Maeda, Wu et al. 2000). There are also no suitable surface groups that 
could be implicated in tumour specific binding. Since the delivery system did not 
alter the activity of cisplatin in vitro it was proposed that the enhanced activity 
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was due to a change in plasma pharmacokinetics. There is no suitable method 
for the detection of cisplatin and breakdown products in biological samples so 
the highly sensitive inductively coupled plasma mass spectroscopy method was 
established and validated to study the pharmacokinetics of cisplatin. The results 
supported the hypothesis that encapsulation altered the plasma 
pharmacokinetics of cisplatin. This study has now been published (Plumb, 
Venugopal et al. 2012). However, the assay only measured elemental platinum 
so it was not possible to determine whether encapsulation did, indeed, protect 
the cisplatin from thiol degradation. It also gave no information on whether the 
cisplatin in the circulation in the mice was retained within the cucurbituril or 
was present as free drug. This problem could be addressed in further studies in 
which both cisplatin and cucurbituril are labelled in some way. The most obvious 
method would be to use a radioactive label since this is least likely to alter the 
properties of the two molecules.  
 
7.1.1 Further development of the delivery system 
Cucurbituril encapsulated cisplatin needs to be characterised further before it 
could be used for clinical evaluation. However, there is a clear proof of principle 
that this drug delivery system can circumvent cisplatin resistance and, the 
promising activity already demonstrated could be enhanced in a number of 
ways. One of the apparent advantages is an increased delivery to tumours but 
this is non-specific. Many groups have exploited the characteristics of tumour to 
target drugs specifically to tumours. Cucurbiturils do not have suitable groups on 
the surface to allow attachment of a targeting moiety. However, it has been 
proposed that cucurbiturils could be incorporated into liposomes or nanosomes 
which can be conjugated to a targeting molecule. Other ideas include 
incorporation of cucurbiturils into a hydrogel which could be implanted into the 
body to allow a sustained release of drug. 
 
7.2 Biophotonic imaging 
Studies of drug sensitivity in vivo in mice have been limited due to the lack of 
techniques to measure tumour growth. Subcutaneous xenografts can be 
measured by callipers and provided that the tumour has a rapid growth rate this 
allows assessment of growth inhibition as a result of drug treatment. One of the 
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most rewarding aspects of this work was the demonstration that biophotonic 
imaging could be used to measure tumour growth in vivo in mice. Although it 
was known that the technique was very good at detecting light within the body 
of mice and could thus show the location of tumour cells it was not clear that 
the technique was sufficiently sensitive to allow accurate measurement of the 
viable tumour mass. However, these results show that provided the luciferin 
substrate is administered by the subcutaneous route and that measurements are 
taken within a fixed time period after injection it is possible to measure tumour 
burden. Interestingly, subcutaneous administration of luciferin is now the route 
recommended by the manufacturers of the IVIS bioluminescence equipment. One 
of the clear advantages of biophotonic imaging is that the bioluminescent signal 
is not affected by the person taking the measurement. Although there can be 
differences in the way the image is analysed the information is stored and can 
be re-analysed at any time. 
 
7.3 A2780-Rab25 model of disseminated human ovarian 
cancer 
Once it was clear that biophotonic imaging was suitable for measurement of 
tumour growth in vivo it was possible to evaluate the activity of encapsulated 
cisplatin in the A2780-Rab25 model of disseminated human ovarian cancer. This 
was an ideal model for these studies since it would extend the observations 
obtained with the subcutaneous xenografts. It was known that expression of 
Rab25 in A2780 reduced their sensitivity to induction of apoptosis under stress 
but these results were the first to demonstrate that Rab25 expression was 
associated with a reduced sensitivity to cisplatin. Although the resistance was 
only four fold this was sufficient to reduce the cisplatin sensitivity of A2780 
when grown as a disseminated tumour in the peritoneal cavity of mice. It was 
therefore encouraging to observe that encapsulated cisplatin retained activity in 
the A2780-Rab25 model. The mechanism of resistance clearly differs from that 
of A2780/cp70 and the fact that activity is retained supports the proposed 
pharmacokinetic basis for the enhanced activity. 
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7.4 The p53 reporter 
The ability to image drug activity in vivo is clearly an advantage in studies of 
drug development. This is now possible through techniques such as PET and MRI 
imaging but these techniques are highly specialised and not generally available. 
The introduction of biophotonic imaging in vivo raises the possibility that the 
reporter assays that are now widely used in studies with tumour cell lines in 
vitro could be translated to studies in vivo. Induction of p53 expression is an 
early response to cytotoxic drug activity and thus provides a suitable marker of 
drug activity. Expression in A2780 of a plasmid containing the p53 TRE linked to 
luciferase allowed the measurement of p53 induction by bioluminescence. Since 
the signal could be quantified by the simple addition of luciferin to the cells and 
capture of the image with the IVIS-50 the technique allowed assessment of 
multiple treatments within a single experiment. A clear advantage when 
compared with measurement by Western blotting. Preliminary studies showed 
that the response to p53 could also be detected in vivo. Time constraints did not 
allow further evaluation of the p53 reporter in vivo. However, in subsequent 
work a colleague has shown a clear dose response to cisplatin in vivo when the 
plasmid was expressed in the A2780-Rab25 cells (Dr Gomez-Roman personal 
communication). 
 
7.5 Conclusion 
These results have identified a novel drug delivery system that could form the 
basis of an effective system for improvement of the clinical activity of cisplatin. 
The results obtained for the use of biophotonic imaging clearly support the value 
of this technology to studies of cytotoxic drug activity in vivo. They also 
demonstrate the importance of such developments in technology since they 
allow the development of more complex mouse models for the study of drug 
activity in vivo. 
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Appendix 1 Buffers, solution and media  
Tris Buffered Saline (TBS) 10X: 
 
Tris Base       24.22g 
NaCl        180g 
Distilled water      1800mL 
Stirred until dissolved, adjusted to pH 7.4 with HCl and made up to volume of    
2 litres with ultrahigh pure deionised water 
 
 
25% Tween-20: 
 
Distilled water      75mL 
Tween 20       25mL 
Mix well and store in the dark room at room temperature 
 
 
TBS-T: 
 
Dilute 200mL TBS (10X) in ultrahigh pure deionised water to make up to 2 litres 
of 1X concentration and add 4mL of 20% Tween-20 
 
3M Sodium Hydroxide: 
 
Sodium hydroxide tablets     1g 
Dissolve in 8.3mL distilled water 
 
 
Phosphate Buffer Saline (pH 7.4): 
 
NaCl        8g 
KCl        0.2g 
KH2PO4       0.2g 
Na2HPO4.2H20      1.44g 
MgCl2.6H2O       2.03g 
Made up to volume of 1 litre with ultrahigh pure deionised water 
 
Cell Lysis Buffer: 
 
MOPS (20mM)       
EGTA (2mM) 
EDTA (5mM) 
Sodium fluoride (30mM) 
Glycerophosphate (40 mM) 
Sodium pyrophosphate (20mM) 
Sodium orthovanadate (1mM) 
Triton-X 100 
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Phenylmethyl sulfonyl fluoride (1mM)  
 
Adjusted to pH 7.2 with 1N NaOH and made up in 100mL ultrapure water. 
Add two tablets of Protease inhibitor (COMPLETE protein lysis kit)  
 
EDTA 100mM: 
 
EDTA         3.7g 
NaOH        2.0g 
Ultra-pure water      80mL 
Adjust to pH 7.4 with HCl and make up to 100mLwith ultra-pure water 
 
 
NaOH 1N: 
 
NaOH        2g 
Made up to volume of 100mL distilled water 
 
Running Buffer: 
 
50mL NuPAGE MOPS SDS running buffer (20x) 
950mL of ultrahigh pure deionised water 
 
Transfer Buffer: 
 
NuPAGE transfer buffer (20x)     50mL 
Methanol        200mL 
Ultrahigh pure deionised water     750mL 
 
Washing Buffer: 
 
25% Tween-20       2mL 
Tris Buffered Saline (10x)      100mL 
Ultrahigh pure deionised water     900mL 
 
Blocking buffer: 
 
Marvel mild powder       5g 
25% Tween-20       0.2mL 
Tris Buffered Saline (10x)      10mL 
Made up to 100mL with ultrahigh pure deionised water 
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Sorensen’s Glycine Buffer: 
 
Glycine (0.1M)       7.5g 
NaCl (0.1M)        5.85g  
Equilibrated to pH10.5 with 0.1M NaOH and made up to 1 litre with ultrahigh 
pure deionised water 
 
 
RPMI 1640 Medium: 
 
RPMI 1640        500ml 
L-Glutamine        5ml 
1M Sodium hydroxide      0.8mL 
Penicillin/streptomycin 100mg/mL (optional)   2.5mL 
G418 1g/mL (optional)      5mL 
Blasticidin 5mg/mL (optional)     250µL   
 
DMEM medium: 
 
DMEM medium       500mL 
L-Glutamine        5mL 
1M Sodium hydroxide      0.8mL 
Penicillin/streptomycin 100mg/mL (optional)   2.5mL 
 
Trypsin solution: 
 
Trypsin 2.5% solution      10mL 
PBS         90mL 
EDTA         1mM 
 
MTT solution: 
 
MTT          1gm 
Sterile PBS        200mL 
Filtered through a stericup vacuum derived pre-sterilised filtration system and 
stored at 4ºC in a dark room 
 
 
1.5% Agarose gel 
 
1 X TAE buffer       100mL 
Agarose        1.5gm 
Bring the solution to boil by heating in microwave for 1-2 minutes. Cool it to 
50ºC and add two drops of ethidium bromide solution 
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Appendix 2 Suppliers 
 
Amersham biosciences    
Amersham place    
Little Chalfont, HP79NA   
United Kingdom 
www.amersham.com  
  
 
Becton Dickinson  
Between Towns Road  
Cambridge, CB4 9ZR 
United Kingdom 
www.bd.com    
 
 
Bibby Sterlin   
Barloworld Scientific Ltd   
Beacon Road    
Stone, ST15 0SA   
United Kingdom 
www.barloworld-scientific.com 
 
 
Bio Rad Laboratories   
Bio Rad House   
Maryland Avenue   
Hemel Hempstead, HP2 7DX 
United Kingdom  
www.bio-rad.com  
 
 
Braun B Biotech  
Thorncliffe Park   
Sheffield, S35 2PW   
United Kingdom  
www.sartorius-bbi-systems.com 
     
Charles River UK   
Manston Road   
Margate, CT9 4LT   
United Kingdom  
www.criver.com 
 
      
Corning International  
Quantum House, Maryland Avenue 
Hemel Hempstead, HP2 7DF 
United Kingdom 
www.corning.com 
 
Drummond Scientific 
Alpha Laboratories 
Eastleigh, SO5 4NU  
United Kingdom 
www.drummondsci.com 
 
 
Elkay Laboratories Ltd 
Unit E, Lutyens Industrial Centre  
Bilton Road, Basingstoke, RG24 8LJ 
United Kingdom 
www.elkay-uk.co.uk 
 
 
Eppendorf 
Endurance House, Chivers Way 
Oxford, OX4 3LY 
United Kingdom 
www.eppendorf.com 
 
 
Fisher Scientific UK 
Bishop Meadow Road 
Loughborough, LE11 5RG 
United Kingdom 
www.fisher.co.uk 
 
 
Fuji Photo Film Ltd 
125, Finchley Road 
London, NW3 6JH 
United Kingdom 
www.fujifilm.co.uk 
 
 
Grant Instruments 
29 Station Road 
Royston, SG8 6PZ 
United Kingdom 
www.grant-scientific.com  
 
 
Inorganic Ventures Ltd 
300 Technology Drive 
Christiansburg, VA 24073 
USA 
www.inorganicventures.com 
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Invitrogen 
Inchinnan Business Park 
Inchinnan, PA4 9RF 
United Kingdom 
www.invitrogen.com 
 
Millipore 
The Boulevard, Blackmoor Lane 
Watford, WD1 8YW 
United Kingdom 
www.millipore.com 
 
      
Molecular Devices 
135, Wharfedale Road 
Workingham, RG41 5RB 
United Kingdom 
www.moleculardevices.com 
 
 
NanoDrop products 
3411 Silverside Road 
Wilmington, DE 19810 
USA 
www.nanodrop.com 
 
 
Novocastra 
Vision Biosytems, Benton Lane 
Newcastle, NE12 8EW 
United Kingdom  
www.novocastra.co.uk 
 
 
Parkin Elmer 
Chalfont Road 
Beaconsfield, HP9 2FX 
United Kingdom  
www.parkinelmer.com 
 
Promega 
Delta House, Enterprise Road 
Southampton, SO1 7NS 
United Kingdom  
www.promega.com 
 
Qiagen 
Qiagen House, Fleming Way 
Crawley, RH10 9NQ 
United Kingdom 
www.qiagen.com 
 
 
Roche Diagnositics 
Bell Lane 
Lewes, BN71LG 
United Kingdom  
www.roche-diagnostics.com 
 
 
Scharfe Systems 
Kramerstrasse 22 
Reutingen, D72764 
Germany 
www.casy-technology.com 
 
Sigma 
The Old Brickyard, New Road 
Gillingham, SP8 4XT 
United Kingdom  
www.sigmaaldrich.com 
 
Surgipath 
Venture Park, Stirling Way 
Peterborough, PE3 8YD 
United Kingdom  
www.surgipath.com 
 
 
Thermo Electron 
Stortford Hall Park 
Bishops Stortford, CM23 5GZ 
www.thermo.com 
 
Thermo Life Sciences 
Unit 5, The Ringway Centre 
Basingstoke, RG21 6YH 
United Kingdom  
www.thermo.com 
 
 
Vector Laboratories 
Accent Park, Bakenwell Road 
Peterborough, PE2 6XS 
United Kingdom  
www.vectorlabs.com 
 
 
Whatman International 
James Whatman Way 
Maidstone, ME14 2LE 
United Kingdom  
www.whatman.com
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Appendix 3 Antibodies and drugs 
Antibody Dilution Supplier 
Anti-actin 1/1000 BD Biosciences 
Anti-p53 1/1000 Leica Microsystems 
Anti-PARP 1/1000 BD Biosciences 
Anti-MLH 1/5000 BD Biosciences 
Peroxidase linked anti-mouse 
IgG 
1/10,000 Amersham  
Peroxidase linked anti-rabbit 
IgG 
1/10,000 Amersham 
Table A.1: Primary and secondary antibodies. The dilution used  and suppliers are given. 
 
Drug Vehicle Supplier 
Cisplatin DMSO Sigma 
Cisplatin (for in vivo use) Normal saline Donation from Beatson 
Pharmacy 
Paclitaxel Sterile water Sigma 
Doxorubicin Sterile water Sigma 
Table A.2:  Drugs and vehicle 
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